Reports ranked by overall diligence score. Newer reports break ties, so the list stays stable as fresh research lands.
The three highest-scoring diligence reports in the collection.
CoolIT clears a strong-pass quality bar as a rare scaled direct-to-chip cooling franchise aligned with the AI data center buildout, though new investor access now sits primarily through Ecolab rather than an independent private round.
Commure is the breadth-and-anchor leader in healthcare AI, and the BUY case rests on KLAS, OBHG, HCA, and the GC Customer Value Fund composing the strongest public proof book in the category.
Candid built one of the most strategically validated autoimmune T-cell engager platforms in biotech, but after UCB's up-to-$2.2B bid the remaining upside depends more on deal close and Phase 2 execution than on hidden asset discovery.
Remaining reports by score.
Intersect Power is a category-defining co-located clean energy platform whose $4.75B acquisition by Google validates the power-first AI infrastructure thesis at scale; the $12B total enterprise value signals strong investor conviction in the co-location model, with significant execution risk tied to permitting, grid interconnection, and supply-chain delivery.
NetSPI is the dominant pure-play proactive security platform at scale, with $500M+ KKR backing, consistent 30–50%+ organic revenue growth through 2023, and an unmatched combination of elite human expertise and AI—making it a compelling strategic asset in the expanding CTEM market.
Hinge Health is the AI-native category leader in digital MSK care, delivering industry-leading revenue growth (+47% YoY), an 85% gross margin, and positive free cash flow as a public company—making it a strong buy for investors with a 3–5 year horizon, with a primary watch item on the FDA TrueMotion inquiry.
Stripe is a premium-quality private fintech compounder, but the current tender price still needs more audited support than public evidence can provide.
CloudWalk looks undervalued relative to its current revenue scale and profitability, but the investment case depends on validating the durability of its FIDC-backed funding and credit engine.
Enter is the dominant AI-powered mass-litigation platform for Brazil's uniquely vast legal market, growing at exceptional speed with blue-chip customers and Tier-1 investors, but carrying key-person and market-concentration risk as it attempts global expansion.
Temporal has achieved rare developer infrastructure category leadership with 183,000+ weekly active OSS users and 2,500+ cloud customers, a 184% NRR confirming durable enterprise expansion, and 380% YoY revenue growth in early 2026. The company is well-positioned to benefit from the AI agent orchestration wave through Nexus. The primary investment question is whether the OSS-to-cloud conversion flywheel can sustain growth as the platform matures and hyperscalers develop competing native orchestration services.
TRM Labs' 150%+ annual growth and rare dual presence in both private-sector compliance and government investigations makes it one of the most defensible blockchain intelligence platforms, but Chainalysis's entrenched position and market cyclicality warrant careful sizing.
EquipmentShare is a Buy at IPO — a vertically integrated construction tech + rental platform trading at a substantial discount to large-cap rental peers, with 34%+ rental growth, a capital-light OWN Program, and an undervalued T3 SaaS layer.
Canva is a world-class design platform — profitable, growing 35%+, and an efficient consumer-to-enterprise flywheel. At 12.7x ARR ($42B), the valuation is fair for the growth/profitability profile but offers limited margin of safety; BUY with medium-high confidence for investors with a 2-4 year institutional horizon.
SpaceX is one of the rare private companies whose public evidence supports both a genuine strategic premium and a disciplined refusal to chase the current price; the right call is track, because the business is exceptional but the valuation already assumes too much future Starship and capital-markets success.
Moneybox is a rare profitable consumer fintech at real UK scale, but the July 2026 PISCES-derived unicorn mark looks fair rather than clearly attractive without post-transaction and data-room proof.
Scaled private CPaaS leader with improving profitability and credible infrastructure moat, but valuation conviction is capped by disclosure and capital-structure opacity.
Tekion is the leading cloud-native DMS disruptor in a $6.8B market, with exceptional growth velocity and a defensible technical moat, but pre-profitability status and CDK competitive response create meaningful risks.
Fal is the leading infrastructure layer for generative media inference, with extraordinary revenue growth, a clear developer moat, and a $4.5B valuation backed by top-tier investors — but faces intense competition and unverified financial disclosures.
Gusto is a buy at $9.3B: $1B+ actual revenue, FCF-positive, accelerating growth, and a 9x multiple that is materially discounted vs. Rippling and Deel—positioning it for significant IPO upside when markets reopen.
Insider is a scaled global martech platform with credible product breadth and customer adoption, but limited public financial disclosure and a rich late-stage price reference argue for disciplined tracking rather than aggressive underwriting.
Applied Intuition is the dominant private platform for autonomous vehicle development infrastructure, with deep OEM penetration and a growing defense franchise; its $15B valuation is stretched on available evidence but defensible if undisclosed revenue confirms the claimed profitability and triple-digit growth trajectory.
Nozomi Networks is the global OT/CPS security market leader with 12,000+ deployments and $100M+ ARR, now operating as a Mitsubishi Electric subsidiary with an estimated EV of $1.4B–$1.8B at 9–11x ARR; recommend Track pending disclosure of deal economics and integration trajectory.
NinjaOne is the category leader in MSP RMM with 70% revenue growth, 35,000+ customers, and a verified G2 #1 position — but the $5B entry valuation is priced for continued high growth and requires blocking diligence (audited financials, NRR, SOC 2) before capital commitment.
Tines is a fast-growing, profitable-architecture workflow automation unicorn with strong ARR growth, deep customer relationships, and an expanding AI product surface — attractive at current momentum but priced for continued hyper-growth.
Hugging Face is the clear network-effect leader in open-source AI infrastructure with dominant platform position, strong ARR growth, and strategic investor alignment — but faces structural monetization risk from its free-tier model and unverified profitability.
Wiz is the fastest-growing enterprise security company ever built — $500M+ ARR in under 5 years, 40-45% Fortune 100 penetration, and a genuinely differentiated Security Graph architecture. At $32B (~64x ARR), the valuation reflects extraordinary expectations. The base-case IPO outcome is $17-25B (25-45% below the last private round). The bull case ($28-32B at IPO) requires sustained 38%+ ARR growth and public market multiple re-rating that current conditions do not support. Wiz is a conditional long: diligence- worthy, but entry at $32B requires explicit conviction in the bull case and a 3-5 year hold horizon.
Abnormal Security is the clearest AI-native disruption story in enterprise email security, with 100% ARR growth, 2,800+ enterprise customers, and a Gartner Magic Quadrant Vision leadership position validated by independent analysts. The $5.1 billion Series D valuation at ~25× ARR is steep relative to public cybersecurity peers (11–15× ARR), but is defensible if the company sustains 70%+ ARR growth through its targeted Q4 2025 IPO. The primary risks are Microsoft Defender's zero-marginal-cost bundling threat and multiple compression if growth decelerates. A **Conditional Buy** for sophisticated investors who can obtain NDR and margin disclosures in due diligence.
Databricks is a premier late-stage data-and-AI platform, but the current $134B price still looks stretched versus public comps and available disclosure.
QI Tech looks like one of Brazil's highest-quality private financial- infrastructure assets, but incomplete financial and operating disclosure keeps the current US$2B+ mark in TRACK territory rather than BUY.
Zerodha is a premium private brokerage platform with elite profitability and strong strategic positioning, but the current public valuation anchor looks fair rather than obviously cheap without better disclosure and transaction-quality price evidence.
Sigma Computing looks like a real scale-stage winner in warehouse-native analytics, but the current public file supports a constructive, conditional view rather than a high-conviction underwriting call because valuation-relevant quality metrics remain private.
Abridge has achieved best-in-class product-market fit in the fastest-growing segment of healthcare AI, backed by top-tier investors and a unique Epic distribution moat. The $5.3B Series E valuation prices in aggressive growth and market expansion that is not yet evident in confirmed revenue. Patient consent litigation and Epic's own AI roadmap are material risks. A compelling hold for existing investors; new investors should require revenue transparency before committing at current valuation.
Ironclad is a market-leading CLM platform with strong enterprise adoption and credible AI upside, but investors should still insist on retention, margin, and term-sheet proof before accepting the old $3.2 billion headline mark at face value.
Gamma is the most capital-efficient path to $100M ARR in AI SaaS and warrants a conditional buy at a 15–20% discount to the Series B price, subject to private diligence confirming net dollar retention, gross margin, and enterprise revenue durability.
DataSnipper has built a defensible Excel-native AI audit automation platform with Big Four validation and Microsoft partnership, but its $1B valuation requires sustained AI-tier ARR acceleration and carries material Microsoft Copilot competitive risk
Astribot is China's leading cable-driven humanoid-robot startup, reaching unicorn status on differentiated actuation technology and unusually fast commercial traction, but undisclosed financials and unproven autonomy keep this a qualified, medium-confidence Buy rather than a clean underwrite.
SmartHR combines a strong domestic compliance-software position with real ARR scale, but investors still need private-company economic evidence before paying a premium growth valuation.
Lenskart is a category-defining Indian eyewear platform with proven profitability, massive underpenetration-driven growth runway, and imminent IPO — but trades at a premium requiring sustained 30%+ growth to justify.
Vi Labs is a qualified BUY as a leading enterprise AI platform for healthcare data intelligence, supported by a $1.64B valuation, a 190M-record data moat, and 100+ enterprise customers, tempered by undisclosed financials.
Octane is a profitable, high-growth specialty fintech lender with a defensible moat in powersports and recreational markets; the $1.3B valuation is fair given GAAP profitability and 29% originations growth, making this a buy for specialty fintech investors with medium confidence pending full financial disclosure.
Gamma is the most capital-efficient path to $100M ARR in AI SaaS and warrants a conditional buy at a 15–20% discount to the Series B price, subject to private diligence confirming net dollar retention, gross margin, and enterprise revenue durability.
Nominal's 7x revenue growth and four-of-five-largest-defense-contractor deployment prove real product-market fit in a structurally underserved niche, but undisclosed absolute revenue and gross margin prevent a buy call at a $1 billion valuation that requires roughly $60–90 million of ARR to be supportable.
ICEYE is one of the strongest private space companies on public evidence, but the current price already assumes sovereign-contract execution and margin durability that outside investors still cannot fully verify.
Supabase has real platform traction and product depth, but limited public disclosure tempers conviction at a $2B valuation.
Nerdio is the category-leading Microsoft EUC management platform with $100M+ ARR, 85%+ growth, profitable operations, and unicorn status, but is subject to existential single-vendor risk from Microsoft and financial opacity that limits investment-grade due diligence.
Lambda Labs is the most credible independent GPU cloud challenger — NVIDIA equity alignment, 10k+ customers, and hyperscaler validation earn a conditional BUY at Series E terms, subject to ARR confirmation and CEO transition monitoring.
Anyscale is a strong buy for infrastructure-focused investors: it owns the dominant open-source distributed ML framework (Ray), has a credible enterprise commercial layer, and is well-positioned to capture the fast-growing AI infrastructure market — but open-source self-hosting risk and hyperscaler competition constrain revenue multiples.
Cribl is the dominant independent telemetry pipeline vendor with $300M+ ARR, 9,000+ enterprise deployments, and a five-product platform that makes switching costs substantial and churn unlikely—a compelling late-stage buy at current $3.5B valuation.
Fleetio is a category-defining fleet maintenance SaaS platform with a durable maintenance-first moat reinforced by the Auto Integrate shop network; the $1.5B+ valuation appears reasonable at 10–15x estimated ARR, but sustained growth execution and competitive resilience against telematics bundling are the key de-risking factors for investment.
Vanta is the leading GRC automation platform with $300M+ ARR, 63% YoY growth, and a defensible integration moat — a Conditional Buy at ~14× ARR contingent on NRR and margin confirmation.
Armis is a Gartner MQ Leader in CPS protection with 35+ Fortune 100 customers, $300M+ ARR, and 50%+ YoY growth; acquired by ServiceNow at 23x ARR — a fair price for a high-growth platform leader facing integration and OT depth risks.
ElevenLabs is the category-defining AI voice infrastructure company: 175% ARR growth, elite investor syndicate, and a defensible quality moat — but Series D entry at 33× ARR compresses new investor returns and requires the platform thesis to beat BigTech bundling.
BVNK looks like a real enterprise stablecoin infrastructure winner with a validated strategic exit, but public economics were too incomplete for a full-conviction pre-close buy call.
Earnix appears to be a strong, scaled vertical-AI decisioning platform for insurers and banks, but public evidence still supports a monitored diligence stance rather than a price-taking buy because retention, margin, and current valuation details remain private.
Astrotalk is a rare profitable, category-dominant consumer marketplace whose $1B unicorn mark is defensible in the base case, but reliance on self-reported metrics, India concentration, and a belief-based category argue for entry discipline rather than a blind chase.
Hadrian has real strategic momentum and unusual policy/customer support, but the August 2026 $7.87B mark leaves little valuation margin of safety without current revenue and margin disclosure.
Molbio Diagnostics has genuine business quality — profitable FY25 operations, WHO-backed TB credibility, and unusual field-deployment relevance — but the right recommendation remains Track until IPO pricing, concentration, and service-quality disclosure catch up with the story.
Foodics is a credible MENA restaurant-tech champion, but the public file still supports tracking rather than buying.
Factorial looks like a real European category leader in SME HR software, but the $2.5B valuation is best underwritten as a premium-growth bet rather than as a low-risk or fully transparent financial story.
Corgi is a high-conviction Series B1 insurtech with extraordinary revenue traction and a compelling full-stack carrier model, but a stretched $2.6B valuation, limited claims history, and unaudited financials warrant disciplined diligence before further investment.
Dataiku looks like a real late-stage enterprise AI leader with fair current valuation support, but the lack of public margin, retention, and cash disclosure keeps it in track rather than buy territory.
Starburst appears to be a strong private data-infrastructure asset with real ARR, retention, and regulated-customer proof, but public disclosure gaps around retention cohorts, concentration, margins, cash, and round structure make research-more a more defensible call than an unconditional buy.
Bambu Lab is a rare profitable consumer-hardware breakout with real platform potential, but the current ~$10B rumor zone looks stretched relative to public comps and still lacks enough disclosure for a buy call.
AlphaSense is a category-leading AI market-intelligence franchise with exceptional growth and a full but defensible $7.5B valuation, gated only by undisclosed profitability and retention.
Corgi is a high-conviction Series B1 insurtech with extraordinary revenue traction and a compelling full-stack carrier model, but a stretched $2.6B valuation, limited claims history, and unaudited financials warrant disciplined diligence before further investment.
Legora has category-leading growth in legal AI, but the current valuation already prices in a large share of the upside.
Kailera is one of the best-capitalized public obesity biotechs and already has unusually strong precommercial efficacy positioning, but public investors still need global Phase 3 confirmation before the valuation case graduates from a catalyst-driven track posture to a clear buy.
Govini looks investable because it has crossed meaningful ARR scale and built a real DoD software moat, but conviction is capped by sparse disclosure on retention, concentration, and unit economics.
Cognite shows real industrial-AI traction and top-tier customer proof, but opaque private-market pricing and incomplete financial disclosure justify a TRACK recommendation rather than an immediate buy.
Illumio is the undisputed microsegmentation leader with 1,000+ enterprise customers, a 12-year technical head-start over Big-4 platform rivals, and powerful regulatory tailwinds from DORA and CISA zero-trust mandates — but private financial opacity, long sales cycles, and Big-4 platform consolidation risk make this a monitored conviction-buy, not a slam dunk.
Nuvemshop is the dominant LatAm e-commerce infrastructure play with a strong moat, but a compressed valuation environment and execution risk on financial services expansion warrant a cautious buy at fair pricing.
CFS is the highest-quality, most credibly funded private fusion company globally, with the world's most advanced Q>1-targeting tokamak (SPARC), the first signed corporate fusion PPAs (Google + Eni), and a $3.2B investor base led by Breakthrough Energy Ventures, Khosla, and Eni. SPARC first plasma (2026) and Q>1 (2027) are the next binary milestones that determine whether CFS can close the $3–5B ARC construction capital gap. At an estimated $5–8B valuation, the market prices a ~65% SPARC Q>1 probability; the primary underpriced risk is tritium breeding (TRL 2–3 globally), which could delay ARC commercial operations regardless of SPARC success. Constructive on a 6–10 year horizon for deep-tech energy transition funds.
Exotec is Europe's most differentiated warehouse robotics vendor with a defensible 3D AMR moat and a $400M Next-Gen backlog — conditional positive at base-case pricing, subject to four pre-investment diligence conditions.
Spinny has built a credible scaled franchise in India's formalizing used-car market, but incomplete disclosure and GoMechanic integration risk make the current valuation hard to underwrite aggressively.
Morpho has a credible claim to becoming a core rail for embedded onchain credit, but public valuation underwriting still hinges on unverified monetization and concentration assumptions.
LiveKit has real strategic relevance in voice AI infrastructure, but the current $1B mark merits tracking rather than aggressive underwriting until ARR, margins, retention, and concentration are disclosed.
Kraken is one of the strongest private utility-software assets in market, but the current $8.65B valuation already assumes a clean transition to software-grade economics and disclosure.
ClickHouse has strong product-market pull, credible cloud monetization, and marquee customer adoption, but its private-market valuation already prices in substantial future execution despite limited public disclosure on revenue quality and margins.
Tailscale looks like a strong, technically differentiated secure-networking company with real customer love and credible category expansion, but the April 2025 Series C valuation remains hard to underwrite cleanly without public ARR, margin, and retention disclosure.
Outstanding enterprise AI platform with real revenue and traction; $7.2B valuation at 36x ARR provides insufficient margin of safety given hyperscaler bundling risk and undisclosed NRR.
Resulticks combines real scale, growth, and profitability with a still-conditional public exit process, making the opportunity attractive but not yet fully de-risked.
DDN looks like a real AI-infrastructure winner, but the public-evidence case is not yet strong enough to call the $5B valuation clearly attractive without deeper diligence or better terms.
Neros Technologies is a high-conviction defense-tech drone company that combines an explosive Series C valuation ($2.5B) with credible evidence of active US military deployments, genuine production scale, and strong investor backing from Sequoia and defense-oriented funds. The primary risks are DoD budget concentration, execution risk on the 1M drones/year target, and regulatory/competition exposure from larger primes. Recommend watch with active follow-on interest.
Dental Monitoring looks like a credible orthodontic workflow leader with unusually strong public customer proof, but current public evidence still supports research-more rather than a confident premium-price buy because retention, financing terms, and audited economics remain private.
Muon Space's end-to-end Mission Foundry model and government contract traction position it as a credible space infrastructure platform, but a $1.5B valuation at 11 satellites in orbit demands flawless manufacturing execution.
Neo4j is a real category leader with strong enterprise proof and credible AI-era upside, but the current ~$2B context looks fair rather than obviously cheap until margin, retention, concentration, and AI-conversion metrics are disclosed.
Genius AI has real category traction and an increasingly credible AI product wedge, but private-company opacity on margins, retention, and governance keeps the stock-underwriting posture at track rather than full conviction.
CAIS is a credible category leader in a growing alternatives-infrastructure market, but the current valuation still warrants TRACK rather than BUY until audited economics and cap-table terms are visible.
HiBob has credible scale, broad product ambition, and strong strategic logic, but investors should treat the current unicorn mark as premium and only partially underwritten until newer audited metrics surface.
EF's $1.3B unicorn valuation is well-anchored by $1.44B implied portfolio equity, validated by world-class informed investors, and driven by a genuinely differentiated pre-idea talent investor model — but the Matt Clifford conflict-of-interest risk and absence of public financial metrics represent material diligence gaps that must be resolved before institutional commitment.
Oxylabs looks like a real AI-era web-data infrastructure winner, but the current $3.6B mark already prices in meaningful quality and leaves too little public-evidence edge for a buy call.
Yanolja combines a valuable Korean travel-platform franchise with a promising higher-margin enterprise software engine, but the frequently cited US$10B valuation looks stretched versus public travel-platform comps and the company’s still-limited disclosure depth.
Square Yards is a fast-growing, newly-minted Indian proptech unicorn with strong revenue growth (48% YoY) and improving profitability (8% EBITDA margin), differentiated by its integrated full-stack model, but facing execution risk from IPO timing, debt structure opacity, and competitive convergence.
Moloco appears to be a scaled, profitable, strategically relevant adtech platform, but the lack of current audited financials, retention data, and clean post-2023 transaction evidence keeps the investment case in track territory rather than buy territory.
Ollin combines unusually strong private financing and encouraging OLN324 head-to-head data, but opaque economics and undisclosed valuation keep the investability call at watchlist level rather than conviction underwriting.
Profound is the best-funded and most-recognized platform in a real and rapidly growing category, but the $1B valuation looks stretched without ARR disclosure, and incumbent SEO vendors are closing the product gap quickly.
Sun King is a category-leading PAYG solar platform with unmatched distribution and capital-markets innovation, but opaque financial disclosure and frontier-market credit/FX risk justify disciplined valuation underwriting rather than an immediate buy.
Synchron has achieved the critical clinical derisking milestone of a feasibility trial primary endpoint and is now the only endovascular BCI with a clear path to FDA PMA. Its minimally invasive profile eliminates the craniotomy barrier — the primary adoption constraint for brain implants — and its Apple and NVIDIA integrations validate the platform for commercial deployment. The $200M Series D at an implied $1B+ valuation prices in successful pivotal trial execution; failure to meet the pivotal endpoint or obtain CMS reimbursement would be existential. A high-conviction track position for investors with multi-year medical device timelines.
Blitzy has proven, named enterprise product-market fit with measurable velocity gains, but faces intense competition at a stretched $1.4B valuation that prices in undisclosed ARR growth.
Mews is the strongest independent challenger to Oracle's hotel PMS hegemony, with genuine category leadership in cloud-native hospitality infrastructure, a $2.5B Series D, and compelling 55% SaaS gross-profit growth — but financial opacity prevents full valuation underwriting and an NYU 2026 study signals structural headwinds for all-in-one platforms.
Altruist has built a defensible vertically integrated RIA custody platform with strong growth metrics, but proceed-with-diligence is warranted pending audited financials and cap-table transparency.
webAI is a differentiated sovereign-AI platform with real production proof, but a $2.5B valuation on undisclosed revenue makes it a track-and-re-underwrite name rather than a conviction buy.
Nord Quantique is a technically credible quantum hardware leader with a genuinely differentiated bosonic error-correction approach, but remains pre-revenue and faces intense competition and execution risk on a demanding 2030 fault-tolerance roadmap.
Well-funded Series C security intelligence platform with strong market tailwinds but unproven unit economics and legacy reputational risk
La Renon is India's standout chronic-therapy branded-generic compounder, with verifiable 25%/30% revenue/EBITDA CAGRs, a Rs 11,000 crore valuation backed by five institutional investors, and a leadership position in nephrology — but the 31–33x EBITDA multiple leaves little margin for execution risk in a private, disclosure-light structure.
Greenko is India's foremost private renewable energy platform with unmatched IRES storage technology and strong sovereign backing, but a leverage-and-execution overhang means its ~USD 7.5B valuation is fair rather than cheap, and the investment case hinges on delivering its FY26-FY27 commissioning-and-deleveraging plan.
Carsome is SE Asia's dominant used car unicorn that achieved its first profitable year in 2024 and is approaching IPO readiness — a compelling late-stage opportunity with execution risk and an aging $1.7B valuation mark.
Zopa Bank is a rare profitable UK neobank unicorn with a strong revenue base, sector-leading unit economics, and a credible path to everyday-banking scale — currently fairly valued with execution and regulatory risks manageable but real.
Gymshark is a high-growth DTC fitness brand with a durable community moat but faces deliberate profit compression, founder concentration risk, and escalating competition from well-capitalised challengers.
Harmonic is the leading formal-mathematics AI company, holding benchmark records at the IMO and VERINA level, but faces unproven monetization and a concentrated key-person risk from Vlad Tenev's concurrent Robinhood CEO role.
Cast AI delivers measurable cloud savings and AI-infrastructure optionality, but undisclosed revenue and round economics keep the unicorn valuation from looking clearly underwritten.
TerraPower is one of the most credible US advanced-nuclear commercialization stories approaching market entry, but public-only evidence still cannot support a clean underwriting call because valuation, economics, and fuel-chain details remain opaque.
Aven has created a genuinely differentiated fintech product—the home-equity-backed credit card—with strong early traction, but execution risk around the CCB bank dependency, FCRA litigation, and the untested 'machine banking' roadmap warrants a careful track rating ahead of any Series F or IPO.
Securiti AI achieved a strong strategic exit at $1.725B — validating its unified data platform thesis — but revenue opacity and post-acquisition integration execution remain the key unresolved questions.
Unitree is one of the few humanoid and legged-robot companies with visible product pricing, real revenue signals, and apparent scale, but policy risk and disclosure gaps justify a disciplined track stance rather than an aggressive buy.
Fictiv is a strategically valuable but still financially opaque digital manufacturing platform: MISUMI's $350M acquisition looks fair against the disclosed 2024 revenue base and public comp ranges, but independent underwriting remains constrained by limited private-company disclosure.
Dream Games is a CONDITIONAL BUY — Royal Match is one of the most capital-efficient mobile games ever built, but single-game revenue concentration, a stale 2022 valuation, and mounting gambling-regulation risk require heavy diligence before committing capital.
Horizon3.ai is the autonomous pentesting category leader with a FedRAMP-validated federal moat, 5,200+ customers, and 102% ARR growth—but its ~$1B unicorn valuation at undisclosed absolute ARR implies a premium multiple that warrants further diligence on revenue scale and customer concentration before conviction investing.
ElevateBio is a differentiated advanced therapy CDMO with a proprietary gene editing platform, $1.25B in total funding, and a strategic Novo Nordisk partnership, but faces meaningful execution risk from a January 2026 CEO transition and a 13% post-Series-D workforce reduction.
ReliaQuest is a well-capitalized late-stage cybersecurity leader with a compelling vendor-neutral Open XDR platform and strong enterprise traction, but faces intensifying competition from platform consolidators (Microsoft, Palo Alto, CrowdStrike) and carries meaningful risk from its undisclosed unit economics and key-person dependence on founder Brian Murphy.
Augury is a category-leading industrial AI company with strong customer proof points and a growing dataset moat, but its $1B+ valuation faces pressure from an incomplete financial picture and intensifying competition from well-resourced incumbents.
Solugen offers a compelling technology platform for sustainable industrial chemicals but faces significant scale-up execution risk as it ramps Bioforge Marshall.
Arctic Wolf is the leading pure-play MDR/SOC-as-a-Service provider with strong ARR growth and a broad platform, but faces valuation compression risk and integration execution challenges after rapid M&A.
Deel's owned-entity moat and $1B ARR at 75% growth justify a conditional buy at $17.3B — but audited margins and RICO litigation reserves are pre-commitment break conditions.
Dexterity has the most commercially validated physical AI platform in warehouse logistics, but the $1.65 B entry price at ~25× ARR requires a near-term Series D to sustain the capital-intensive RaaS deployment model.
Kiteworks is the compliance-grade private content network leader: profitable, growing at $130M+ ARR, with a defensible FedRAMP moat — but Accellion's breach legacy and an unaudited financial profile require disciplined diligence.
ThreatLocker is a high-growth unicorn with a differentiated default-deny Zero Trust approach and strong MSP channel traction, but faces revenue transparency gaps and increasing competition from well-funded incumbents.
Porter has established dominant market leadership in India's intra-city logistics segment, reached unicorn status in 2025 with strong revenue growth and first-ever profitability, but faces structural gig-economy regulatory risk and an unclear IPO timeline.
Twelve has the right technology, team, and customers to become the defining PtL-SAF company—but the entire thesis hinges on AirPlant One's commercial performance, which remains unproven.
Altana holds a defensible government-validated moat in supply chain AI compliance with a proprietary data flywheel and no direct certified competitor, but private financials and professional services complexity require data room validation before committing.
Notion is the AI workspace category leader with 100M+ users, $500M+ ARR, and accelerating AI monetization — but trades at a stretched 22x ARR multiple vs. public comps, with key unit economics (NRR, gross margin) undisclosed.
Flo Health is the dominant consumer femtech app globally with a defensible data moat, strong MAU growth, and confirmed positive cash flow, but opaque financials, ongoing privacy litigation, and Apple's native competition constrain the risk-adjusted upside at $1B+ valuation.
Saronic is the leading pure-play autonomous naval vessel startup with strong Navy traction, but its premium valuation and single-customer concentration warrant careful monitoring.
Runway is the best-positioned independent generative video AI company, with strong revenue momentum, a differentiated product roadmap anchored by GWM-1, and deep enterprise partnerships — but faces meaningful legal, competitive, and profitability risks that stretch its $5.3B valuation.
Agility Robotics has achieved what no other humanoid robot company has: a proven, production-grade commercial deployment at scale. With 100,000+ totes moved at GXO Logistics, a $641M funding base, and a dedicated manufacturing facility targeting 10,000 units per year, Agility holds a 12–24 month commercialization lead over the field. The central investment question is whether it can convert this first-mover advantage into durable market position before better-funded competitors (Figure AI at $39B valuation, Tesla Optimus with manufacturing scale) close the deployment gap. Unit economics are unproven at scale, customer concentration is a real risk, and cooperative safety certification remains the gating technology for broader adoption.
MENA's most valuable fintech and dual-year profitable BNPL leader enters IPO runway at a stretched $3.3-4.5B valuation; dominant KSA positioning and wallet expansion support a Track rating pending audited IPO financials.
Vercel is the dominant Frontend Cloud with genuine competitive moats through Next.js stewardship and the AI deployment flywheel. At $9.3B (27x ARR), the valuation is fair on a growth-adjusted basis but thin on margin of safety — CONDITIONAL PASS pending NRR and gross margin disclosure.
KLAS #1 Healthcare AI Platform at Reasonable Forward Multiple — Conditional Positive Subject to ARR and Gross Margin Diligence
Monzo is the UK's first profitable digital bank at scale — fair entry at $5.9B with 2–3× MOIC if IPO re-rating occurs; track with conviction pending FY2026 revenue print.
Cursor is the fastest-growing developer SaaS in history at $2B ARR, with category- defining AI coding leadership and 64-70% Fortune 500 penetration (company-claimed). At $29.3B valuation (14.7x ARR), the entry is defensible against high-growth public comps but priced for gross margin improvement that has not yet materialized. The SpaceX $60B acquisition option caps near-term returns at ~2x; investors must secure governance rights to the acquisition decision and confirm gross margin improvement trajectory before this investment clears a 3x+ return threshold. Recommendation: SELECTIVE BUY (conditional).
Synthesia is the enterprise AI video market leader — a conditional investment at $4.0B. The company's top-decile metrics (142% NRR, 66% ARR growth, 77%+ gross margin, 70%+ Fortune 100 penetration) justify a premium revenue multiple, but the 27x trailing ARR valuation leaves little margin for execution error. Key risks — EU AI Act compliance gap, undisclosed GRR, and Microsoft/Google AI video bundling — require diligence completion before commitment. CONDITIONAL PROCEED for high risk-tolerance investors with AI regulatory expertise. HolonIQ added Synthesia to its EdTech unicorn list in December 2025 at $4.0B, validating enterprise L&D adoption quality.
OpenPayd combines real scale, regulatory progress, and differentiated stablecoin-linked infrastructure, but the announced valuation already assumes meaningful future proof on margins, retention, and concentration that public sources do not yet fully disclose.
Emerald AI has a real product and market wedge in AI-power flexibility, but the August 2026 $1.05B Series A already prices in substantial forward revenue conversion that public evidence does not yet prove.
Megazone Cloud is a real scaled cloud leader, but the current >KRW 4T private mark already prices in a premium that public evidence has not fully closed.
Fivetran looks like a high-quality enterprise data-integration asset, but the current 8.42B qualification mark still appears stretched without private financial disclosure.
Metsera proved it could build a strategically valuable obesity platform quickly, but the standalone investment opportunity ended when Pfizer acquired and delisted the company in 2025.
LaunchDarkly looks like a real late-stage infrastructure winner, but the public evidence still supports a track posture with price discipline rather than an aggressive premium-entry call.
CARS24 has enough scale, market position, and FY26 operating improvement to stay investable, but the public-evidence recommendation remains track because the $3.3B anchor is stale and too many valuation- critical disclosures remain private.
Monte Carlo looks like a real late-stage category leader with credible customer and product proof, but current public evidence still supports a track / research-more stance rather than a clean buy because valuation and operating-economics support remain incomplete.
Emergent Cold LatAm is a likely category leader in Latin American cold-chain logistics, but public evidence still supports only a research-more recommendation because the exact valuation and core economics remain undisclosed.
Cambridge Aerospace has built the most credible low-cost drone-interceptor franchise in Europe in under two years, but at $3.4B it is priced for a future that is still largely unproven at scale.
Dhan looks like a real, profitable challenger in Indian retail broking, but concentration in derivatives and thin private-company disclosure keep the last-round valuation in the fair rather than clearly attractive bucket.
Base Power has real operating momentum and a differentiated residential-battery model, but the August 2026 $13B Series D already prices in national-scale execution and economics that public evidence still does not prove.
Compelling synthetic-behavior platform with marquee enterprise proof and elite research lineage; current $2B price is plausible but full given unresolved economics, governance, and terms disclosure.
Icertis looks like a real late-stage enterprise software asset with durable category demand and strong ecosystem leverage, but current valuation still requires disciplined diligence because disclosure remains partial and governance continuity is newly important.
Cockroach Labs looks like a real late-stage infrastructure winner candidate, but the current private-market price appears stretched relative to public evidence on revenue and efficiency.
Blip has credible scale, profitability signals, and dense customer proof, but public evidence still does not reveal the current round price, preference stack, or enough retention and margin detail for a high-conviction buy call.
Global Eggs is a scaled and strategically credible multinational egg consolidator, but the announced valuation already prices in integration success and earnings quality that the public file does not fully prove.
Raise/Dhan looks like a real, profitable challenger in Indian retail broking, but concentration in derivatives and thin private-company disclosure keep the last-round valuation in the fair rather than clearly attractive bucket.
TRACK: Uzum has credible national scale, ecosystem breadth, and reported profitability, but the current $2.3 billion reference point looks fair-to-stretched for new common equity until valuation terms and segment economics are cleaner.
Baseten is a high-quality AI inference infrastructure company with real enterprise traction and strong category positioning, but public financial disclosure is too thin to justify treating momentum pricing as a high-conviction buy.
MaintainX is a strong vertical SaaS operator in industrial maintenance, but the $2.5B Series D mark looks stretched without audited revenue, NRR, or margin disclosure.
Nourish has built a scaled, payer-aligned virtual metabolic-care platform with strong clinical and distribution signals, but the reported $1.75 billion 2026 valuation looks stretched until management discloses revenue, margins, and reimbursement durability in more detail.
Alan has built the strongest full-stack digital health-insurance franchise in France, but unresolved underwriting opacity, cyber dependency, and public-sector concentration keep the current €5B valuation in watchlist rather than buy territory.
Mollie is a profitable, fast-growing European payments platform with a credible SME leadership position, but its €5.4B Series C mark faces post-2021 multiple compression and a meaningful GoCardless integration execution risk.
Netskope is a best-in-class SSE/SASE platform with 116% NRR and 32% revenue growth, but trades at a 50% discount to cloud-security peers post-IPO, warranting a track/cautious-buy stance pending competitive clarification from Microsoft Entra SSE.
Coalition is the most differentiated technology-enabled cyber insurer in the US market, but complete financial opacity and the unpriced risk of systemic tail events mean a conditional proceed — not a buy — until the data room confirms the financial thesis.
Track Quantum Systems with price discipline: customer and product proof are strong, but private financials and regulatory/Ukraine exposure keep underwriting confidence at medium.
Moniepoint is Nigeria's dominant SME payment and banking infrastructure — 14B transactions, $294B TPV, 6M+ businesses — at a $1B valuation that implies ~1.7x revenue (compressed vs peers), but active CBN enforcement, NPL opacity, and no audited financials demand disciplined open-book underwriting before any new capital commitment above $2B pre-money.
Spring Health is the best-evidenced employer mental health unicorn globally, with a JAMA 2025 peer-reviewed RCT providing gold-standard clinical outcomes proof unavailable from any direct competitor. The $3.3B Series E valuation (April 2024) is the highest for an independent employer mental health benefits company and implies 11–25× ARR at a wide analyst estimate range ($130–300M). The investment thesis is a conditional buy: strong clinical proof, MHPAEA enforcement tailwind, and Alma-enabled multi-channel optionality support a premium valuation, but financial opacity (zero ARR disclosure), MHPAEA NQTL compliance risk, and unquantified Guide AI clinical liability create material conviction gaps that require data room access before term sheet. For growth-stage investors with a 4–7 year horizon.
Island has category leadership and a financial services moat, but the $4.85B Series E prices in near-perfect execution — NDA diligence on NRR and burn is required before any investment.
Carrier Network Moat and 30%+ Growth Earn Conditional Buy at Secondary Discount — NRR and Gross Margin Disclosure Required Before Full Commitment
Revolut's banking licence, $4B revenue, and $1.4B profit justify a CONDITIONAL BUY at $75B; regulatory execution risk and crypto revenue cyclicality bound the margin of safety.
Rippling looks like one of the strongest compound-software companies in workforce operations, but public evidence is still too thin to endorse the $16.8B mark with confidence.
A rare, profitable, bootstrapped FMCG compounder now institutionally validated at a demanding ~₹35,000 crore — strong franchise, but a stretched multiple and private-company opacity warrant close tracking.
Lancium has genuine strategic value at the intersection of Texas power scarcity and AI campus demand, but the reported ~$10B mark still outruns the public disclosure set and requires disciplined, milestone-based underwriting.
Bitwarden is a well-positioned cybersecurity unicorn with strong open-source community trust and expanding enterprise reach, but faces monetization-opacity and trust-shock risk in a crowded credential-security market.
Base Power has a differentiated residential-battery plus retail-power model and real early Texas traction, but the latest $4B mark already prices in durable ERCOT economics and successful multi-state replication that public evidence does not yet prove.
PointClickCare is the dominant LTPAC EHR platform with structural retention moat and active IPO preparation — a compelling business at the right price, but unresolved revenue baseline ($480M–$673M), undisclosed NRR, and information-blocking litigation require resolution before committing at the $5B secondary market price.
Vivriti looks like a real scaled franchise in Indian mid-market credit, but leverage, concentration, and incomplete post-demerger transparency keep the current valuation in the fair rather than obviously attractive bucket.
Property Finder appears to be a strong regional property-marketplace asset with credible profitability signals and product breadth, but private-financial opacity keeps the current stance at research-more rather than buy.
Base Power has a differentiated residential-battery plus retail-power model and real early Texas traction, but the latest $4B mark already prices in durable ERCOT economics and successful multi-state replication that public evidence does not yet prove.
A fast-scaling sovereign AI infrastructure platform with real revenue and customer proof, but still too many valuation-critical unknowns to underwrite at full confidence from public evidence alone.
Beeline appears to be a strong private lupus-first immunology company with serious capital, credible mechanisms, and multiple shots on goal—but the right current call is research-more because public evidence still does not disclose the valuation, cap table, burn, or retained asset economics needed for price conviction.
Keyfactor appears to be a strong private trust-infrastructure asset with real enterprise and government proof, repeated sponsor validation, and broad product relevance—but public evidence still leaves enough ARR, retention, margin, concentration, and structure gaps that the right call is research-more with strict price discipline rather than an unconditional buy.
Oasis Security looks strategically important in a fast-growing identity category, but the current public file supports continued diligence more than outright conviction because valuation-relevant operating metrics remain undisclosed.
Augment looks like a serious enterprise AI coding platform with strong customer proof and a plausible near-unicorn valuation, but thin public economics keep the investment posture at track rather than aggressive buy.
Blackpoint Cyber looks strategically strong in MSP-first MDR, but public evidence still cannot underwrite a precise valuation.
Zero Hash appears to be one of the best-positioned compliance-first digital-asset infrastructure vendors, but the absence of public revenue and concentration data keeps the recommendation at track rather than buy.
RunPod has scaled to a reported ~$240M ARR with strong developer adoption and clear cost-positioning in GPU cloud, but limited disclosure and intense infrastructure competition keep the upside balanced by execution risk.
QuEra is one of the strongest private neutral-atom quantum companies, but public evidence still supports Track rather than Buy because repeatable economics and round terms remain opaque.
CtrlS is India's scaled domestic hyperscale data-center leader, but private-company opacity keeps the current price anchor in the track rather than buy bucket.
Juniper Square looks like a credible category leader in private-markets fund operations, but the public-evidence case is stronger for tracking than aggressive buying because valuation is full and audited financial disclosure remains limited.
UltraGreen.ai pairs rare public-market profitability with a strong consumables-led surgical imaging moat, but disclosure inconsistencies and execution questions keep the stock in track-not-buy-now territory.
Infra.Market is a scaled and differentiated construction-materials platform with real operating density and IPO relevance, but debt and cash-conversion quality keep the current valuation in the fair rather than attractive bucket.
Sonar is the category-defining code-quality and clean-code leader with massive developer adoption and deep Fortune 100 penetration, but financial opacity, a four-year-stale $4.7B mark, and AI-era SAST commoditization warrant tracking rather than conviction.
Modal has earned a track call by demonstrating $300M ARR with 5x growth in seven months, a diversified high-quality customer roster, and a technically differentiated serverless platform with Sandbox revenue exceeding one-third of total ARR — but the 15.5x ARR multiple is stretched, three major outages in May–June 2026 signal reliability risk, and complete opacity on gross margin and NRR prevents a buy call at the current price.
Deepgram appears to be a credible category leader in real-time voice AI, but the current $1.3B mark looks worth monitoring rather than aggressively underwriting until private financial denominators are disclosed.
Fresha has enough scale, product breadth, and profitability signal to merit active tracking, but public disclosure is still too thin and the >$1B mark looks stretched for a fresh buy.
Zenobē has real sponsor backing, operating proof, and infrastructure-scale relevance, but the public record is still too thin on economics and equity terms to underwrite a precise price.
ACS has unusually strong early military proof for a young counter-UAS startup, but the $2.2B Series B is ahead of public economic disclosure.
Pathos AI has assembled a credible AI drug development platform with strong pharma partnerships and a multi-asset oncology pipeline, but clinical and regulatory derisking remains early-stage with material key-person and concentration risks
Stoke Space's reusable upper-stage thesis is a real differentiator and its financing base is unusually strong, but a ~$3.42B secondary valuation already prices in significant execution before orbital proof, named customer conversion, or revenue disclosure are public.
EliseAI has crossed $100M ARR with dominant multifamily penetration and tier-1 backing, but a 22x ARR multiple and unresolved fair-housing regulatory exposure make the current price stretched for investors without regulatory diligence access.
Divergent has credible technical edge and defense-aligned market timing, but private-market pricing and sparse financial disclosure argue for a track stance rather than immediate conviction buying.
Base Power has a differentiated residential-battery plus retail-power model and real early Texas traction, but the latest $4B mark already prices in durable ERCOT economics and successful multi-state replication that public evidence does not yet prove.
Pathos AI has assembled a credible AI drug development platform with strong pharma partnerships and a multi-asset oncology pipeline, but clinical and regulatory derisking remains early-stage with material key-person and concentration risks
J&T Express is a scaled, profitable HKEX-listed express operator trading below prior private and IPO-era reference points; Buy for valuation, but only with medium confidence because China pricing, platform concentration, and governance risk keep the risk rating high.
Caris is a scaled precision-oncology platform with credible growth, improving profitability, and ample liquidity, but the stock looks closer to fair value than bargain territory while DOJ, reimbursement, and controls risks remain open.
Tulip is a credible industrial SaaS platform at the Series D stage with strong product differentiation and a strategic Mitsubishi Electric alliance, but revenue opacity and valuation premium at USD 1.3B require deeper financial diligence before conviction.
Delinea is a scaled identity-security platform with >$400M ARR, a broad product surface, and credible customer proof, but valuation and capital-structure opacity keep the name in track territory until a real pricing and disclosure event emerges.
Sysdig is the open-source-led CNAPP pioneer behind CNCF-graduated Falco, last valued at $2.5B in a May 2023 Series G, now navigating a more crowded and consolidated cloud-security market in which Wiz commands the agentless premium while Palo Alto and CrowdStrike bundle runtime security into platform sales; November 2024 layoffs and a 24-month financing pause warrant a conditional-buy / track stance pending verified ARR, NRR, and burn disclosures.
Figma is a market-defining design platform with best-in-class unit economics; selective buy below $38/share given limited margin of safety at current valuation.
Qonto has built the leading B2B neobank brand in France and is expanding profitably across Europe, but faces a valuation that implicitly prices sustained 20%+ growth in an increasingly competitive and regulated market.
Checkout.com is a technically differentiated, direct-acquiring enterprise payment platform with first-ever full-year profitability in 2025 and accelerating TPV growth, but the $12B valuation — a 70% discount from its 2022 peak — reflects genuine opacity risks from Jersey holding structure, key-person concentration, and the absence of new institutional capital for 3+ years.
Market-leading Indian bike-taxi platform with strong revenue growth and rapid loss compression, but elevated valuation multiple and persistent regulatory risk warrant a cautious buy stance.
Plaid is the structurally dominant US open-banking infrastructure layer with ~$546M estimated ARR, 70%+ market share, and accelerating product diversification, but private disclosure opacity, regulatory headwinds from CFPB Section 1033, and a Series D valuation overhang warrant a track stance at the current $8B implied valuation pending IPO S-1 confirmation.
Oura is the undisputed smart-ring category leader with clinical-grade biometric validation and a growing subscription revenue base, but the $11B valuation at an estimated 20-30x ARR is stretched and demands revenue and retention transparency before committing capital.
Redwood Materials has built a defensible position in US battery recycling with real technology, strong OEM partnerships, and critical IRA tailwinds, but faces substantial execution risk on its manufacturing scale-up and a challenging lithium price environment.
Mercury is a profitable, high-growth fintech banking platform with strong product-market fit among startups, a clear path to broader SMB expansion, and a defensible NIM-driven revenue model, but faces regulatory concentration risk from its partner bank model and growing competition from well-funded rivals.
Zepto is a high-growth Indian quick-commerce leader with strong revenue momentum and institutional backing, but faces significant profitability challenges and governance risks ahead of its IPO.
Vinted is a compounding European internet business — profitable, growing at 38%, with an integrated moat — but the April 2026 €8B secondary entry price (7.3x trailing revenue, 53x EBITDA) offers only modest base-case upside and material bear-case downside from regulatory and execution risks.
Vertically integrated autonomous weapons platform with deep DoD relationships; priced for perfection at $30B but uniquely positioned for defense AI secular tailwind.
Stord is a profitable cloud supply chain platform with G2 OMS leadership and $10B+ GMV — fair entry at $1.5B with 1.3–3x MOIC potential; favorable with material diligence conditions on churn, debt covenants, and SOC 2.
Astronomer appears to be a real category leader in enterprise Airflow and DataOps, but the public record supports a track decision rather than a clean buy because valuation, concentration, and margin transparency lag the strength of the product and customer evidence.
Cresta appears to be a real scaled contact-center AI platform, but absent trustworthy pricing and revenue-quality disclosure, the investable stance remains track rather than buy.
Crypto.com is a scaled and strategically broad crypto-financial platform with credible regulatory reach and a fresh $20 billion institutional price anchor, but the company still needs deeper private diligence before that valuation can be underwritten with high conviction.
Bucketplace has stronger fundamentals than many consumer unicorns because Ohouse now pairs category-leading home-living reach with real profitability, but the public record still does not justify paying confidently above the prior unicorn band without deeper diligence.
Quest Global is a credible scaled engineering-services platform with strong customer quality and a legitimate 2026 valuation anchor, but incomplete public disclosure keeps the underwriting case in track rather than buy territory.
SHINE is one of the more credible private nuclear-technology platforms on public evidence, but its undisclosed 2026 valuation terms and still-unproven Chrysalis economics justify a track stance rather than a buy call.
Recover has graduated from circular-fashion narrative to real commercial platform: it has scaled recycled-cotton capacity, named blue-chip customer proof, and a credible policy tailwind. But the company still withholds the financial detail needed to underwrite a premium late-stage price with conviction, so the current public-evidence conclusion is TRACK with a stretched valuation stance.
Research more: PDG is a serious APAC digital-infrastructure platform with fresh unicorn-plus validation, but public evidence is still too thin on realized economics and security terms to underwrite a narrow valuation.
Ionic has crossed the threshold from distressed mining successor to credible AI infrastructure platform, but the current valuation still requires patience because customer diversification and post-listing execution are not yet proven.
Lumin looks like a credible scaled digital-banking platform, but public disclosure is still too thin to underwrite the current private-market mark with high conviction.
Dash0 shows credible product-market pull and exceptional founder-market fit, but the unicorn valuation is difficult to underwrite without public revenue-quality metrics.
Nimble has credible product and strategic proof, but the $1B unicorn anchor still needs stronger public evidence on utilization, customer durability, and unit economics.
Gong has exceptional scale, growth, and category leadership in revenue AI, but current public evidence supports a watchlist stance because the 2021 primary valuation is stale and key underwriting metrics remain undisclosed.
Nord Security has enough scale, brand strength, and category breadth to merit continued diligence, but the current public record still supports research-more rather than buy.
Invisible Technologies has genuine enterprise AI traction and credible product breadth, but the latest >$2 billion price already assumes stronger forward growth and software-like economics than public evidence currently proves.
Ualá has real regional scale, product breadth, and continuing sponsor support, but limited consolidated disclosure and Mexico credit risk keep the case at TRACK with high residual risk and a fair, price-sensitive current valuation.
Socure looks like a real, scaled identity-and-risk platform with unusually strong private-company growth evidence, but unresolved valuation, disclosure, and control-system questions keep the investment posture at track rather than buy.
Grafana is a genuine late-stage observability platform leader with open-source-led scale and >$400M ARR, but the last hard >$6B valuation still looks fair-to-stretched until private financial quality becomes more transparent.
Tanium remains a scaled, strategically relevant endpoint-security platform with credible post-2024 unicorn valuation support, but investment underwriting still needs refreshed ARR, margin, retention, and cap-table disclosure before the legacy $9 billion narrative can be treated as fully durable.
CONDITIONAL INVEST — Enterprise Sovereign AI at 29x ARR with Copyright Overhang
Anthropic has real frontier-AI demand and a defensible $380B headline mark, but public disclosure still falls short of a clean buy case.
ClearScore is a scaled and profitable UK consumer-fintech platform, but the rumored 2026 IPO range looks stretched versus public comparables; track pending fuller disclosure or lower entry pricing.
Gatik has unusually strong commercial proof for autonomous freight, but the undisclosed round price and opaque economics keep the investment case conditional.
LiblibAI appears commercially real and strategically interesting at late-stage private scale, but the current valuation already prices in strong execution, so the right stance is disciplined tracking unless private diligence proves retention, margins, and moat quality.
OKX is a scaled and strategically important private crypto platform whose operational breadth justifies serious attention, but whose legal history and financial opacity still argue for price discipline and deeper diligence before paying a premium valuation.
Twenty has real strategic relevance and rare public customer proof in offensive cyber, but the current $1B mark warrants a track posture until revenue quality, margins, renewals, and control evidence are opened to diligence.
Kling has become one of the clearest breakout companies in AI video, but the reported July 2026 price already assumes substantial future execution success and leaves the risk-adjusted stance at Track rather than buy.
Track: Multiverse is one of Europe’s more credible sovereign-AI infrastructure stories, but the current $2.3B post-money valuation still looks stretched relative to the public economic proof available today.
Moss has credible late-stage fintech scale, differentiated European finance-workflow fit, and a fresh unicorn price anchor, but the current public record still leaves too much opacity on audited economics and capital-structure terms to justify a high-conviction buy at the latest mark.
Quantum Space pairs a differentiated national-security mobility thesis with real government traction, but the announced $1.2B valuation still sits ahead of flagship flight proof, funded- backlog transparency, and mature servicing-market evidence.
Eliyan appears strategically relevant and technically differentiated, but the visible unicorn valuation still runs ahead of the visible operating proof.
Reliable Robotics looks like a serious autonomous aviation leader, but the current private mark already prices in substantial certification and commercialization success.
Path Robotics has credible product, customer, and market proof, but the public record is still too opaque on economics and current pricing to support price-insensitive underwriting.
Veeam appears to be a scaled, high-quality private data-resilience leader, but the public record still does not fully justify paying above the known $15B secondary mark without targeted confirmatory diligence.
Meshy is the scale and mindshare leader in AI 3D generation with an exceptional user base and growth, but its ~$1.5B valuation prices in roughly 50x ARR against unproven monetization, intensifying big-tech and open-source competition, and a China-linked investor base.
Fast-growing, AI-native RCM platform with exceptional company-reported growth and retention, but an undisclosed valuation and largely private financials warrant deeper diligence before underwriting.
Arena looks like a real category leader in AI evaluation, but public evidence does not yet justify underwriting the reported $1.7B valuation with buy-level conviction.
Aledade looks like one of the strongest private physician-led value-based-care platforms, but the visible 2026 valuation still appears stretched relative to public comps once debt, policy risk, and disclosure gaps are considered.
Atom is one of the most credible neutral-atom quantum platforms, but a $2.06B private valuation on sparse public economics still supports RESEARCH-MORE rather than a conviction-priced entry.
Emergent has real breakout growth and a valuation that is supportable in context, but the public record still points to TRACK rather than a high-conviction buy.
Aira has built Europe's best-funded residential electrification platform, but must prove its subscription economics can sustain a ~EUR1.8B valuation against a policy-sensitive, still loss-making heat-pump market.
Track: Karrot is one of Asia's strongest local-network consumer platforms, but underwriting it above the reported 2025 private mark still requires more disclosure and more proof that ads and international expansion can compound cleanly.
Fast-growing category leader in grid digital twins with blue-chip utility traction, but backed by opaque financials and a valuation that looks stretched against estimated revenue.
Research more: Abound looks like a credible, profitable, and scaled UK open-banking lender, but exact valuation still depends on private evidence about round terms, debt structure, loan-book quality, and Render economics.
I-TRACING is a scaled French and increasingly pan-European MSSP with credible operating proof, historical profitability, and strong sponsor support, but the absence of a clean public current valuation and combined-group margin disclosure keeps the case in track rather than buy territory.
Firmus has unusually strong strategic validation for a private AI-infrastructure platform, but the current valuation already assumes successful multi-campus commercialization before public economics are mature enough to underwrite aggressively.
A category-leading institutional-blockchain platform with rare TradFi backing and live market-infrastructure workflows, but priced ahead of any disclosed revenue — a high-conviction, high-uncertainty track candidate.
Assort Health shows real product-market pull in healthcare patient access, but opaque unit economics and meaningful privacy, workflow-safety, and competitive risks keep the current $1.2B mark in watchlist territory rather than clear buy territory.
Exiger has credible scale, strong federal-grade differentiation, and a plausible AI-led supply-chain workflow moat, but opaque financial disclosure and concentration risks keep the reported unicorn valuation from being fully underwritten.
Track: Pine Labs is a scaled Indian merchant-commerce platform with improving profitability and credible valuation upside, but tax, breakage, and disclosure risks still block a cleaner buy case.
Motive's AI fleet platform has real scale and strong customer proof, but IPO execution and an active Samsara trade-secret suit are the key overhang risks at $3.08B.
Tessera has achieved the pivotal transition from platform company to clinical-stage asset, with TSRA-196 entering a global Phase 1/2 trial in early 2026 under FDA Fast Track and Orphan Drug designations. The Regeneron collaboration ($150M + $125M milestones) provides non-dilutive validation and a credible path to commercialization. Gene Writing's large-payload, no-double-strand-break mechanism is technically differentiated from CRISPR but unproven in humans. The January 2026 workforce reduction signals financial discipline but also execution risk concentration. The 2022 $1.7B valuation may not fully reflect current biotech market conditions; investors should model a 2028–2030 data readout horizon. A Track / research-more position is warranted pending Phase 1 safety and efficacy data.
KreditBee has credible scale, profitability, and a fresh unicorn valuation, but the public evidence does not yet make the April 2026 price look clearly cheap versus its credit, funding, and disclosure risks.
DevRev is a structurally differentiated AI-native enterprise platform with founder pedigree, rapid ARR growth, and a unique knowledge graph moat — but at 11.5x ARR it is priced for execution the company has not yet proven at scale.
Rohlik is Europe's most credible full-basket online grocer — profitable, growing at 34%, and building a technology moat via Veloq — but high capex, Germany losses, and a private market at an IPO crossroads keep the risk rating elevated.
Juspay is a scaled and now-profitable Indian payments infrastructure leader with real enterprise depth and an unusual open-source moat, but the current $1.2B valuation already prices in sustained growth despite India concentration and gateway-disintermediation risk.
Ather combines real EV scale, a differentiated charging-and-software ecosystem, and improving losses, but current public-market pricing already discounts much of the near-term upside; TRACK is the right stance.
HUMAN Security appears strategically relevant and plausibly fairly valued on disclosed scale and cybersecurity-peer benchmarks, but public evidence is not strong enough on ARR quality, retention, margin, and debt status to support a conviction investment call.
Highspot is a category-leading sales enablement platform at an inflection point — strong ARR scale and AI product momentum are offset by merger execution risk and an uncertain post-consolidation trajectory.
MoMo is Vietnam's undisputed #1 digital wallet with 56–60% market share, first profitable year in FY2024, and confirmed unicorn status — a strong position but facing intensifying competition from ZaloPay, regulatory friction, and a 4.8x revenue multiple that offers limited upside at the current $2B+ valuation.
A fast-growing LATAM identity-verification leader with real scale and revenue, but a stretched reported valuation, concentration, and biometric regulatory exposure warrant close tracking before conviction.
Galbot is a strategically credible but financially opaque Chinese humanoid robotics leader with real industrial deployments, world-class embodied AI, and state-backed capital — warranting close research and diligence before a commitment.
Kpler is a category-defining physical trade intelligence platform with a hard-to-replicate AIS data moat, confirmed rapid ARR growth, and 12,000+ enterprise customers—but the June 2026 Sixth Street entry at an implied 13–20x ARR multiple is stretched relative to public data-analytics peers, and zero disclosed unit economics (NRR, gross margin, churn) combined with the UK CMA antitrust review and a co-founder leadership transition prevent a buy call.
Basis appears to be a real category leader in agentic accounting automation, but the current valuation is ahead of what public economics can support.
Darwinbox shows real enterprise HCM momentum and a plausible path to $100M ARR, but public evidence still supports a TRACK / stretched stance rather than a clear buy at current pricing.
Quantexa is a scaled and strategically relevant Decision Intelligence platform, but public evidence supports TRACK rather than BUY until private diligence closes gaps on exact ARR, margin quality, burn, and the late-stage preference stack.
GlossGenius looks like one of the stronger beauty-vertical SMB software platforms in the U.S., but public evidence still leaves too much uncertainty on durability and economics to support more than a track posture at the unicorn valuation.
Semperis is the definitive identity-resilience platform for Active Directory and Entra ID, with $100M+ ARR, 1,000+ enterprise customers, and a durable AD-specific moat — but the $1B+ valuation at ~10x ARR is priced for continued high growth, and Microsoft bundling, opaque financials, and platform-consolidation pressure from CrowdStrike and SentinelOne make this a research-more rather than an outright buy at current price.
Bolttech has credible global embedded-insurance scale and strategic momentum, but public disclosure is still too thin to underwrite the June 2025 unicorn valuation with conviction.
Exabeam is the strongest independent SIEM/UEBA challenger thanks to its AI-native Nova platform, but near-term value depends on executing the LogRhythm integration without material customer attrition.
Bugcrowd is a genuine crowdsourced cybersecurity market leader—FedRAMP Moderate authorized, 1,200+ enterprise customers, 40%+ reported revenue growth, and a differentiated AI+human platform post-Mayhem acquisition—but the informal ~$2B valuation mark is stretched versus a base-case analysis of $1.2B–$1.7B, six critical diligence items remain unresolved, and financial opacity (no audited revenue, NRR, or gross margin disclosure) limits conviction; Track / Research-More pending data-room access.
Wireless Logic appears to be a scaled, profitable, strategically credible IoT connectivity platform, but the current private-market price still outruns the public evidence base.
Zum has built real late-stage scale in student transportation, but incomplete disclosure on margins, concentration, and EV project economics keeps the stock-story equivalent at research-more rather than buy.
Flatpay has rare SMB-merchant growth and a compelling simplicity pitch, but the public record still does not prove durable unit economics or enough disclosure to underwrite a €1.5B entry with high confidence.
n8n is one of the fastest-growing enterprise automation platforms in Europe, with compelling community moat, strong AI-native positioning, and institutional validation—but stretched Series C valuation and absent unit economics warrant a disciplined track rather than immediate buy.
Group14 is one of the most credible private battery-materials platforms in advanced anodes: it has real commercial deployments, a blue-chip strategic cap table, and a now-operating Korean production asset. But the underwriting case is constrained by BAM-2 execution slippage, policy and supply-chain dependencies, and sparse financial disclosure. On today's estimated valuation, the name looks interesting enough to track closely, but not yet de-risked enough to underwrite aggressively.
Chime looks like a scaled public consumer-fintech winner, but the current discount mostly reflects real sponsor-bank, regulatory, and disclosure risks rather than market misunderstanding alone.
Banco Plata's extraordinary growth — 3.4 million customers and USD 596 million annualized revenue in under three years — validates its model, but a 23.9% cost of risk, pre-profitability, concentrated wholesale funding, and a USD 3.1 billion valuation that demands sustained execution justify a TRACK stance until a clearer path to profitability and deposit funding is visible.
Writer has credible enterprise AI traction and differentiated full-stack product depth, but the $1.9B valuation already prices in sustained hyper-growth despite limited financial disclosure.
Track PathAI through Roche deal close: the strategic price looks reasonable, but standalone economics remain too opaque for a stronger call.
Underdog is a scaled consumer sports-gaming asset with real customer and revenue traction, but public evidence only supports a track recommendation because legal exposure and private-company disclosure gaps leave the current Series C valuation merely fair rather than clearly attractive.
Heartflow is a real, scaled public coronary-AI platform with strong growth, high gross margins, and meaningful installed-base proof, but at roughly 9x forward EV/revenue the shares already discount much of that quality before plaque economics, retention, and concentration are publicly visible.
Process Intelligence category leader at a stale $13B mark — track for IPO clarity, audited financials, and SAP-suit resolution before adding risk.
Saviynt pairs strong identity-security positioning and credible operating momentum with fresh KKR capital, but the current ~$3B mark still needs deeper diligence on round structure and audited economics.
Agibot is a credible production-scale humanoid robotics contender with a rare industrial proof point, but absent financial disclosure and growing geopolitical constraints justify a track-not-buy posture.
Employment Hero looks like a credible scaled SMB employment platform, but public disclosure is still too thin to underwrite the current private-market mark with high conviction.
Klarna is a scaled BNPL pioneer that reached public markets in 2025, but its post-IPO profitability path and regulatory headwinds in its two largest markets make the valuation case evidence-sensitive.
Insilico Medicine has the strongest clinical proof in AI drug discovery, but financial opacity and Phase 3 binary risk prevent a buy recommendation today.
Navan (NAAM) is a well-differentiated corporate T&E platform with strong NRR and expanding margins, but GAAP profitability has not yet been confirmed; CONDITIONAL HOLD at $18.46 with BUY trigger at $14-16 or first GAAP profitable quarter.
Isomorphic Labs holds the strongest IP position in AI drug design via AlphaFold 3 commercial exclusivity and three signed pharma partnerships, but its $16 billion private valuation embeds milestone-conversion assumptions unsupported by any public clinical evidence; TRACK pending ISM8969 Phase I data and first milestone payment.
ConcertAI is a conditional BUY at the ~$1.9B implied valuation; a differentiated multi-modal oncology AI stack and near-monopoly pharma penetration support the thesis, but unresolved CEO vacancy, opaque financials, and inability to verify the Goldman Sachs round from primary sources require blocking diligence before conviction.
Pentera is the clear AEV category leader at $100M ARR and a $1B valuation, but NRR opacity, competitive commoditization risk, and Israel-based operational exposure warrant rigorous private diligence before investing at current multiples.
Harness has real enterprise-DevOps traction and a credible AI differentiation story, but the 22x ARR entry multiple demands NRR, margin, and FedRAMP validation before conviction.
Pennylane is the category leader in French cloud accounting with a defensible dual-channel model and a regulatory tailwind, but the €3.6B valuation at centaur ARR implies a 30-35x revenue multiple that demands sustained 40%+ growth and successful international expansion.
Stegra is the most advanced large-scale green-steel project in Europe with strong customer commitments and ~€7.9B in disclosed financing, but pre-revenue first-of-kind construction risk, green-hydrogen cost uncertainty, and the recent €1.4B 2026 add-on raise keep underwriting confidence in the medium band.
Lightmatter is the leading photonic interconnect bet for AI infrastructure, but its $4.4B valuation demands near-term commercial proof that remains unverified; track with a focused list of diligence catalysts before committing.
KoBold Metals has built the most commercially validated AI mineral exploration platform in the world — as evidenced by BHP and Rio Tinto JV partnerships — and holds the Mingomba copper-cobalt deposit, one of the world's highest-grade undeveloped copper projects. The $2.1B Series C valuation is broadly defensible at base copper prices, but the investment requires patient capital (10-15 year horizon), carries above-average geopolitical risk (Zambia/DRC), and depends on an unverified AI performance premium. Recommendation: Conditional Hold — await the Mingomba Bankable Feasibility Study as the first major de-risking catalyst.
FourKites is a proven supply chain visibility leader with durable enterprise relationships and a credible agentic AI pivot, but limited financial transparency and a challenging late-2022 valuation anchor make a watchful track posture appropriate until a liquidity event or re-rate materializes.
WHOOP enters 2026 with credible IPO optionality, 103% bookings growth, and a $10.1B valuation that is rich but defensible against the closest private comparable (Oura) and anchored by positive free cash flow.
Meesho's zero-commission model and Tier-2/3 reach make it a structurally differentiated IPO at an attractive 1.4x EV/NTM Revenue, but thin take rate, profitability timeline, and intense competition from Flipkart and Amazon justify a selective accumulate stance rather than outright buy.
Research-more: Back Market is the undisputed global leader in refurbished electronics with proven unit economics and first profitability, but its 2022 peak valuation ($5.7B) has compressed meaningfully; secondary signals and multiple compression suggest a fair-value range of $4.5–6.5B, warranting deeper diligence on cap-table structure, competitive erosion in Germany, and IPO timing risk.
Maven Clinic is the category-defining leader in employer-sponsored women's and family health, with strong traction and clinical ROI evidence, but an unproven path to profitability and a $1.7B valuation that requires sustained 30–50% ARR growth to justify.
ClassDojo owns an unassailable K-12 distribution moat but its $1.25B valuation is stretched at ~12-13x unconfirmed ARR; the investment thesis requires Plus conversion acceleration and institutional SaaS traction to close a significant valuation gap before a 2026-2028 exit window.
Snyk is the defining developer-security platform with over $300M ARR and 4,478 customers, but faces material valuation compression risk, intensifying platform-native competition from GitHub and GitLab, and uncertainty around its IPO exit path given the gap between its 2022 peak valuation and current SaaS market multiples.
Collaborative Robotics is an early-commercial-stage AMR company with exceptional founding pedigree, strong enterprise customer proof, and a well-funded runway, positioned to compete in a large and growing warehouse automation market — but hardware economics, competitive pressure, and key-person concentration warrant a watchful posture with a conditional buy recommendation subject to financial and IP diligence.
Torq is the most credible pure-play AI-SOAR challenger to incumbent SOAR platforms, but the core thesis rests on an unaudited autonomous resolution claim and a 1–2 year window before XDR native AI triage commoditizes its Tier-1 value proposition.
Groq has compelling speed moat and developer traction, but the $6.9B valuation requires execution on $500M+ revenue and a successful Gen2 LPU ramp amid intensifying competition.
Huntress is the defining SMB MDR vendor with strong channel scale and product breadth, but its $1.5B+ valuation demands proof of ARR velocity and margin quality not yet in the public record.
Zipline is the drone delivery category leader with a verified operational track record, but the $4.2B Series F prices in US consumer unit economics that have not yet been demonstrated — a conditional positive for patient investors with regulatory risk tolerance.
Motive's AI fleet platform has real scale and strong customer proof, but IPO execution and an active Samsara trade-secret suit are the key overhang risks at $3.08B.
Chainguard has built the deepest supply chain security moat in the market — SLSA L3 provenance, nightly zero-CVE rebuild, and Wolfi OS represent 4+ years of engineering investment that is hard for CNAPP incumbents to replicate. Strong regulatory tailwinds (EO 14028, NIS2, DORA) and a growing developer-led pipeline support the long-term thesis. However, the 87.5x trailing ARR entry multiple is priced for perfection and leaves no margin for execution failure. Recommendation: HOLD — upgrade to BUY on confirmed FY2026 ARR ≥ $80M with NRR ≥ 120%.
Harvey is the defining legal AI franchise at an aggressive but potentially defensible $11B valuation — with elite customer anchors, deepening data moats, and a credible path to $1B+ ARR, but meaningful dependency, audit, and multiple-compression risks.
Preply looks like one of the more credible surviving edtech unicorns, but the $1.2B mark still needs private financial proof.
Wujie pairs unusual early capital with one of the strongest disclosed Chinese humanoid order signals, but opaque economics and concentrated commercialization risk keep the company in track territory.
Zhuji Dynamics has achieved a late-stage humanoid robotics financing and IPO-preparation milestone, but public evidence still leaves customer economics, deployment scale, and governance transparency too thin for a buy recommendation.
Guardio looks like a legitimate late-stage consumer-cyber breakout with a differentiated browser-security wedge, but the public record is still too thin on retention, margin, and partner economics to underwrite the current valuation with high conviction.
Vestwell is a scaled, category-relevant savings-infrastructure company with a defendable $2B public valuation anchor, but the absence of public margin, retention, and concentration detail keeps the investment call conditional.
Material Security has credible cloud-workspace security differentiation and unusually strong customer proof, but the 2022 unicorn mark is now too stale—and the current financial record too opaque—to support a full-price conviction call from public evidence alone.
boAt is a scaled and now-profitable Indian consumer-hardware brand with real public-market potential, but governance overhang, service-quality friction, and category commoditization make it a price-disciplined track rather than a high-conviction buy.
Track: Zhiyuan is a credible China humanoid frontrunner with real deployment proof, but the current public mark already prices in more confidence than the public economics can yet support.
Carousell has improved enough operationally to justify serious investor engagement: FY25 revenue reached US$141M, recommerce is now 45% of revenue, and the group reported positive EBITDA. However, the company still sits in a difficult middle ground between premium private recommerce winners and cheaper public resale comps, while trust, competition, and disclosure gaps keep the 2021 unicorn valuation from becoming an easy premium case. The right posture is conditional: track closely, lean in on diligence, and only upgrade conviction if FY26 proves durable, risk-adjusted profitability.
Cover Genius has credible global embedded-insurance scale and real partner proof, but public disclosure is still too thin on economics, concentration, and security terms to underwrite the July 2026 USD 1.9B mark with high confidence.
Main Func remains investable on public evidence, but only for investors willing to do proof-heavy diligence and maintain price discipline against a valuation that has already stepped up aggressively.
Newsela looks like a real district-scale instructional platform with enough ARR and customer proof to merit active tracking, but the public record still supports price discipline rather than a fresh buy at the historical unicorn reference.
Cabify looks operationally stronger than many mobility peers because public evidence supports scale and profitability, but exact valuation confidence remains limited by stale pricing anchors, regulation, and thin structural disclosure.
Crusoe has built a differentiated power-first AI infrastructure platform, but the post-Series-E valuation already assumes successful hyperscale execution that public evidence does not yet fully underwrite.
Kairos Power is one of the strongest strategic platforms in advanced nuclear, but public-only evidence supports a track stance rather than a buy because valuation and economics remain under-disclosed while first-of-a-kind execution risk stays high.
Palmetto appears to be a strategically interesting private residential clean-energy platform with real scale, repeat financing access, and credible product breadth—but public evidence still leaves enough margin, portfolio-performance, and capital-dependency gaps that the right call is research-more with strict valuation discipline rather than an unconditional buy.
Kakao Mobility looks strategically important and competitively resilient in Korea, but the public case still deserves a discount for antitrust overhang, sponsor complexity, and thin standalone financial disclosure.
Expel looks like a real, premium MDR asset with credible growth and customer proof, but the current valuation should only be underwritten after private confirmation of retention, margins, concentration, and runway.
Research more: Datavant appears to be the leading U.S. healthcare-data connectivity platform, but public evidence is still too thin on current economics to underwrite a premium valuation with high conviction.
X Square Robot is a strategically credible embodied-AI startup with a real model-and-data flywheel and elite capital backing, but opaque economics and a stretched valuation keep the right call at research-more.
Crusoe has built a differentiated power-first AI infrastructure platform, but the post-Series-E valuation already assumes successful hyperscale execution that public evidence does not yet fully underwrite.
nesto's C$1.47 billion Series E valuation is anchored by genuine operational scale — C$80B+ MUA, C$37B+ 2026 originations, and confirmed profitability — and by high-quality institutional backing from La Caisse and Fidelity, but revenue opacity, balance-sheet funding dependency, and unresolved M3 channel concentration prevent conviction; the evidence supports a track recommendation at a fair valuation.
Eve has real plaintiff-law workflow traction and elite investor backing, but public revenue and retention opacity still make the unicorn valuation difficult to underwrite aggressively.
Vuori appears to be a genuinely strong and profitable premium activewear brand, but the last $5.5B mark still looks too expensive to underwrite confidently without audited financial disclosure.
1KOMMA5° has real scale and plausible software upside, but public evidence still supports a RESEARCH-MORE stance because valuation support, preference terms, and realized Heartbeat economics remain too thin for a conviction buy.
Rokt merits tracking at the US$3.5 billion secondary valuation because public evidence supports scale, growth, and strategic breadth, but private-company opacity prevents a higher-conviction underwriting call.
Anaconda is a real, profitable Python platform with enterprise reach, but the public evidence still falls short of underwriting the last round with high conviction.
Lighthouse looks like a category-leading hospitality software platform, but public evidence is still too thin on audited growth, retention, and capital-structure terms to support a full buy recommendation at the last unicorn mark.
BioCatch is a scaled, sponsor-backed fraud platform with credible bank traction and a more supportable valuation than in 2024, but public evidence still supports only a track posture until private economics, concentration, privacy controls, and deal terms are verified.
Aragen is a credible scaled Indian CRDMO with improving disclosure and customer depth, but the last-round ~$1.4 billion benchmark already prices in much of the visible upside while execution, compliance, and utilization evidence remains incomplete.
Halter has built a credible category-leading livestock operating platform with real customer and product-scale proof, but public evidence still supports only a research-more posture at the $2B mark until private unit economics, governance, and welfare durability are underwritten.
Awardco appears to be a high-quality, capital-efficient HR-tech platform with a real product moat and meaningful scale, but the current >$1B valuation already assumes continued 30%+ growth that public data cannot fully verify.
VAST Data looks like a genuine AI infrastructure winner with real scale, strong ecosystem proof, and differentiated data-platform technology, but the current $30 billion valuation still requires private diligence on revenue quality, concentration, and cap-table terms before new money can be underwritten confidently.
Mech-Mind has real industrial-AI deployment depth and credible technical integration, but public disclosure still supports only a research-more stance at unicorn pricing.
OPay is a scaled and strategically important Nigerian payments leader, but limited audited disclosure, Nigeria concentration, and recurring compliance or fraud-control issues keep the case in track territory and make the reported IPO ambition look stretched.
DeepL is a real, scaled Language AI platform with premium enterprise positioning, but the last $2 billion private mark still looks stretched until audited revenue, margin, retention, and term- sheet evidence closes the remaining underwriting gaps.
Cohesity is a scaled post-Veritas cyber-resilience platform with a defensible official >$7B value anchor, but the equity case is not premium-underwriteable until debt, ownership waterfall, and cohort-retention disclosure improve.
Claroty is a scaled OT/CPS security leader with real strategic value, but late-stage entry remains hard to underwrite until current ARR, preference stack, and the absolute Series F valuation are verified.
Speak has credible AI-language-learning traction and real unicorn momentum, but public evidence still undersupports the $1B mark.
Cleo looks like a real scaled AI-first consumer-finance company, but incomplete price and risk disclosure keep the current call at track rather than buy.
Liquidity is a credible AI-driven private credit platform with strong institutional partners, but it remains too opaque for high-conviction underwriting at a premium to its stale 2023 unicorn mark.
Thrive has built a real AI-enabled services platform with public revenue support above $600M, but the current $12B mark remains stretched until consolidated margins, retention, and regulatory scalability are disclosed.
Qianxun passes on strategic importance and market position, but only a price-disciplined entry around the last well-supported public mark offsets the company’s disclosure and geopolitical risk.
CodeRabbit is a high-momentum AI change-management company with credible enterprise proof, but the $1.5B Series C already prices in execution and economics that public data does not yet confirm.
Suki has enough product, customer, and market evidence to remain investable in principle, but current public disclosure still supports research-more rather than a premium-price conviction call.
Lumilens has stronger-than-average early proof for a private AI optics startup, but public evidence still supports a track-and-verify posture rather than paying a full late-stage price with limited visibility into revenue quality, diversification, and cap-table terms.
Ivalua looks like a credible, scaled procurement-software asset with real sponsor and customer validation, but public disclosure is still too thin to support a high-conviction valuation call without deeper private diligence.
Zenity looks like a real and potentially category-defining AI-agent security company, but the current late-stage price should be treated as stretch-sensitive until private metrics validate the public narrative.
Xiaohongshu is a valuable social-commerce asset, but the cleanest current conclusion is to track it rather than chase upper-end private marks before prospectus-grade disclosure arrives.
Digital Edge appears strategically credible and likely valuable, but public evidence still supports RESEARCH-MORE rather than a conviction-priced entry at an unknown valuation.
Elroy Air has a differentiated and strategically relevant autonomous cargo-aircraft thesis with real partner and customer validation, but the current public record still leaves too much contract, operating, and financial opacity to underwrite the announced $1 billion valuation with high conviction.
Interswitch appears to be a durable Nigerian payments infrastructure franchise with real revenue and renewed profitability, but the public record still favors further diligence over paying materially above its stale 2019 unicorn anchor.
Kela looks like a strategically important early defense-platform company with real deployment proof and exceptional financing momentum, but the current private valuation already discounts a great deal of future execution that public evidence does not fully underwrite.
Lighter has enough public scale, technical differentiation, and investor validation to merit serious continued diligence, but the $1.5B valuation is not fully cleared by public evidence because revenue quality, customer concentration, and regulatory durability remain under-disclosed.
IM Motors looks like a real premium Chinese EV contender, but the current public evidence still supports a watch / track call rather than paying up for a fully validated unicorn-quality valuation.
OriCell is one of the more credible China-origin clinical-stage CAR-T stories in 2026, with real financing momentum and meaningful product milestones, but the public evidence does not support underwriting a hidden unicorn valuation or a buy call. The right posture is research-more: track the company closely, demand terms-level diligence, and re-engage on a disclosed price-bearing round or a stronger proof point.
Track: Fever looks like a real scaled category leader with strong partner proof and plausible operating leverage, but the current private valuation already prices in meaningful success and remains only conditionally supportable without private revenue, retention, and concentration data.
Spectro Cloud appears strategically relevant in AI infrastructure management, but the current $1B-plus private valuation is better treated as a research-more situation than a buy because public economic proof is still incomplete.
Pulumi looks like a real platform-engineering winner in the making, but the current late-stage valuation case still depends on private metrics and round verification that are not visible publicly.
SenseTime Medical looks strategically promising enough to stay high on the diligence list, but not yet transparent enough to justify a high-conviction buy at its current private-market mark.
Track: Lead Bank is one of the few profitable, fast-scaling sponsor banks with genuine marquee-fintech traction and a proven operator-CEO, but BaaS regulatory scrutiny, partner concentration, and a premium ~13.6x revenue valuation warrant close monitoring rather than an unconditional buy.
Konfío looks like a real, scaled SME-finance platform with credible product breadth and institutional support, but unresolved valuation, credit-quality, and license-timing questions keep the posture at track rather than buy.
Axiom is one of the most credible proof-first AI startups in public evidence, but commercialization and valuation support remain under-disclosed.
Keyrock looks strategically relevant and increasingly regulated, but the March 2026 unicorn valuation still runs ahead of public underwriting evidence because current economics and round terms remain largely undisclosed.
OpenRouter has real strategic relevance in the multi-model AI stack, but the public evidence still does not support underwriting a reported $1.3B valuation with high conviction.
Credible industrial AI platform with strong customer proof and integrated product design, but incomplete financial disclosure keeps the investment case short of full underwriting.
Category-defining premium berry platform with branded pricing power and meteoric growth, but a private, capital-intensive grower whose $1B+ mark and IPO ambitions rest on undisclosed financials and climate/tariff-exposed agriculture.
Nscale has assembled one of Europe's most ambitious AI infrastructure platforms, with sovereign AI positioning, elite investors, and Microsoft-anchored demand — but the public record still lacks revenue disclosure, the customer base is hyperconcentrated, leverage is rising, and UK planning friction keeps the current $14.6B valuation in stretched territory.
Teleport has real product depth and enterprise proof, but investment underwriting is constrained by a stale 2022 unicorn valuation, unverified current ARR, and licensing and procurement friction risks.
Attentive is a category-leading consumer martech platform with credible scale, strong AI-led product expansion, and durable customer traction, but the current ~$7B valuation remains too rich relative to public comps and too opaque for a high-conviction buy.
OnlyFans is a dominant and highly profitable creator-payments platform, but the current price already reflects material regulatory, payment, and governance risk.
Coralogix has real product breadth, customer traction, and funding momentum, but the public record is still too thin on revenue quality, retention, and cap-table terms to justify aggressive underwriting at the $1.6B mark.
Starling is one of the few profitable European neobanks, but public evidence supports a TRACK rather than BUY stance until post-fine regulatory rehabilitation, FY2026 profit recovery, and clearer Engine economics are visible.
Profitable multi-product consumer-credit platform with meaningful scale, but the 2025 private mark already prices in a lot of future execution.
Pudu Robotics combines real global deployment scale and strong category breadth with improving capital access, but public evidence still leaves too much uncertainty on revenue quality, margins, concentration, and round terms to underwrite the April 2026 unicorn valuation aggressively.
Sierra combines elite founders, exceptional early enterprise traction, and deep capital access, but the May 2026 $15.8 billion valuation leaves little margin for error without deeper diligence.
IQM is one of Europe's strongest quantum hardware assets, but the current de-SPAC entry still depends on unaudited revenue, a binary transaction close, and proof that sovereign-heavy deployments can compound into durable commercial economics.
Ayar Labs is the best-funded pure-play in-package optical I/O company, with a blue-chip strategic cap table, a working TeraPHY+SuperNova stack, and a credible 2026-2027 ramp window — but commercial revenue is unproven, NVIDIA and Broadcom's in-house CPO programs raise real competitive risk, and the exact Series D valuation premium versus Lightmatter and Celestial AI is hard to justify without revenue visibility. Track closely; not yet de-risked enough to underwrite aggressively.
Teamworks looks like the leading vertical software platform for elite sports — with unusually deep league penetration, a broad workflow suite, and strong AI-oriented acquisitions — but the current $1B+ valuation sits on top of a public record that is far richer on scale and fundraising than on revenue quality, margin structure, or integration economics.
Shadowfax is a scaled and now-profitable Indian logistics platform, but current public-market pricing and customer-concentration risk justify a TRACK stance rather than aggressive upside underwriting.
Loft Orbital has credible platform, constellation, and sovereign traction, but limited financial disclosure and execution dependencies keep the stock of evidence at track, not buy, around an approximately $1 billion valuation.
OLIPOP: Category-leading prebiotic soda brand with profitable growth, but litigation and exit risk cap near-term upside
Aikido Security is a credible developer-first security platform with strong growth and product breadth, but the $1B valuation is ahead of what retained public operating evidence can support.
Linear is a standout workflow product, but the public evidence base is still too thin to justify paying the last unicorn round price with confidence.
InoBat looks like a real but still high-risk battery platform: stronger on strategic partnerships, product breadth, and storage traction than on disclosed financial proof.
Color Health is strategically interesting and operationally real, but the public evidence set supports a TRACK call rather than a BUY because the stale $4.6B 2021 mark looks stretched against today's revenue proxy and disclosure quality.
Instinct is a $2.5B consumer AI assistant with extraordinary ARR momentum but material privacy, security, and governance risks that make the valuation stretched at current evidence quality.
Grid-edge platform with strong utility footprint acquired by Octopus at ~50% discount to prior peak valuation
PalmPay looks like a real scaled African fintech and likely unicorn, but incomplete disclosure, Nigeria concentration, and control-sensitive risk keep the current case in track territory rather than buy territory.
Keeper has credible multibillion-dollar platform value and real regulated-market strength, but public evidence still supports only a track / research-more call because price proof lags company proof.
River AI enters the enterprise AI training cloud with a record $1.1B raise backed by NVIDIA and General Catalyst, but is four months old with an unproven product, undisclosed revenue, and intense competitive pressure from both open- and closed-model incumbents.
Bright Machines is a well-funded factory-automation innovator riding the AI infrastructure boom, but long sales cycles, capital-intensive deployments, and opaque economics keep the best public call at track rather than buy.
Category-leading, founder-controlled US yogurt brand compounding revenue at a stretched but defensible ~$20 billion private valuation, gated by opacity, leverage and capital intensity.
Kraken has real sovereign customer proof and strategic sector positioning, but the July 2026 unicorn valuation still depends on fundamentals the public record does not disclose.
Octopus Energy combines the UK’s leading digital green retailer with a globally scaled utility software platform; the opportunity is credible, but underwriting still hinges on unverified Kraken economics and regulatory execution.
Fresh Life Cold Chain is a scaled Chinese cold-chain unicorn with real infrastructure and digital-control depth, but the current public mark already prices in substantial execution success.
Kraken has real sovereign customer proof and strategic sector positioning, but the July 2026 unicorn valuation still depends on fundamentals the public record does not disclose.
Coda is a strategically differentiated gaming-native payments and commerce platform with real scale and useful post-Recharge optionality, but the stale US$2.5 billion anchor is only investable with pricing discipline because public disclosure on combined economics remains thin.
Ominimo has a rare mix of speed, underwriting signal, and capital-light expansion, but the current unicorn valuation still outruns the quality of public disclosure.
Kurly has proven its dawn-delivery model structurally profitable after 10 years of losses, but razor-thin margins and Coupang's dominant scale leave IPO-stage upside contingent on sustaining Q1 2026's exceptional growth momentum.
Pigment is a credible enterprise xP&A platform with strong product narrative and elite customer logos, but insufficient public financial disclosure to support a buy at the last disclosed $1B+ valuation — research-more pending data room access
Dongchedi has dominant scale in China's automotive content vertical and a defensible ByteDance distribution moat, but opaque financials, heavy parent dependency, and a challenged comparable set make the $3 billion private valuation only fair at current transparency. The pending Hong Kong IPO is the key catalyst; materially higher conviction requires revenue disclosure.
Flex is a credibly fast-growing fintech unicorn with a differentiated owner-finance thesis, but the $1.2B valuation prices in platform execution that is not yet fully proved in the public record.
Octopus Energy pairs the UK's highest-NPS energy retailer with a $8.65B AI utility platform; entry at $9B is defensible if Kraken ARR and churn are verified — but the data-room gaps are blocking.
MGT is a credible and differentiated SLED technology platform with institutional validation at unicorn scale, but the investment case requires private diligence to verify audited revenue, debt structure, and organic growth quality before a buy recommendation can be supported.
Evoken has rare scale for a young AI video and creative-software company, but public underwriting still depends on unaudited ARR, evolving regulation, and third-party model economics.
Virta appears to be one of the higher-quality private metabolic-health companies in the market, but the available public record still supports tracking the business rather than underwriting a fresh entry at roughly $2 billion.
Alentis has assembled a credible first-in-class CLDN1 platform across oncology ADCs and fibrosis, backed by a large Series D and visible clinical momentum. The strongest public signals are target coherence, high-quality financing, and multicenter trial activation; the weakest are valuation transparency, cash/runway disclosure, and human efficacy proof. A Track / research-more stance is warranted until priced-round terms or clean human data materially reduce underwriting uncertainty.
Quwan looks like a real scaled gamer-social asset with unusually strong historical profitability, but public disclosure is still too stale to underwrite the old unicorn mark with high conviction.
Fast-growing Chinese AI creative-platform unicorn with exceptional ARR growth, but valued on unaudited metrics and exposed to content-safety, copyright and aggregator-margin risks.
PixVerse has achieved a >$2B valuation on real product momentum, strong user growth, and world-model optionality, but the absence of public revenue disclosure and fierce AI-video competition keep the current mark in track territory.
Super.com is one of the more compelling consumer fintech stories in the 2026 private market — profitable, growing at 50%, and building a membership flywheel — but investors need segment economics before underwriting the 6x revenue valuation with high confidence.
LeapXpert appears to be a credible governed-communications platform with real regulatory relevance, meaningful customer proof, and strong sponsor backing—but public evidence is still too thin on economics and valuation to support a premium-price buy call.
Research more: Stori shows enough scale, product breadth, and entity-level profitability to stay actively engaged, but a fair valuation stance is more defensible than a strong buy until cohorts, partner economics, and risk-adjusted durability are clearer.
XAG combines real product depth, global agricultural automation traction, and a demonstrable profit turn, but underwriting remains constrained by competitive pressure from DJI and limited visibility into normalized long-term margins and valuation.
Fox ESS is a credible unicorn-scale residential-storage leader with real revenue and shipment momentum, but Europe concentration, regulatory scrutiny, and thin disclosure keep the investment case in track territory rather than making it an obviously mispriced growth asset.
Safe Security is a credible category leader in enterprise cyber risk management with strong Forrester and analyst validation, but limited financial transparency keeps the $1B+ entry multiple at the borderline of fair-to-stretched without audited unit economics.
Galaxy Bot is a strategically credible Chinese embodied-AI robotics contender with real deployment evidence and unusually deep capital backing, but opaque unit economics and concentrated partner risk keep the underwriting case speculative.
Element Labs combines elite semiconductor founder pedigree and strong financing momentum, but public proof of customers, economics, and governance still trails its reported >$4B valuation.
Cadence is a high-growth AI chronic care platform with strong clinical validation but material regulatory risk from RPM billing scrutiny that warrants close monitoring.
AppsFlyer is a scaled, profitable, independent measurement leader whose June 2026 $2.7B strategic round validates the franchise, but a March 2026 SDK trust event, opaque financials, and platform dependency make it a disciplined track-to-conditional-buy rather than a clean entry.
Twenty may be an early category leader in offensive cyber software, but the current public record supports only a strategic watch position rather than a high-conviction buy at $1B.
Redaptive looks strategically credible and financing-capable, but current public evidence still does not support a confident entry price above the last visible unicorn-era mark.
Highway has credible category leadership and customer adoption in freight fraud prevention, but public disclosure is still too thin for a price-sensitive investment call.
Viam offers a credible and differentiated machine-software control plane backed by strong founder-market fit and growing enterprise proof points, but undisclosed revenue and valuation make it a track rather than buy at this stage.
Category-leading warehouse-robotics franchise with its first adjusted profit and #1 global AMR share, but priced for perfection as a China-headquartered hardware exporter exposed to tariff, margin and de-rating risk.
Drools is India's dominant homegrown premium pet food brand at a $1B+ valuation, benefiting from pet-food premiumization and strategic validation from Nestlé, but still constrained by limited public disclosure on margins, governance, and transaction terms.
Pindrop is a category-leading voice-security franchise with unusually strong named proof and a large growing market, but an unwinnable-feeling deepfake arms race and undisclosed financials cap conviction and argue for disciplined diligence before any investment.
Formlabs is a cash-generative professional 3D printing leader with $250M+ revenue and rare FCF profitability, but the $2B 2021 valuation anchor is unsupportable at current public-market multiples; Track at secondary-market pricing of $700–$900M.
Allica Bank is a profitable UK SME challenger bank at unicorn scale with strong growth momentum; the investment case is supported by sustainable NIM and three profitable years but capped by credit-cycle risk, declining capital ratios, and private-company opacity.
A profitable, fast-growing identity-verification leader whose quality is high but whose price is unconfirmed against a three-year-stale $1.5B mark.
Forrester EU Wave Leader MDR pureplay at the low end of the public-comp band, with the 2-year stalled Evercore sale process and rising Microsoft / CrowdStrike bundling pressure as the dominant adverse signals — MONITOR with conditional INVEST on sale-process close at base case plus NRR ≥95% and top-10 channel partner ARR <40%.
X-energy has assembled a uniquely deep advanced-nuclear package — Xe-100 HTGR plus TRISO-X fuel, DOE ARDP cost-share, Dow + Energy Northwest + Amazon offtake, an 11 GW orderbook narrative, and a fresh Nasdaq listing — but with no Xe-100 reactor yet built, Q1 2026 opex running ~2.5x revenue, undisclosed reactor economics, and a long licensing and FOAK construction path ahead, current valuation is a probability-weighted strategic option rather than a defensible cash-flow story, and the appropriate stance is research-more with attractive optionality and high execution risk.
A top-tier AI-inference asset with elite founders and hypergrowth, priced for perfection against ~50% margins and structural commoditization risk.
Erebor targets a credible post-SVB startup-banking gap, but its public operating proof still trails its multibillion-dollar valuation.
Bending Spoons looks like a real software compounder with rare scale and recurring-revenue quality, but leverage, incomplete segment disclosure, and recurring user-trust backlash keep the right call at research-more until the IPO file is fuller and priced.
Attractive category position and customer proof, but public evidence still supports research-more rather than a fresh aggressive entry because revenue support is opaque and the prior valuation already prices in a large share of the upside case.
Luma AI has documented product traction and a credible $4B private mark from a sovereign-backed investor, but zero revenue disclosure means the valuation cannot be underwritten confidently from public evidence alone.
Goodfire looks like a category-defining interpretability company, but the public record still does not justify underwriting the February 2026 valuation as a clear bargain.
Hightouch is a real late-stage winner in warehouse-native marketing software, but the $2.75B Series D looks too expensive to underwrite from public evidence alone.
Harmattan AI has assembled unusually strong sovereign-defense proof points for a two-year-old startup—dual MoD Programs of Record and a Dassault Rafale F5 partnership—but the lack of public financial disclosure keeps the investment case in research-more territory.
Calm is a scaled and durable mental-wellness brand with real consumer and sponsor reach, but private-company opacity, leadership-transition risk, and a stale 2020 US$2 billion valuation anchor keep the current stance at track rather than buy.
Varda has exceptional operational proof and a genuine dual-use platform, but the $1.58 billion Series D price requires private financial disclosure to underwrite at medium confidence and high risk.
JSW One Platforms has a credible full-stack industrial-commerce thesis and a strategically useful JSW Group moat, but the ~$1B valuation still depends on unaudited FY25 operating data and a fast- scaling credit/distribution model that carries meaningful execution and governance risk.
Decagon pairs real enterprise AI-CX traction and strong product depth with a valuation that has moved faster than the public denominator, leaving the current $4.5 billion mark hard to underwrite without private diligence.
Parloa's 150% NRR, 117% ARR growth, and blue-chip enterprise proof justify a premium, but the January 2026 Series D prices the company at ~58x ARR—a stretched multiple that leaves limited cushion for execution misses. Prudent stance is Research More until gross margin, GRR, and forward-growth evidence catch up to the $3B mark.
Liftoff Mobile holds a durable dual-sided marketplace position in mobile advertising, but AppLovin's data advantages and privacy headwinds create structural competitive pressure.
CompanyCam has built a defensible contractor documentation moat with 285,000+ users, proven 2x ARR growth to $68M in 2024, and Nebraska's first unicorn valuation—but a ~29x 2024 ARR multiple demands ongoing acceleration that public evidence cannot yet confirm, warranting a track posture pending current ARR disclosure.
OneTrust is the category-defining privacy-to-AI governance platform at a $4.5B last mark, but new capital is not actionable without confirmed NRR, EBITDA margins, and PE acquisition structure.
Kalshi's CFTC regulatory moat and explosive revenue trajectory are real, but the $22B Series F price embeds a favorable legal outcome for sports event contracts that is not yet in evidence, making the valuation stretched and the appropriate posture research-more until key litigation catalysts resolve.
Melio is a strategically valuable but still hard-to-underwrite SMB payments platform: Xero's deal confirms real scale and distribution value, yet the standalone economics remain too opaque to treat the strategic acquisition price as a reusable entry mark.
Carro is a scaled Southeast Asian automotive platform with visible profitability progress and credible IPO optionality, but opaque capital structure, missing customer / unit-economics disclosure, and rumor-heavy valuation talk keep the risk-reward in TRACK territory around the US$3.0 billion anchor.
SendCutSend looks like a high-quality software-enabled manufacturing platform, but the May 2026 unicorn valuation already prices in a large share of the execution story while audited financials, debt terms, and preference-stack details remain private.
BuildOps is a high-growth commercial FSM unicorn with a defensible vertical niche, but the $1B valuation — ~10× estimated ARR with no disclosed NRR or gross margin — demands exceptional execution and demands caution at entry.
Truveta has a differentiated provider-governed health-data moat and meaningful genomics optionality, but current valuation already discounts much of the upside given opaque economics and material privacy and execution risk.
The Bot Company combines an elite founding team, exceptional capital formation, and a genuine product opportunity in household robotics, but the complete absence of product proof, revenue, or customer validation — combined with a $2B confirmed valuation, Cruise founder liability, and deep sim-to-real technical risk — justifies a TRACK stance at high risk with low confidence.
Suno has built an unusually large, fast-monetizing AI music business, but unresolved copyright exposure and opaque unit economics keep the verified $2.45 billion mark in track-only territory.
Trade Republic is a credible European neobroker decacorn with 10 million customers, €150 billion AUM, and three profitable years, but the June 2026 PFOF ban creates an unquantified revenue cliff, the €12.5 billion secondary mark implies a 25–31× estimated P/S that screens stretched, and private financial opacity precludes independent valuation verification.
TravelPerk is a rare late-stage SaaS unicorn achieving EBITDA break-even alongside >50% revenue growth, but gross margin opacity and an undisclosed-NRR gap prevent high-conviction underwriting at the current 13x revenue multiple.
Platform Science holds a structurally differentiated OEM-native moat in fleet management SaaS, with named enterprise customer proof at scale, but undisclosed financials and OEM channel concentration limit conviction; recommendation is Research-More pending financial diligence.
Alumis enters 2026 as the best-in-class oral TYK2 inhibitor pre-NDA story with Phase 3 PASI 90 of ~65%, $569.5M cash runway, and a strong-buy analyst consensus implying ~60% upside; a buy at $3.16B market cap with medium confidence reflecting single-asset binary FDA risk.
Bolt is Europe's most credible Uber challenger with proven cashflow-positive super-app economics, but the IPO thesis faces a material £200M+ UK legal liability and an EU labour-cost restructuring cycle that investors must model before committing.
Flutterwave is Africa's most significant payments infrastructure franchise with $26B+ annual TPV, but the $3B last-round valuation is stretched relative to current comparable multiples and the company carries unresolved regulatory, security, and IPO-readiness risk.
Lyra Health is the category leader in employer mental health benefits with 20M+ covered lives and strong brand recognition, but its $5.58B last-round valuation requires 20-30x ARR multiple justification that current market conditions and competitive dynamics make difficult to sustain.
Thunes' broad regulatory license stack (MAS, FCA, ACPR, HK MSO, 50-state US MTL), proprietary Direct Global Network across 130+ countries, and stated positive EBITDA at Series D position it as one of the most credible private B2B cross-border payments infrastructure platforms, but the absence of any disclosed Series D valuation, audited financials, or quantified retention metrics keeps conviction in track territory until data-room access is available.
Mujin holds a defensible motion-planning software moat in Japan's automation boom but faces opaque financials, US market immaturity, and intensifying AI-native competitors that temper conviction.
Vestiaire Collective is the leading European luxury resale unicorn with strong brand positioning, a Kering strategic relationship, and a sustainability narrative resonating with younger luxury consumers, but its $1.7B (2021) valuation looks stretched against public comparables and its path to profitability remains unconfirmed.
GreyOrange is a global warehouse robotics unicorn with a differentiated AI orchestration platform, but faces intense competition, hardware capital intensity, and limited financial transparency that warrant a 'track' stance pending revenue disclosure.
Devoted Health is a credibly executing, founder-led Medicare Advantage payvidor with category-leading Star Ratings and a 121% YoY member-growth print, but its ~$13B private mark trades at a 3-4x EV/Revenue premium to distressed public MA comps and depends on continued capital, V28 risk-model absorption, and a turn to consolidated profitability that state filings have not yet shown.
Cerebras has built a genuine hardware breakthrough in WSE-3 with the world's fastest AI inference, but 86% revenue concentration in a CFIUS-scrutinised customer and a delayed IPO create existential risk alongside the compelling technical moat.
Headway is the structurally strongest position in insurance-native behavioral health tech with 34,000+ providers and 45+ payer contracts, but the $2.3B Series D valuation prices in significant execution on Medicare/Medicaid expansion and reimbursement rate stability — both of which carry material regulatory and payer-concentration risk. Conditional positive pending financial disclosure diligence.
Astranis has built the only commercially validated small-GEO dedicated-capacity satellite product with five named customers, a government anchor contract (PTS-G), and $455M Series E runway — but the high-risk profile (anomaly track record, unproven manufacturing scale, capital intensity, ITAR obligations) and price-sensitive Series E entry require completion of five specific diligence items before capital commitment. Recommendation: Conditional Proceed — begin primary diligence; do not commit without resolving insurance, manufacturing yield, PTS-G terms, ITAR audit, and IP freedom-to-operate.
India's largest contract-manufacturing marketplace at IPO inflection - underwrite the growth, price the losses, and gate the recommendation on DRHP customer-concentration and unit-economics disclosure.
High-growth cloud physical security platform with strong product-market fit but material risk overhang from 2021 breach, regulatory enforcement, and limited financial transparency.
1X Technologies has rare commercial traction in enterprise robotics with EVE, strong backing, and a compelling NEO consumer vision, but faces autonomy gaps, competitive pressure, and financial opacity that warrant careful diligence before a Series C commitment.
Antora Energy has best-in-class fundraising and technology credibility, but remains pre-commercial — no named customers, no disclosed revenue, and a hidden valuation cap.
Drata is the compliance automation category leader with strong integration moat, AI-native platform expansion, and 8,000+ customers — but financial opacity and stale $2B valuation require a data room before conviction can be established.
NEURA Robotics is Europe's most advanced humanoid robotics company with a differentiated cognitive architecture and strong strategic partnerships, but remains pre-revenue with high burn, intense US competition, and no confirmed large-volume customer commitments.
Nimble is a compelling warehouse robotics bet anchored by a $1B Series C valuation, FedEx scale distribution, and a self-supervised AI moat, but near-term risk is dominated by extreme FedEx concentration and unverified revenue/margin claims.
Nuro offers a credible and differentiated AV software licensing play in a hyper-growth robotaxi market, anchored by the Lucid-Uber partnership, but remains pre-commercial with material Lucid solvency and Uber multi-sourcing risks that warrant conditional entry at the $6B valuation.
Semgrep is an investment-grade developer AppSec platform with a genuine technical moat and strong developer adoption, but elevated competitive risk from GitHub GHAS and financial opacity prevent unconditional conviction — Conditional Interest pending data room confirmation.
Shield AI is the leading AI autonomy platform for defense with exceptional growth but trades at a stretched ~47x revenue multiple that prices in substantial execution risk on its X-BAT and Hivemind enterprise scaling ambitions.
Waabi's world-class AI founder and billion-dollar backing position it as an AV 2.0 contender, but a missed driverless milestone and full revenue opacity demand verification before investment.
Physics Wallah is India's most affordable and fastest-growing digital test-prep platform, with dominant market position and strong brand, but remains loss-making with key-person and exam-policy risks that warrant a watch-and-accumulate stance post-IPO.
Halcyon occupies a defensible niche in anti-ransomware with strong technical differentiation and rapid growth, but limited financial transparency and platform consolidation risk warrant a Track recommendation at medium confidence.
Scale AI holds a defensible position in AI infrastructure with strong government exposure, but faces customer concentration risk, a CEO transition, and a pivotal business model shift away from data-labeling.
Cato Networks is the Gartner-recognized single-vendor SASE leader with authentic architectural differentiation, strong mid-market momentum, and 4,000+ customers — but undisclosed NRR/margin data and an IPO-freeze create valuation uncertainty at the $4.8B asking price.
Octopus Energy pairs the UK's highest-NPS energy retailer with a $8.65B AI utility platform; entry at $9B is defensible if Kraken ARR and churn are verified — but the data-room gaps are blocking.
Axonius has durable CAASM leadership and government penetration, but the $2.6B flat valuation, CEO transition, and unresolved financial opacity demand private diligence before institutional commitment.
Cyera leads the cloud-native DSPM category with exceptional ARR velocity, but the $9B Series D is fully priced for best-case execution with no margin of safety for Series D investors.
Sword Health is the credible AI MSK leader with 2,500+ enterprise clients, FDA clearance, and cash-flow positive operations — but Hinge Health's post-IPO advantages and self-reported outcome metrics limit conviction at the stretched 16.7x ARR valuation. Track; re-enter at $350M+ ARR with independent validation.
Whatnot has built the US live collectibles commerce market — $3B GMV, authentic seller community, unique break room product, and pre-sale authentication moat — but its $11.5B Series F valuation at 33× estimated revenue leaves minimal margin of safety for new investors. The base-case exit scenario (25–35% GMV CAGR through 2027, exit at 3–7× revenue) implies negative returns from Series F entry. TRACK until valuation reset, profitability timeline visibility, or TikTok Shop US regulatory resolution changes the risk/reward.
Mistral AI is Europe's leading open-source AI company with a sovereign AI moat, MoE compute efficiency advantage, and ~$200M ARR. The $6B valuation at 30x ARR is fair for 100%+ ARR growth but carries high risks from Big Tech resource asymmetry and undisclosed financials. Track for Series C entry.
Gecko Robotics has real strategic traction in defense and energy, but the public record is still too thin to justify paying the last $1.25B price with confidence.
Marvell paid $3.25B upfront for the most technically advanced silicon photonics scale-up interconnect asset available at a critical inflection point. The acquisition thesis — converting Celestial AI's Photonic Fabric into $500M+ ARR by FY2028 via Marvell's hyperscaler relationships — is coherent, but rests on a pre-revenue foundation with 18+ months of execution runway before revenue recognition. The 6.5x 2-year forward ARR multiple is at the conservative end of AI silicon comps, making the upfront price defensible if the earn-out milestones are achieved; the $2.25B contingent consideration appropriately aligns incentives. Risk rating is high given technology, timing, and talent execution variables.
Tarana has credible deep-tech broadband infrastructure and real operator adoption, but the public disclosure package still lags the valuation levels implied by late-stage private-market screens.
Epos Now looks like a real late-stage SMB merchant platform with credible embedded-finance upside, but public evidence remains too incomplete to justify paying a unicorn headline without strong price discipline and direct diligence.
Papaya Global looks strategically relevant in global payroll and EOR, but the investment case remains constrained by execution risk, competitive pressure, and limited financial disclosure.
Zhisquare is strategically important and plausibly a future national-champion-style robotics winner, but the current private mark appears rich relative to publicly disclosed fundamentals.
Kunlunxing is a founder-exceptional humanoid robotics entrant with strong capital-market validation, but the valuation narrative currently runs well ahead of public product and customer proof.
Visby Medical is a category-defining molecular diagnostics company with real first-mover FDA regulatory advantages in OTC PCR testing, but a $1B valuation against only ~$35M estimated revenue demands strong consumer adoption evidence before it can be underwritten with high conviction.
Track Viz.ai: the company looks like a real scaled clinical-AI platform, but the public record does not support paying its stale 2022 unicorn valuation without materially stronger private proof.
Starship looks like the strongest scaled sidewalk-robotics company in public view, but incomplete revenue and term disclosure keep the current case in research-more territory rather than buy territory at or above the last explicit $1.2 billion mark.
Traveloka looks like a strategically relevant regional travel platform with improving financial posture and plausible fair value near recent private marks, but disclosure gaps and persistent trust or regulatory concerns keep the call at track rather than buy.
QuintoAndar appears to be a scaled late-stage proptech winner, but public evidence is still too thin on audited margins, reserve exposure, and current pricing to justify more than a track / research-more stance at premium valuation.
Stark Bank looks like a real, scalable, profitable corporate-finance platform, but the current valuation cannot be underwritten tightly from public evidence alone.
Shengshu is one of the more credible Chinese AI-video startups, with strong product momentum and strategic backing, but missing ARR, margin, and cap-table disclosure keep the name in Track rather than buy territory at opaque unicorn pricing.
Mahindra Last Mile Mobility has enough scale, category leadership, and strategic backing to merit serious diligence, but the July 2026 unicorn price still looks stretched until standalone economics and governance disclosure improve.
Rillet looks like a real category contender in AI-native finance infrastructure, but the $1B Series C price already demands fundamentals that public evidence does not yet verify.
Research-more: ArsenalBio is a high-quality solid-tumor CAR-T platform, but the reported ~$1.9B valuation already assumes more public proof than is currently disclosed.
Gravis Robotics has credible product and partner proof in a painful market, but its new unicorn valuation already prices in execution that public revenue and margin evidence do not yet verify.
Culture Amp looks like a credible scaled employee-experience platform, but public disclosure is still too thin to underwrite the current private-market mark with high conviction.
CarDekho is a credible, scaled auto-commerce platform with a real 2026 IPO path, but incomplete segment disclosure and perimeter ambiguity keep the risk-reward in TRACK territory around the proposed Rs 13,000-15,000 crore range.
BharatPe now looks operationally healthier than its governance-era reputation, but the current private valuation already prices in much of that recovery before the hardest diligence questions are publicly answered.
CygnuSemi has enough strategic and technical proof to merit continued diligence, but the reported ~$1.5B valuation should be treated cautiously until customer breadth, revenue, gross margin, and runway are disclosed.
Playlist's $7.5B valuation is stretched relative to services-heavy comparable companies, but its three-sided fitness platform with 100M+ end-user touchpoints and post-EGYM scale creates a defensible category position that warrants deeper private diligence.
Yotta is a strategically valuable sovereign-AI infrastructure platform, but the current reported valuation still looks stretched versus public comps and available disclosure.
Yimu appears to be one of China’s more strategically interesting tactile-infrastructure companies, but the current unicorn valuation still outruns the public evidence on revenue quality and downside structure, supporting a TRACK stance rather than a buy.
Cult.fit is a scaled and strategically interesting Indian fitness platform, but the visible valuation already prices in more proof than the public record currently delivers.
Shippo looks like a real shipping-infrastructure asset with broad platform reach, but the public record supports research-more and a stretched valuation stance rather than underwriting the stale 2021 unicorn mark at face value.
Kodiak has crossed into real commercial and public-market evidence, but its valuation still depends on scaling a concentrated customer base without repeating the financing and safety stumbles that damaged prior AV trucking peers.
Kahoot is a credible, scaled learning software asset, but the public evidence supports the business more cleanly than it supports paying at or above the 2024 sponsor-entry valuation.
Kajabi appears to be a durable, scaled creator-business platform, but the business is better supported by public evidence than the stale 2021 unicorn valuation.
EcoCeres has enough plant, customer, and policy proof to merit close tracking, but the public evidence is still too thin on economics to justify high-conviction underwriting at rumored IPO-level valuations.
Snorkel has credible product depth and customer proof in one of AI's most important workflow layers, but the current valuation still requires diligence on retention, concentration, and software-like economics.
Large, strategically validated telematics platform with real customer proof, but public economics remain too opaque for a conviction entry call.
Kredivo has enough scale, bank optionality, and investor quality to remain highly relevant, but public evidence still supports a track / research-more stance rather than a clean buy at an opaque premium valuation.
Moove has crossed from narrative to real scale, but the $2.1B mark looks fair rather than clearly cheap until margins, contracts, and liability structure are better disclosed.
HappyRobot pairs genuine category leadership in agentic AI for logistics with a confirmed $1.2B unicorn mark, but company-claimed metrics and undisclosed financials keep the call at track rather than buy.
CertiK has enough category relevance, product breadth, and customer proof to justify continued diligence, but the current public record still supports research-more rather than paying the historical $2B mark on trust alone.
Neo has built a credible premium-wealth platform with meaningful asset scale and strong investor backing, but the public file still lacks the revenue, margin, governance, and retention disclosure needed to underwrite the March 2026 unicorn valuation with high conviction.
DayOne has a credible premium infrastructure story, but the reported US$20 billion IPO target already prices in unusually strong execution before public-company disclosure is ready.
Polarium has real scale, a credible telecom-to-distributed-energy expansion story, and visible turnaround progress, but current public evidence still supports only a track stance because the stale unicorn mark sits ahead of disclosure quality.
Purplle is strategically interesting and credibly scaled, but public evidence still supports a research-more stance because disclosure, service quality, and forward financial verification remain incomplete.
Kry has built one of Europe's more credible hybrid-care platforms, but unresolved financing terms, labor-heavy economics, and channel opacity keep the stock in track territory rather than buy territory.
A scientifically differentiated but still binary preclinical ADC payload platform whose $1.5B announced Novartis exit validates strategic scarcity more than clinical proof; worth tracking, but not treating as de-risked.
Category-leading promise, but public fundamentals lag the valuation: compelling workflow wedge with a stretched current price pending KPI proof.
EigenQ sits in an attractive quantum-safe infrastructure wedge, but the announced ~$3B SPAC valuation still outruns the public evidence base and supports RESEARCH-MORE rather than conviction buying.
Research-more: Assured looks like a real and strategically interesting vertical-AI company, but public valuation support trails public company-quality signals.
Research-more: Crimson has real scale, a differentiated multi-product education portfolio, and a plausible claim to its unicorn mark, but the lack of audited economics and cap-table transparency keeps the current valuation from being a conviction-priced entry.
Antares has delivered a rare hardware milestone and a government-anchored orderbook, but a ~$1.3B pre-revenue valuation prices in flawless execution against nuclear's long history of delay.
Crystalys has a credible late-stage gout asset and ample funding, but the absence of public price and launch economics still supports TRACK rather than a priced-in buy call.
Track AdvanCell rather than underwriting aggressively today: the company looks strategically valuable, but the public record is still too opaque for precise valuation confidence.
Pasqal is one of Europe’s most credible quantum-computing platforms, but the current ~$2B valuation still needs materially more revenue, renewal, and production proof to look attractive.
Category leadership in AI 3D creation and credible adoption make Vast worth tracking, but the reported unicorn valuation still outruns public revenue disclosure and carries real China-risk haircuts.
Cedar appears to be one of the stronger private patient-financial-engagement platforms, but public evidence still leaves too much uncertainty around current financial quality and pricing to support a high-conviction premium valuation call.
Checkmarx has real enterprise scale and contemporary unicorn evidence, but public data is still too incomplete to underwrite a $2.5B+ target with high conviction.
ZeroAvia has assembled one of the stronger public strategic stacks in hydrogen-electric aviation, but the investable question is still pricing and milestone conversion rather than company quality alone.
Zyphra has unusually strong public technical and partner evidence for a private AI startup, but its customer proof and economics disclosure are still too thin to justify price-insensitive underwriting. The report supports a research-more / track stance: constructive near the last supported unicorn mark, but cautious toward rumored 2026 step-up pricing until customer and financial proof improves.
Mirakl has the scale and profitability of a serious late-stage software asset, but the visible private mark still looks stretched enough that the right public-evidence verdict is track, not buy.
Postman has clear category leadership in API collaboration and workflow context, but public evidence is still too contradictory on revenue and too thin on governance and capital structure to underwrite the company confidently at or near its 2021 peak valuation.
Ledger is strategically compelling and plausibly worth several billion dollars, but the public record still supports a track / research-more posture rather than an aggressive premium underwriting call.
Quicktron is a strategically credible warehouse-robotics company, but the investment case still depends on research-more diligence and disciplined pricing rather than on narrative momentum alone.
LimX Dynamics has secured top-tier Chinese strategic and Middle Eastern backing and a >US$1B valuation for its modular legged-robot and humanoid platform, but trails volume leaders Unitree and AgiBot and carries undisclosed financials plus mounting geopolitical risk.
Track: Klook is a real scaled APAC travel marketplace and the ~US$1.4B mark is defensible, but not cheap enough to ignore retention, governance, and cap-table uncertainty.
Docplanner has enough scale, workflow depth, and geographic breadth to merit continued diligence, but current public evidence supports a research-more stance because leverage, compliance burden, and opaque financing / retention details keep the valuation from looking clearly attractive.
Category leadership in AI 3D creation and credible adoption make Tripo worth tracking, but the reported $1.5B mark still outruns public revenue disclosure and carries real China-risk haircuts.
Kopi Kenangan has proven regional scale and reached profitability, but limited disclosure and a reported secondary-sale range that already embeds a premium multiple keep the stock-picking answer at track rather than buy.
DayOne is a premium digital-infrastructure asset with genuine hyperscale demand and unusual capital access, but the reported US$20B valuation remains ahead of the public evidence on earnings power and contract quality.
Kapital looks like a real full-stack SMB banking platform with regulated-bank profitability and scale, but public evidence still does not show the consolidated revenue, cap-table, and preference-stack detail needed to underwrite the September 2025 unicorn price aggressively.
Nearfield has real strategic and technical proof, but the current $1.6B round still lacks enough public financial disclosure to justify a buy recommendation.
Venice AI pairs rare profitability and strong adoption in a growing private-AI market with token and regulatory uncertainty, making it a high-quality but high-variance opportunity to monitor rather than commit to at ~14x ARR.
Neo has built a credible premium-wealth platform with meaningful asset scale and strong investor backing, but the public file still lacks the revenue, margin, governance, and retention disclosure needed to underwrite the March 2026 unicorn valuation with high conviction.
Brevo appears to be a scaled and increasingly profitable European marketing SaaS platform, but the current unicorn-era pricing is harder to underwrite than the company-quality story because public disclosure is still thin.
Inceptio has unusually strong commercialization proof for a private autonomous-trucking company, but the lack of public financial disclosure keeps the investment case in track rather than buy territory.
Black Forest Labs has real technical and commercial momentum in visual AI, but the current private mark still requires deeper diligence on economics, concentration, and regulatory durability.
Bose Quantum looks strategically important and technically credible enough to keep diligencing, but public disclosure is too thin on revenue, round terms and valuation to justify underwriting at an undisclosed price.
Andromeda appears to solve a real GPU procurement problem and has meaningful early traction, but the current $1.5B price is hard to underwrite without better evidence on margin quality, concentration, and governance.
Nexthop has a credible open-Ethernet AI-networking product and strong investor backing, but thin public proof on revenue, customer breadth, and margins keeps the company in track-not-buy territory at the current $4.2 billion mark.
BlueVoyant is a credible late-stage cybersecurity platform with real MDR and TPRM scale, differentiated regulated-industry positioning, and strong Microsoft ecosystem leverage, but its private-company opacity and unresolved valuation/revenue conflicts justify a track posture rather than a conviction buy.
GoCardless has built a strong European bank-payments position and is showing credible profitability improvement, but the pending Mollie sale, price opacity, and unresolved regulatory/governance details keep the investment case at Track rather than Buy.
CAIT is a strategically credible CATL platform extension with real OEM interest and a strong parent moat, but today’s public evidence supports tracking rather than underwriting the business aggressively because revenue, customer conversion, and standalone economics remain opaque.
SHEIN combines one of the most powerful demand-sensing and supply-chain engines in global consumer internet with one of the heaviest regulatory, legal, and reputational overhangs in retail; the business is too large and capable to dismiss, but the current risk stack and uncertain IPO path support TRACK rather than an aggressive buy posture.
Tuduoduo is a scaled and profitable industrial B2B platform with credible category depth, but unresolved parent-governance, compliance, and disclosure gaps keep the supportable call at research-more rather than buy.
LMArena appears to be the category leader in AI evaluation, but the $1.7B Series A price leaves little margin of safety until governance, neutrality, and customer-concentration questions are resolved.
Kriya has assembled a rare combination of capital, manufacturing ambition, and chronic-disease gene-therapy scope, but the public evidence base is still too thin on clinical efficacy, valuation, and burn discipline to support a clear buy posture.
Trackunit has genuine category leadership in construction telematics and strong recurring-revenue quality, but the 2025 buyout price already bakes in much of that upside while leverage, macro sensitivity, and limited disclosure constrain conviction.
Fireflies is a rare profitable, capital-efficient AI meeting-assistant unicorn, but its secondary-set $1B mark implies roughly a 90x public-revenue multiple that public evidence cannot underwrite.
Onebrief has rare planner-native traction inside the U.S. defense establishment and a credible "command OS" trajectory, but its 3.3x valuation step-up in twelve months rests on fundamentals it does not disclose, leaving the $2.15B mark hard to underwrite from public evidence.
Strategically credible Chinese electrolyzer leader with real project momentum, but public-only diligence does not yet justify paying a full private-round premium.
Kapital looks like a real full-stack SMB banking platform with regulated-bank profitability and scale, but public evidence still does not show the consolidated revenue, cap-table, and preference-stack detail needed to underwrite the September 2025 unicorn price aggressively.
Interos has real strategic value in government-grade supply chain risk intelligence, but stale 2021 unicorn pricing, credit-led financing, and limited financial disclosure keep it in research-more territory.
Huma looks strategically credible as regulated digital-health infrastructure, but the current public data set is too thin on revenue, margin, and cap-table details to justify a buy call.
Moonshot AI has crossed from impressive product story into real commercial relevance, but the current valuation already prices in sustained hypergrowth, cleaner regulation, and a smoother IPO path than the public evidence can yet prove.
Resolve AI pairs exceptional founder-market fit and marquee customer proof with unusually thin financial disclosure, making the business strategically interesting but not yet fully underwritable at a $1.5B mark.
Tripledot looks like a credible scaled mobile-gaming platform with a directionally defensible implied ~$2.0 billion post-close mark, but audited revenue quality, debt, and preference-stack opacity keep the most supportable call at track rather than buy.
Talos is a strategically strong institutional digital asset infrastructure platform with credible product breadth and customer traction, but its current valuation already prices in substantial future execution while public disclosure remains too thin for high-conviction underwriting.
Moneyview has enough scale, profit, and IPO readiness to stay on the active watchlist, but DLG exposure, partner concentration, and incomplete durability disclosure keep the right stance at track rather than buy.
Preferred Networks remains Japan's most credible vertically integrated AI platform, but a thinly disclosed revenue base and a conflicted ($1.0B vs $2B+) third-party valuation make the headline unicorn price hard to underwrite from public evidence alone.
Genspark's pivot from AI search to agentic workspace is compelling, but public disclosure still lags the valuation narrative.
Assured looks strategically credible in AI claims automation, but incomplete public operating disclosure and a full unicorn price keep the investment posture at research-more rather than buy.
Lovable has rare growth velocity, a compelling prompt-to-production product wedge, and real enterprise signal, but public evidence still does not support buy-grade confidence at current prices because enterprise mix, retention, margins, headcount, and cap-table terms remain too opaque relative to the valuation climb.
Pivot Bio has genuine agronomic proof and meaningful commercial reach, but opaque economics, regulatory uncertainty for next-generation products, and a stretched current mark keep the name in research-more territory.
N26 has re-established growth and a credible path to sustainable profitability, but ongoing supervisory pressure and stale private-market price discovery make the current valuation case investable only with caution.
CHAOS is a serious distributed-radar defense startup with real procurement-path signals, but the public record is still too thin on revenue quality and customer economics to support the latest price without more diligence.
Avathon has credible industrial AI product breadth, government traction, and sector-specific customer proof, but unresolved financial opacity and conflicting valuation signals make it a research-more opportunity rather than an invest-now conviction call.
Mambu appears to be a real, strategically relevant cloud-banking and payments infrastructure platform, but the lack of current financial disclosure leaves the public investment case attractive only at a meaningfully lower entry point or after deeper private diligence.
Nirvana shows credible AI-native underwriting momentum and fresh Series D backing, but public disclosure is still too thin to underwrite the $1.5 billion valuation with conviction.
Garner appears to be a credible late-stage healthcare navigation winner with real scale and a differentiated data-and-incentives model, but the $2.74 billion Series E already prices in premium execution while public disclosure on margins, retention, and capital structure remains too thin for a clean buy call.
Clip has real strategic value as a scaled Mexican SMB-payments platform, but limited audited disclosure and a demanding $2 billion price keep the call at RESEARCH-MORE with medium confidence and a stretched valuation stance.
At-Bay has built a credible InsurSec platform with meaningful SMB distribution, own-paper underwriting control, and an emerging security upsell engine, but public evidence still supports a research-more recommendation because underwriting, retention, and cap-table economics are not disclosed well enough to underwrite a clean entry near the estimated $2.1B mark.
ID.me is a real reusable-identity asset with national-scale reach, but the current >$2B private mark still runs ahead of the public evidence on revenue quality, margins, concentration, and policy durability.
Research more: Mynt / GCash is a systemically important Philippine fintech with real earnings contribution, dense customer reach, and broad product breadth, but the marketed IPO range is stretched until prospectus-grade disclosure closes the main financial, credit, and retention gaps.
Track Persona: it is a scaled, strategically relevant identity platform, but the $2B Series D valuation is stretched on public evidence until private ARR, retention, margin, concentration, legal-reserve, and cap-table diligence support it.
Serval has exceptional investor conviction and a credible AI-native ITSM architecture, but the unanchored revenue growth claim, all-tech-startup customer base, sub-30-person headcount, and complete absence of disclosed unit economics leave the $1B valuation impossible to underwrite from public evidence alone.
Track: Wave combines rare mobile-money scale and strong price-led adoption with limited financial disclosure, meaningful regulatory complexity, and stale public equity price discovery.
True Anomaly is strategically relevant and increasingly well-capitalized, but the public record still supports a cautious, high-risk, price-sensitive stance because mission proof outpaces economic disclosure.
Midi has built a scaled, insurer-friendly menopause telehealth platform, but the current unicorn valuation outstrips what public evidence alone can underwrite.
Scaled payer-connected mental-health platform with real network breadth, but the investment case still hinges on proving revenue quality and managing reimbursement-heavy execution risk.
StackAdapt looks like a real, scaled, and likely profitable adtech winner, but the secondary-heavy 2025 round, premium reported valuation, and incomplete financial disclosure keep the current underwriting case in the track-not-buy bucket.
Gradiant appears to be a real and strategically relevant premium industrial-water company with differentiated technology and strong market tailwinds, but the current $2B headline valuation already prices in much of the upside before investors receive audited financial disclosure.
HawkEye 360 looks strategically real—differentiated RF GEOINT capability, meaningful government traction, backlog, and new public-market liquidity are all visible—but concentrated public-sector exposure, backlog-quality caveats, capital intensity, and still-opaque recurring economics justify a track stance rather than a buy call at the current public valuation.
Airalo is a real, scaled leader in travel eSIMs with broad consumer and channel reach, but public evidence remains too thin on current revenue quality, margins, and downside terms to justify more than a track posture at the 2025 unicorn valuation.
Moon Active combines rare mobile-gaming scale with likely cash generation, but Coin Master concentration and private-company opacity keep the investment case in track rather than buy territory.
Oishii looks like one of the more credible survivors in indoor farming, but the public case still leans on brand and capital more than fully disclosed economics.
Thyme Care looks like a credible scaled oncology-navigation platform with real payer/provider traction, but public financial opacity and a likely stretched late-stage mark keep the current call at track rather than buy.
Creditas is a scaled Brazilian secured-credit platform with improving margins and strategic funding optionality, but it remains too opaque and rate-sensitive for high-conviction underwriting at the latest mark.
OpenEvidence has built unusually strong clinician adoption and a genuine premium-content moat, but the January 2026 $12 billion valuation runs far ahead of public evidence on revenue quality, advertiser durability, enterprise depth, and governance disclosure.
Aura has enough scale, product breadth, and partner distribution to merit continued diligence, but the combination of private-company opacity and trust overhang keeps the recommendation at research-more rather than buy.
PostHog looks like a real multi-product developer platform, but public evidence still does not justify paying the reported $1.4B price with discipline.
XBOW has unusually strong technical and ecosystem proof for a two-year-old cybersecurity startup, but the current valuation still outruns the public financial evidence.
Socket has real product-market fit in software supply chain security — strong AI/developer customer proof, transparent seat pricing, and a differentiated behavior-plus-reachability stack — but the May 2026 $1 billion Series C still looks slightly stretched on public evidence because ARR, retention, margins, burn, and cap-table terms remain undisclosed.
Go1 appears to be a scaled and strategically relevant enterprise learning platform, but the public evidence supports the business more cleanly than it supports the latest private valuation.
Bitsight is a category-defining cyber risk intelligence platform with real scale, strategic relevance, and a plausible valuation anchor around the last public $2.4B mark, but the lack of audited economics, current financing terms, and clear preference-waterfall disclosure supports a research-more recommendation rather than a clean buy call.
WorkOS is a high-quality developer-first enterprise identity platform with unusually strong AI-customer proof, but the $2B March 2026 round still outpaces the public operating disclosure needed for a conviction buy call.
Eight Sleep has credible product differentiation and a fresh $1.5B financing anchor, but opaque financials, trust-sensitive product risks, and a premium valuation keep the stockless underwriting case in track-not-buy territory.
BillionToOne merits a TRACK rating: the platform, growth, and liquidity are strong, but at roughly $3.95 billion and about 8.5x-8.8x 2026 revenue the shares look fairly valued versus unresolved reimbursement, litigation, and control risk.
Vention shows credible platform momentum, strong named customer proof, and a potentially valuable physical-AI position, but public evidence still supports only a track stance until financial disclosure and cap-table opacity are resolved.
Nexamp looks like a scaled and financeable community-solar platform, but current public disclosure is too thin to underwrite the equity confidently.
SafetyCulture is a credible frontline-operations category leader with real scale, but the AU$2.5B headline price implies a 15-21x ARR multiple that outruns peers and the disclosure package.
Shiprocket combines real platform scale, improving unit economics, and strong cohort stickiness, but litigation overhang, courier concentration, and a stretched $1.21B private mark justify a TRACK stance until IPO pricing is visible.
Aidoc is a credible scaled clinical-AI platform, but public evidence is still too opaque on price and economics to support more than a research-more stance.
Aqua Security remains a credible CNAPP pioneer with Trivy-driven distribution, runtime/container depth, and real enterprise reach, but flat valuation since the 2021 unicorn round, 2025 restructuring, and persistent private-company disclosure gaps justify a TRACK recommendation and stretched valuation stance until private diligence proves materially stronger ARR, retention, margin, and cash-efficiency than the public record.
Vectra AI appears strategically valuable and commercially credible, but the absence of current financial and cap-table disclosure makes the stock-selection equivalent call a disciplined track rather than an investable buy.
Included Health looks like a credible late-stage digital-health platform with product breadth, marquee buyer proof, and visible profitability, but the lack of audited financial disclosure, retention transparency, and fresh price discovery keeps the investment case in research-more territory.
Together AI shows credible inference-cloud product and traction at a Series B valuation that requires multi-year ARR scale to underwrite a strong exit.
RELEX has rare ARR durability and deep retail vertical moats, but the unadjusted 2022 valuation and April 2026 workforce reduction create material diligence asks before re-entry.
Guild Education built the largest employer-sponsored tuition benefit platform in the United States, anchored by IRS Section 127's structural tax subsidy and a multi-sided network of 500+ employers and 150+ education institutions. The June 2022 Series F at $4.4B represented a peak valuation reflecting COVID-era labor shortage tailwinds and edtech enthusiasm. Since then, the business has navigated two large-scale restructurings, high-profile client cancellations (Disney, Macy's), and an unconfirmed Walmart Workforce Edge threat — while launching Navigator as the growth catalyst required to justify any premium to distressed public comps. At an implied current EV of $1.5-2B (secondary market), the investment case is a conditional buy at or below $2.0B: the structural market is intact, the platform has demonstrated utility at scale, but financial opacity, decelerated growth (~6% YoY), and execution uncertainty during the CEO transition prevent high-conviction commitment without data room access.
Ramp's 100%+ growth, 25,000 customers, and AI-native moat justify TRACK status; the $13B secondary valuation at 18–26× unconfirmed ARR is aggressive and demands primary diligence before conviction.
Mainspring has real strategic momentum and credible project proof, but public evidence still supports research-more rather than a price-sensitive buy call.
Arcadia looks strategically important, but current public evidence still does not support a clean entry-price decision.
Cyberhaven shows credible category leadership and enterprise traction, but the $1B Series D still requires private diligence on financial quality, litigation exposure, and architecture hardening.
Opentrons has real product, customer, and investor relevance, but the public record is still too thin to justify paying the 2021 unicorn price with confidence.
Real consumer-AI scale story with strong operating signals, but not enough public denominators to justify a buy recommendation at the disclosed unicorn price.
Regent has crossed from concept to credible industrial program, but public evidence still does not support underwriting its 2026 valuation without private diligence.
Shenji is a real and strategically valuable automotive-chip platform, but at the current private mark the upside is capped by opaque economics, heavy NIO dependence, and unresolved merchant-commercialization risk.
Blue Energy has rare financing and partner quality for a 2023-founded nuclear startup, but the current unicorn mark is only directionally credible rather than fully underwritten because project economics, financing terms, and repeatability beyond one flagship remain private.
Clipboard Health has built a large and operationally credible healthcare staffing marketplace, but public evidence still leaves too much uncertainty on revenue quality, retention and contractor-model resilience to recommend underwriting the old unicorn mark aggressively.
Hostaway looks like a real late-stage category leader in STR software, but the current unicorn valuation floor is better supported than any premium above it; recommendation: research more.
Strategically strong fleet-charging platform, but public economics and price support remain too thin for a high-conviction entry call.
Research-more: BioRay has real revenue, high-margin commercial infrastructure, and credible innovation optionality, but public evidence does not yet justify paying aggressively at its last unicorn-scale private anchor.
Obsidian has genuine category leadership in the emerging AI-agent-governance market and a confirmed $1.1B unicorn mark, but the valuation rests on estimated rather than disclosed ARR in a rapidly crowding field, supporting continued tracking over conviction pricing.
Genki Forest: real brand and channel scale, but current valuation support remains too opaque for an aggressive fresh entry
Avaada has real scale, financing credibility, and strategic optionality, but current entry underwriting is limited by opaque group valuation, capital structure, and entity-level decomposition.
EasyPost appears to be a real and strategically relevant shipping infrastructure company, but the reported 2026 unicorn valuation is not well enough supported by public evidence to justify a clean investment recommendation.
Track: AI21 has real technology, real customer proof, and a plausible Maestro-led wedge, but the latest visible unicorn mark offers too little public margin of safety for a higher-conviction recommendation.
Exceptional regulatory asset (OCC charter) justifies attention; conditional invest pending FDIC approval confirmation, technology diligence, and management depth validation.
Aerospace Yuxing has real product and customer proof, but the public record still supports tracking the company more than paying peak-narrative pricing.
A fast-executing European humanoid robotics leader with elite partnerships and a large pre-order book, but a $1.35B pre-revenue valuation that rests on still-unproven commercial conversion.
Research-more: Satispay has built real network scale and platform breadth, but the current unicorn valuation still runs ahead of public disclosure quality.
YMTC is strategically important and commercially real, but sanctions, capital intensity, and opaque earnings still cap conviction at current valuation talk.
Track: Envision Energy is strategically important and already very large, but disclosure, geopolitics, and capital-intensity risks keep the public-evidence call at TRACK with medium confidence.
Earendil looks like a real AI-biologics platform with rare blue-chip validation, but the current unicorn mark still demands more proof than the public record provides.
Castelion combines rare DoD demand pull, credible founder-market fit, and a manufacturing-first thesis that could matter if the Pentagon truly shifts hypersonics from boutique programs to mass procurement, but the current ~$2.8B valuation already prices in substantial execution and production success.
Strong founder-market fit and a coherent governed-semantic platform have produced real enterprise traction, but thin public durability disclosure and rising bundle pressure leave Omni as a track, not buy, at $1.5B.
Forus has built a real prescription-access network with strong growth and strategic value, but the reported $1B valuation remains hard to underwrite without margin, concentration, and governance disclosure.
Acko has built a strategically relevant digital-insurance platform with credible scale, improving financial direction, and a real embedded-distribution edge, but public evidence still shows governance overhang, customer-tail risk, and incomplete unit-economics disclosure, so the current IPO range belongs on a conditional watchlist rather than in the portfolio.
Research more: KnowBe4 has real scale, strong customer proof, and high-quality recurring revenue, but elevated leverage, active risk clustering, and limited private-company disclosure keep the current valuation case only fair rather than clearly attractive.
Research more: M-KOPA looks like a scaled pan-African fintech with credible unicorn economics, but public evidence still does not justify paying a large premium above roughly $1.7 billion without lender-grade portfolio, cap-table, and governance disclosure.
Egnyte is a rare profitable, founder-led content platform with durable regulated-vertical niches, but its ~$1.5B PE-era valuation, opaque financials, and structural exposure to Microsoft/Google bundling warrant close monitoring rather than conviction.
Strong founder-market fit and a coherent governed-semantic platform have produced real enterprise traction, but thin public durability disclosure and rising bundle pressure leave Omni as a track, not buy, at $1.5B.
Granola's bot-free meeting-notes product shows strong, well-corroborated funding momentum and customer proof, but its $1.5B Series C valuation cannot be checked against any disclosed revenue, ARR, or margin figure.
TensorWave has real infrastructure and customer proof, but the June 2026 $1.55 billion mark still looks stretched until debt structure, customer quality, and audited operating metrics become clearer.
Tianji appears to be a real and scaling Chinese robotics supplier with credible dual-arm productization, legacy industrial deployments, and top-tier strategic funding, but the May 2026 RMB8-10 billion valuation still outruns the public financial evidence needed to underwrite it confidently.
Defense Unicorns has real attributable traction in air-gapped defense software delivery, but the $1B+ Series B valuation still depends on economics the public record does not disclose.
GigaAI is a technically ambitious Beijing physical-AGI company with strong 2026 capital access and credible early deployment signals, but public evidence still does not support underwriting its unicorn valuation with the same confidence one would apply to a more disclosed robotics peer.
Ent is a high-pedigree, high-ambition workspace security startup with a rare $100M seed and credible product wedge, but the absence of disclosed financials, named customer depth and independent efficacy benchmarks makes it a monitor-now rather than invest-now situation.
Liquid Death's category-defining brand, 133,000+ door distribution, and rapid scaling to ~$333M revenue are real and well-evidenced, but a premium ~4x revenue valuation, thin disclosed economics, and concentration risk warrant TRACK / research-more with medium confidence.
Flexe is a category-defining flexible warehousing platform with credible enterprise traction, but stale financing, opaque unit economics, and post-2023 restructuring keep valuation risk elevated.
Scribe has credible enterprise workflow adoption and a differentiated AI-context wedge, but public evidence still supports only a cautious underwriting view at the 2025 $1.3B valuation.
Forterra has credible defense-autonomy traction and a widening partner stack, but the public record still lacks the revenue, margin, and governance detail needed to underwrite the reported unicorn valuation confidently.
Cloaked has built a credible and fast-growing consumer privacy platform with real customer and funding momentum, but the undisclosed 2026 post-money valuation and lack of public unit-economics disclosure keep the recommendation at research-more.
Boston Metal pairs differentiated electro-metallurgy IP and a blue-chip investor base with real partner validation, but unproven steel-scale economics, Brazil restart risk, and valuation opacity justify a track stance rather than an immediate underwriting call.
Black Lake appears to have real product-market fit in China's cloud manufacturing software niche and a credible industrial-AI upsell story, but the company still discloses too little about revenue quality, retention, and cap-table terms to justify an invest-now call at its April 2026 private-market valuation.
Amca has a credible industrial thesis and meaningful early scale, but the $1B-plus mark is hard to underwrite without audited financials or customer-concentration disclosure.
Track: K2 Space has stronger contract proof and more differentiated product ambition than most private satellite manufacturers, but the $3 billion entry price still requires on-orbit validation, manufacturing execution, and much better financial transparency.
Vantaca appears to be a category leader in HOA/community-management software with credible growth, real product breadth, and a validated 2025 financing anchor, but public disclosure is still too thin to justify an aggressive underwrite at the last unicorn valuation.
Higgsfield has real hypergrowth and product-market pull in AI video marketing workflows, but the current underwriting case is constrained by unresolved safety, governance, and quality-of-revenue risk.
Forus has built a real prescription-access network with strong growth and strategic value, but the reported $1B valuation remains hard to underwrite without margin, concentration, and governance disclosure.
Periodic Labs combines one of the strongest founder teams in frontier AI and materials science with an ambitious autonomous-lab thesis and exceptional investor validation, but the company remains far from commercially proven and the reported 2026 financing mark prices in success well before public revenue or customer evidence justifies it.
Real multi-orbit orchestration proof and a credible government-commercial wedge, but the $1.3B round already prices in software-like upside ahead of disclosed economics.
Strategically relevant AI-native financial crime platform, but the current valuation is difficult to underwrite without private revenue, retention, and term data.
SKIMS has reached real global brand scale and category relevance, but the current $5 billion private valuation already prices in continued hypergrowth while audited financials, governance detail, and celebrity-concentration risk remain unresolved.
Forus appears to be a real and strategically valuable prescription-access workflow asset, but the public evidence is still too thin to justify paying the current unicorn valuation with conviction.
Aurora Solar appears to be a genuine category leader in solar workflow software, but public evidence still points to stretched valuation, market-driven operating pressure, and too much missing financial disclosure to underwrite the company confidently at its benchmark.
Fireblocks is a real institutional digital asset infrastructure leader with verifiable enterprise scale, but the unchanged $8B Series E mark is indefensible at current 4–6x EV/revenue multiples implied by BitGo's IPO and Anchorage's financing, and the company's continued opacity on margins, NRR, and litigation resolution makes a research-more call the only defensible position.
Zelos appears to be a real, unusually scaled autonomous-logistics operator with strong partner-backed deployment proof, but hidden economics, mixed valuation reporting, and unresolved legal/governance questions keep the case in research-more territory.
OnX appears to have built a real, scaled outdoor-mapping subscription platform, but the public record still lacks enough revenue-quality, retention, and term disclosure to underwrite the July 2025 ~$1.4B valuation with conviction.
Retool has credible product-market fit and strategic relevance in governed internal software, but the last disclosed $3.2B valuation still looks stretched against 2026 public comps and the company's thin public financial disclosure.
Razorpay looks like one of India's strongest private merchant-fintech assets, but the public record still supports tracking and further diligence rather than paying the highest private valuation headlines with conviction.
Poolside has a credible sovereign-enterprise product thesis and meaningful upside if secure coding AI becomes a durable high-ACV category, but public evidence is still too thin on revenue quality, customer proof, and infrastructure execution to support an aggressive buy recommendation.
Real payer-workflow scale, but undisclosed price and economics keep Cohere in research-more territory.
Castelion combines rare DoD demand pull, credible founder-market fit, and a manufacturing-first thesis that could matter if the Pentagon truly shifts hypersonics from boutique programs to mass procurement, but the current ~$2.8B valuation already prices in substantial execution and production success.
Redpanda combines strong Kafka-compatible technology, blue-chip production references, and real market tailwinds, but the April 2025 $1B Series D price remains difficult to justify without disclosed unit economics or independently corroborated scale metrics.
MNT-Halan has built genuine late-stage fintech scale, but incomplete disclosure on credit quality, margins, and capital structure keeps the investment case in research-more territory.
Handshake looks like a real category leader in early-career recruiting with meaningful platform optionality, but the public evidence is still insufficient to underwrite the stale 2022 unicorn price with confidence.
Marshmallow has a real and differentiated UK-newcomer insurance franchise with credible scale and a 2024 profitability inflection, but the >$2B 2025 mark still outruns the public disclosure needed for a buy call.
Strava is a scaled, premium-capable social fitness network, but the latest private-market mark still looks rich relative to what public evidence proves.
Clio is a scaled, profitable legal-workflow leader with genuine product breadth and customer reach, but the current US$5 billion valuation (about 10x ARR) and persistent disclosure gaps support only a track stance.
Radiant Nuclear has become one of the most credible private microreactor developers on public milestone evidence, but the current >$1.8B valuation signal still looks premature relative to zero disclosed revenue, stacked fuel and licensing gates, and concentrated customer proof.
Upwind looks strategically relevant and commercially real, but the current $1.5 billion valuation is ahead of what the public record can actually underwrite. Recommendation: research-more until private diligence closes ARR, retention, margin, and cap-table gaps.
Skydio has built a durable U.S. defense/public-safety drone position, but the April 2026 $4.4B price still assumes software-grade economics that public evidence does not yet prove.
o9 has credible product depth and strategic value in enterprise planning, but public evidence still falls short of justifying an unqualified positive call at the last disclosed $3.7 billion mark.
Fanatics is a real, scaled sports platform with credible diversification optionality and public revenue anchors around $7B to $8B, but stale valuation marks, opaque segment economics, and cap-table uncertainty keep the investability call at research-more rather than buy.
OpenAI has real frontier-AI scale and demand proof, but the $852B entry mark still outruns the public disclosure package.
WeLion has real commercialization proof, rare Chinese semi-solid battery credibility, and a plausible IPO path, but the current RMB 18.5-20.0bn valuation narrative still runs ahead of public evidence on revenue, margins, customer concentration, and manufacturing quality, making Track the most defensible call at low confidence.
MediTrust Health is a real scaled China healthcare-payments infrastructure asset with strong insurer and pharma reach, but current public evidence still points to high execution and pricing risk, making the last private valuation look stretched unless investors get better disclosure, a discounted entry, or explicit downside protection.
Tebra is a meaningful independent-practice software platform, but the public record still lacks the revenue, retention, margin, and cap-table proof needed to underwrite a ~$1B mark with conviction.
Fluidstack has a credible strategic position in the AI infrastructure buildout, but the current $7.5B valuation still outruns the quality of public financial and concentration disclosure.
Baichuan combines real healthcare differentiation, credible funding, and visible commercialization progress, but the current public evidence still supports TRACK rather than an aggressive underwriting call at the last visible private mark.
Neon is a credible scaled Brazilian fintech with improving economics and real institutional validation, but the investment case still hinges on proving customer depth, credit quality, and valuation terms behind the unicorn label.
Clara looks like a credible LATAM corporate-finance platform winner in formation, but the absence of clean public unit economics and a fresh priced valuation makes this a research-more / price-discipline story, not a blind chase.
Prove looks like a serious identity infrastructure company with credible customer and product proof, but the price and evidence gap still argue for research-more rather than a clean buy call.
Upstage has earned its unicorn mark through real model benchmarks, product breadth, and sovereign backing, but a Track recommendation follows because the current valuation is running ahead of publicly verifiable economics.
Aerofugia has enough milestone, partner, and customer proof to merit continued diligence, but not enough economic transparency to justify a price-insensitive endorsement.
NextSilicon has real technical differentiation and flagship HPC proof, but the public record is still too thin on commercialization economics and valuation structure to underwrite a premium private mark with high confidence.
Portside is a credible aviation-operations consolidator with real product breadth and customer proof, but the right call remains track: public economics, retention, and current financing terms are too opaque for a conviction-priced investment.
Valar is now one of the fastest-moving U.S. advanced-nuclear startups, but public evidence still supports research-more rather than paying through its reported $6 billion August 2026 mark.
Research-more in 2026: TruKKer appears to be a real GCC freight platform with low-end unicorn credibility, but the public record does not justify paying a premium above the US$1B threshold without audited economics, receivables-quality proof, and cap-table clarity.
TRACK — Real Strategic Option Value in Embodied AI, but Public Proof Still Trails the Unicorn Narrative
OneCard looks like a real scaled Indian consumer-fintech asset, but the correct current stance is track rather than commit, because regulatory remediation and private risk metrics matter more than brand strength alone.
Track: Micro Connect may be building a genuinely differentiated market for small-business cashflow investing, but public disclosure is still too thin to underwrite the story at any price.
PatSnap looks like a real scaled innovation-intelligence platform with meaningful ARR and customer proof, but public-only evidence still supports a research-more stance because the rumored IPO valuation appears full before retention, margin, governance, and float-structure details are proven.
Watch: Locus has real enterprise traction and a plausible route to higher-value automation, but public evidence still does not justify paying the last private benchmark without an opacity discount and deeper financial diligence.
DriveNets looks like one of the more credible late-stage network-infrastructure stories in the market, but the June 2026 $8.5 billion valuation still appears stretched until public or private diligence fills in the missing revenue and margin denominator.
Lila is one of the best-capitalized AI-for-science startups in market, but the current valuation already assumes scientific and commercial proof that the public record has not yet fully shown.
Ai.tech appears to own strategically relevant ad-tech assets and may directionally merit unicorn status, but weak operating disclosure keeps the investment case in research-more territory.
Celero Communications is a technically credible coherent DSP startup with Alphabet backing and elite semiconductor founders, but is pre-scale with unverified revenue and high execution risk at a ~$1B entry valuation.
Talkdesk has real scale, enterprise customer proof, and a credible AI-led product stack, but the public evidence still does not justify high-conviction underwriting at its historical $10B private mark.
NotCo has a credible AI-platform differentiation story, but current valuation support remains too opaque for anything stronger than track.
WeDoctor appears to be a real, strategically important China digital-health platform, but the last widely cited private valuation looks expensive relative to public-comparable evidence and current disclosure quality.
SPIC Hydrogen Energy looks strategically stronger than many hydrogen peers, but the public record is still too thin to justify aggressive entry above the last disclosed CNY13B private mark.
Stardust Intelligence has achieved genuine early commercial traction with its cable-driven humanoid but must prove manufacturing scale, unit economics, and the durability of its unconventional actuator approach before its aggressive valuation is justified.
Proxima Fusion is the strongest European fusion asset on paper — IPP/W7-X heritage, a peer-reviewed stellarator concept, blue-chip strategic backing, and Europe's largest fusion war chest — but it is a pre-revenue science moonshot priced at €2.4B with net energy still unproven and grid revenue more than a decade away, so the right call is to track it closely with venture-style, option-value discipline rather than underwrite it on fundamentals.
Real regional logistics platform with meaningful public revenue and customer proof, but still too opaque to justify paying the old unicorn mark without refreshed diligence.
inDrive is a differentiated and clearly scaled mobility platform, but the valuation case is constrained by preliminary financials, live regulatory and labor risk, and incomplete disclosure on cash, unit economics, and cap-table terms.
Research more: ABLY is a scaled Korean fashion-tech platform with credible growth, strategic validation from Alibaba, and improving operating performance, but the current headline price still looks rich relative to commerce-like public comps until private economics and round terms are disclosed more fully.
Research more: LINE MAN Wongnai has real Thai scale, credible ecosystem breadth, and signs of improving profitability, but the current public record is still too thin on audited financial quality, control-transaction terms, and subsidy-normalised cohorts to justify a premium-priced IPO or private entry above roughly THB55 billion.
High-velocity Chinese humanoid robotics pioneer with breakthrough consumer pricing and strong policy alignment, but unproven unit economics and significant bubble risk in an overcrowded market.
Research more: RedotPay has credible product-market pull in stablecoin payments and unusually fast fundraising momentum, but the reported $4 billion IPO target looks stretched until audited financials, partner disclosures, and active-user quality metrics become public.
Track: Navi is a scaled Indian fintech with real regulated-product breadth, lending-arm profitability, and a large consumer funnel, but regulatory scar tissue, debt-heavy funding, and unsigned valuation terms keep the case short of a buy recommendation.
Nordic Knots looks like a genuinely strong premium home-textiles brand with real growth and profitability, but the public record still supports a research-more call because the March 2026 valuation implies a ~31x revenue multiple without audited financial disclosure.
AIsphere has enough product, scale, and financing evidence to stay investable, but the current unicorn-level price is still too under-documented on ARR quality, margin durability, and security terms to justify a buy call.
Track: OYO's filed turnaround and global-scale repositioning now support a real IPO conversation, but leverage, litigation, profit-quality adjustments, and a stretched $7-8 billion ask still require disciplined underwriting.
Tibber has a real smart-energy product and household flexibility platform, but the public record is still too conflicted and incomplete to justify a high-confidence investment stance at the current private-market mark.
Research more: Slash's growth and product differentiation look real, but the $1.4 billion Series C already assumes margin durability and control depth that public evidence still does not verify.
Rogo is a fast-compounding, well-financed vertical AI platform for Wall Street with concrete institutional traction, but its $2 billion Series D price has outrun every public revenue, margin, and retention disclosure, warranting research-more rather than a directional buy or avoid call.
Tide has built a scaled UK-and-India SME finance platform with improving filed financials, but the latest $1.5B valuation already assumes better monetisation, cleaner support outcomes, and clearer group economics than public evidence currently proves.
Wonderful may become a category-defining enterprise AI workflow platform, but the public evidence does not yet justify price-insensitive conviction at a $2B valuation. Product depth and customer proof are real; retention, margin, concentration, and preference-stack evidence are not.
Ro has built a real scaled asset in D2C healthcare with strong GLP-1 growth and meaningful vertical integration, but the stale $7B mark, lack of audited disclosure, and heavy dependence on regulated manufacturer channels keep the company in watchlist rather than clear-buy territory.
9fin has built a credible AI-native platform with proven penetration across all top-10 global investment banks and 350+ institutions, warranting a Track stance while financial opacity prevents a clean underwrite of the $1.3 billion valuation.
Merama looks stronger than many global aggregator failures, but thin public disclosure, debt-funded expansion, and brand/platform concentration keep the recommendation at TRACK with medium confidence and a stretched valuation stance.
Musinsa combines category leadership, real profitability, and strong Korean fashion consumer mindshare, but the current private/IPO valuation ambition runs materially ahead of disclosed fundamentals and the company still carries regulatory, trust, and international-execution risk.
SPAN has credible product differentiation and increasingly important channel partners, but the public evidence still supports TRACK rather than a high-conviction buy because valuation markers and operating disclosure remain too far apart.
TARS is China's best-funded pre-revenue humanoid robotics startup with a credible technical edge in dexterous manipulation, but the absence of customer proof, revenue, and disclosed financials warrants a Research-More stance ahead of Series A diligence.
MatX is a technically credible but pre-de-risked bet on a frontier LLM training chip: exceptional founding team, $625M runway, and a differentiated architecture, but no silicon, no customers, and an undisclosed valuation make this a high-conviction speculative position contingent on 2027 tapeout execution.
Deep Robotics has moved beyond robotics narrative into real industrial revenue and first-time profitability, but private/pre-IPO status, capital intensity, and noisy valuation evidence keep the right call at track rather than buy.
Andela remains a relevant global talent platform with meaningful scale and AI-era repositioning, but stale valuation data, limited financial disclosure, and rising AI/competitive pressure keep the investment case in watchlist territory.
Pristyn Care has real operating reach and clear category fit in Indian elective surgery, but opaque disclosure, still-large losses, and a flat-priced bridge at a preserved unicorn valuation keep the recommendation at RESEARCH-MORE.
Owkin has real strategic validation from top-tier pharma, differentiated federated-data access, and encouraging K Pro commercialization signals, but persistent financial opacity and an unrefreshed primary valuation make it a monitor-not-buy name today.
Compelling humanoid robotics unicorn with strategic Luxshare manufacturing partnership, but pre-revenue with high China geopolitical risk — conditional pass with proof gates.
Avoca has genuine vertical AI traction and elite investor validation in an underpenetrated home-services market, but the $1 billion valuation on undisclosed eight-figure ARR creates too wide an uncertainty band to underwrite without data-room access — warranting a track posture until key unit economics are verified.
Rain has built a genuinely differentiated stablecoin payments infrastructure platform with rare dual-network card membership and striking growth metrics, but the $1.95B valuation demands revenue disclosure that remains absent, and Mastercard's acquisition of BVNK is a direct competitive threat that could reshape enterprise pipeline dynamics.
Decart has built rare momentum in real-time world models and AI infrastructure, but the current ~$4 billion valuation is ahead of what the public revenue record can yet support.
Yinwang is strategically important and clearly scaling, but its RMB 115 billion mark already prices in a great deal of upside before standalone economics are publicly provable.
Ninja has achieved unusually fast Saudi quick-commerce scale and a credible pre-IPO profile, but incomplete disclosure on revenue quality, margins, and governance keeps the current $1.5 billion mark in track-not-buy territory.
Flexiv is a credible Stanford-pedigreed adaptive-robotics franchise with a differentiated force-control stack and unicorn financing, but private disclosure and US-China geopolitics keep the valuation hard to defend.
Clay has achieved exceptional product-market fit, capital efficiency, and community moat at $100M ARR, but the $5B tender-implied valuation embeds unverified NRR and gross-margin assumptions that prevent a conviction buy without data-room access.
HistoSonics has rare private-medtech proof for a first-of-kind non-invasive tumor platform, but missing commercial economics and a full 2025 valuation anchor leave it in research-more territory rather than justify fresh capital at current terms.
ShopMy has built a credible, fast-scaling creator-commerce platform with real platform-sales and profitability signals, but the public record still supports only a track stance because the latest $1.5 billion valuation sits ahead of disclosed fundamentals and detailed financing terms.
Sonatype appears to be a credible, profitable software-supply-chain control-plane asset with strong regulated-enterprise proof, but private-equity opacity, bundled-platform competition, and incomplete debt and retention disclosure keep the report in research-more territory.
Tipalti is a real scaled fintech platform with broad product depth and strong customer adoption, but the combination of regulated payments exposure, debt-funded expansion, layoffs, and a stale 2021 valuation anchor makes this a research-more name until management proves current economics and fair value.
Performance Drone Works shows credible defense-market traction, product breadth, and manufacturing ambition, but public evidence is still insufficient to price the business confidently because revenue, backlog, margin, headcount, and post-money terms remain opaque.
Render has real product breadth, strong developer adoption, and a credible AI-native wedge, but public monetization evidence remains too thin to comfortably underwrite its $1.5B valuation.
Salt Security remains a credible API security category pioneer with meaningful enterprise traction, but the gap between public operating disclosure and the 2022 unicorn valuation is still too large for a high-conviction investment call.
Voodoo has rare private-company scale and confirmed profitability, but opaque unit economics, B-rated leverage, and an unproven BeReal bet make this a track / research-more at any premium multiple.
Lunar is a real integrated battery and Gridshare VPP platform with meaningful traction and capital access, but opaque economics, California- and partner-heavy exposure, and conflicting valuation signals keep the right call at research-more.
Owner appears to have built a real and increasingly scaled restaurant-software platform for independent operators, but the public record still does not provide enough denominator detail on revenue quality, retention, margins, or financing terms to justify underwriting the May 2025 $1B valuation with conviction.
LangChain is a category-defining agent engineering platform with real enterprise traction, but the last disclosed revenue range still falls far short of supporting the 2025 $1.25B price from public evidence alone.
Liquid AI has differentiated edge-deployment technology and credible strategic backing, but the $2.3B private valuation still outruns the public commercial disclosure package.
Framer looks like a real design-led website-platform winner, but the current $2B valuation already prices in strong enterprise conversion and leaves too little disclosure on retention, margins, and revenue mix to justify an aggressive entry.
Moglix is a scaled, improving B2B industrial-procurement platform at an inflection point, but the $2.5–2.6B last-round valuation remains stretched relative to public comparables; track pending profitability confirmation and IPO-readiness disclosure.
Skyryse has built a differentiated software-defined flight-control platform with real certification progress and credible dual-use partner pull, but the $1.15B valuation already prices in substantial execution success before public revenue proof exists.
Strong outcomes and category momentum make Pomelo worth tracking, but public evidence does not yet justify confident underwriting at a $1.7B valuation.
osapiens has enough growth, product breadth, and customer proof to justify continued diligence, but the public record still does not defend paying above a $1B valuation with conviction.
Iterative Health shows unusually strong public proof of network performance and strategic relevance, but the current unicorn valuation still requires revenue and margin evidence that has not been disclosed.
Lila is one of the best-capitalized AI-for-science startups in market, but the current valuation already assumes scientific and commercial proof that the public record has not yet fully shown.
MiniMax has built one of the broader product surfaces among private AI companies and appears commercially real at meaningful scale, but live IP litigation, governance and financial opacity, and intense pricing competition keep the story in Track rather than buy territory at reported late-stage marks.
Whop has real creator-commerce scale and increasingly differentiated payments rails, but the February 2026 $1.6B mark already prices in premium execution despite limited audited disclosure and live trust, moderation, and dispute-handling risk.
Flock Safety is a real, scaled public-safety platform, but the 2025 round already prices in a favorable margin-and-trust outcome that the public record does not yet prove, so the right call remains TRACK rather than buy.
Zama looks like the clearest public leader in FHE-based confidential blockchain infrastructure, but the current valuation sits ahead of disclosed commercialization proof, supporting a research-more stance rather than a buy call.
Zip has credible product-market proof, category leadership signals, and large-enterprise customer traction, but the current $2.2B reference valuation is stretched against publicly unverifiable revenue quality and still-opaque financing terms.
Cera has real AI-enabled home-care scale and credible public-sector demand, but debt-heavy financing and incomplete disclosure support a watch posture rather than an aggressive entry.
Quantinuum is one of the strongest pre-IPO quantum platforms, but a $10B valuation on only $30.9M of 2025 revenue, a $192.6M net loss, and unresolved Honeywell control terms keeps the name in track territory rather than buy territory.
Enveda's Phase 1b ENV-294 data and $517M capital base establish real clinical credibility, but a binary Phase 2a readout, undisclosed financials, and an unconfirmed unicorn valuation keep it in watch-and-track territory.
Bedrock Robotics has credible early field proof and a strong autonomy pedigree, but its valuation already prices in execution that public economics and retention data do not yet verify.
Chai Discovery is a technically credible AI antibody platform with blue-chip backers and a landmark Lilly partnership, but its $1.3B valuation is entirely premised on unvalidated preprint benchmarks, a single disclosed revenue partner, and zero public financial data—warranting deeper diligence before any commitment.
Rapyd is strategically credible after PayU and clearly has real global payments scale, but opaque standalone disclosure, multi-entity execution risk, and only fair value at the 2025 mark support a TRACK recommendation rather than a buy.
Sakana AI is the leading Japan-native AI research company with production deployments at MUFG, SMBC, and ATLA, but its $2.65B valuation at ~88x estimated ARR and unresolved AI Scientist quality concerns warrant a TRACK stance pending third-party product audits and pricing normalization.
Koloma is the best-funded natural hydrogen explorer worldwide, backed by tier-1 climate and energy investors, but remains pre-revenue with unconfirmed well results and significant geological, commercial, and regulatory uncertainty at a likely $600–900M implied valuation.
Kavak pioneered formal used-car markets across LatAm with a unique financing-integrated model, but a 75% valuation haircut, continued losses, heavy debt, and market exits reveal deep execution challenges that must be resolved before the company can justify its original unicorn premium.
Silverfort's agentless identity security architecture is genuinely differentiated and the market tailwind is real, but the $1.5B Series D valuation carries a 20–50% premium over public comps and cannot be underwritten at high conviction without audited ARR, NRR, and burn-rate disclosure — warranting a conditional-buy stance pending diligence completion.
Research-more: Xaira's science, team, and capital justify continued diligence, but public evidence and unknown pricing do not yet support underwriting a premium private valuation.
Generate is a rare AI-native biotech with a real Phase 3 asthma asset and strong post-IPO liquidity, but the stock already sits near fair value while revenue quality and late-stage execution risk remain unresolved.
Netradyne is a credible AI fleet-safety platform worth researching further, but public evidence is not enough to underwrite a premium valuation without private financial and legal diligence.
Airwallex's $1B+ ARR at 90% growth, $8B valuation, and 80+ licenses represent a CONDITIONAL WATCH at current stage; US expansion execution, financial transparency, and governance maturity are the key thesis-validation milestones before a formal commitment.
Skild AI is the early platform leader in hardware-agnostic robotics AI with genuine technical differentiation, but its $14B valuation at ~467x ARR leaves no margin for execution risk — warrant research-more pending audited economics and public benchmarks.
Transcarent has assembled a compelling post-Accolade platform (20M+ members, 1,700+ clients, >$550M guided combined revenue) led by a proven CEO, but the investment case hinges on unverified standalone financials, unresolved integration execution risk, and a $2.2B valuation that looks stretched against the sector's 2022-2024 de-rating. Defer commitment until FY2025 audited financials and post-merger churn data are available.
Apptronik is an AI-native humanoid robotics company with deep NASA heritage, a Google DeepMind partnership, and $1.28B in funding — but remains pre-commercial with no confirmed pilot-to-commercial conversions, a stretched $5B valuation, and significant competitive and scaling risks.
Einride is a commercially-validated autonomous freight TaaS company with blue-chip CPG references and 500K+ AV km — rich at 39-42x 2024 revenue; monitor with conviction entry on SPAC close with >$100M trust net proceeds.
Form Energy has real manufacturing and customer proof, but the public evidence package still stops short of a priceable underwriting case.
Perplexity AI: Fastest AI-Search ARR Ramp in History, Priced for Perfection at 40× ARR
VNLIFE is a real scaled Vietnamese payments platform with durable strategic relevance, but thin public economics and only an indicative >US$1B secondary valuation anchor support a RESEARCH MORE recommendation rather than an aggressive buy.
Yuanxin has real scale and category leadership, but the RMB 19.5B pre-IPO mark looks stretched relative to its low margins, slower growth, and unresolved IPO/dilution risk.
Happy Health has enough regulatory and workflow proof to stay on the diligence list, but not enough valuation or financial disclosure to justify a high-confidence premium entry price.
Xingyuanzhi has a credible embodied-brain thesis and real momentum, but public disclosure is still too thin to justify a price-insensitive investment call at unicorn-band levels.
Modern Health looks like a credible, scaled employer mental-health platform, but the visible unicorn valuation anchor is ahead of the proof public investors or crossover buyers would want.
Fasset looks like a credible new fintech unicorn, but the current mark is only fairly supported and still too underdisclosed for a decisive buy recommendation.
Glow Security has real category potential and real launch proof, but the public file is still too thin and too structurally inconsistent for a confident buy call at the current price.
Ant International's network scale, product breadth, and strategic relevance support a RESEARCH-MORE posture, but the US$11.2B price and incomplete standalone disclosure make entry discipline and hard diligence gates essential.
SiFive is the leading late-stage commercializer of RISC-V CPU IP, but the $3.65B Series G still prices in revenue quality and royalty conversion that public sources cannot yet verify.
Automation Anywhere looks strategically relevant and commercially real, but public evidence still supports a disciplined research-more stance rather than a clean late-stage buy.
HiDream.ai has enough technical and strategic substance to justify deeper diligence, but its current unicorn-plus valuation is supported more clearly by financing momentum and product proof than by publicly disclosed economics, leaving the stock of evidence in research-more territory.
Create Music Group is a genuine independent-music monetization leader with aggressive catalog M&A, but the $2.2B valuation is better supported by scale narrative and capital access than by any audited economics; recommendation: research more.
EcoFlow is a real scaled energy-hardware brand with premium category breadth and global reach, but the lack of audited economics means a late-stage entry cannot be cleanly underwritten from public evidence.
Abogen has matured into a credible frontier-mRNA platform with real late-stage and oncology milestones, but public evidence still does not justify premium-price conviction without private financial and term-sheet diligence.
HeyTea has the brand, scale, and product engine of a serious consumer platform, but thin public economics and private-company opacity keep the investment call at track rather than buy.
Aether looks like a serious regional enterprise-AI company, but the current $1B valuation already prices in premium outcomes that the public evidence cannot yet fully prove.
Ajaib combines real retail scale, strong product breadth, and credible growth signals, but public evidence still leaves too much uncertainty on consolidated financial quality, customer-quality metrics, and risk-adjusted valuation to underwrite the unicorn mark aggressively.
Track: Castelion has credible strategic importance and real government traction, but public evidence still does not justify aggressive pricing without deeper diligence on economics, conversion, and factory execution.
Yubi is a strategically credible debt-infrastructure unicorn, but the current private mark is best approached with discipline because public proof on monetization, concentration, and regulatory cleanliness still lags the strength of the platform story.
Destinus has credible product, partner, and defense-demand momentum, but public evidence does not yet justify underwriting the rumored >€5B 2026 valuation.
Research-more: Walden may be one of the strongest new industrial physical-AI entrants, but the current $1.1B seed valuation is too proof-light to underwrite confidently from public evidence.
A fast-growing, state-backed Saudi digital bank whose full ~US$1.6B valuation rests on undisclosed unit economics — attractive to watch, premature to underwrite with conviction.
FieldAI combines elite field-robotics talent, strong investor validation, and a differentiated hardware-agnostic embodied AI stack, but the lack of audited financial disclosure and limited named customer proof make the $2B valuation difficult to underwrite from public evidence alone.
Nextop AI addresses a real AI-networking bottleneck with unusual founder and investor quality, but the public record is still too thin to justify aggressive entry at the current $4.2B valuation.
DeepRoute.ai has become a commercially relevant Chinese intelligent-driving supplier with real deployment scale, but regulatory tightening, customer concentration, and opaque economics keep the recommendation at track rather than buy.
Harbinger has credible capital, customers, and product coherence, but the public record still supports a track stance because the company’s late-stage valuation outruns the disclosure quality available on revenue, margins, and scaled field execution.
Research more: Jetti has real strategic value and unusually strong public proof for a mining-tech startup, but the current ~US$2.5B mark already prices in substantial future execution despite sparse public financial disclosure.
Terralayr has real capital, credible utility counterparties, and meaningful German BESS scale, but its undisclosed valuation and thin financial disclosure block a price-sensitive investment call.
Meril is a real, scaled Indian medtech platform with disclosed profitability and export reach, but live Myval litigation, heavy capital intensity, and a July 2025 valuation already implying premium medtech multiples support only a Track call.
Beacon has a credible AI-enabled software-acquisition thesis and exceptional capital access, but public disclosure is still too thin to underwrite the 2026 valuation confidently.
COOWA is the most commercially mature urban-robotics company in this report cohort — real revenue, operating profitability, and 10,000+ deployed robots — but the US$3B valuation at ~21x revenue multiples prices near-flawless execution for an IPO that has not yet been filed.
Mesh has credible product and partner proof in a large, fast-forming stablecoin-payments market, but the public record still lacks the revenue and margin evidence needed to underwrite its $1B valuation with conviction.
Mosyle appears to be a credible, scaled Apple-only management and security platform, but public evidence is still too incomplete and internally inconsistent to underwrite a confident buy case at or above a unicorn valuation.
ModelBest looks like an investable edge-AI company with real open-source traction and strategic investor support, but the current unicorn-threshold price is still under-documented on revenue, pricing, and security terms.
GSR has credible scale, institutional positioning, and strategic-bank validation, but sparse current financial disclosure and under-defined financing terms keep the unicorn valuation in research-more territory.
Track: Unico has real scale, product breadth, and recent profitability momentum in a structurally growing Brazil identity market, but the active Serasa Experian litigation, thin public disclosure, and stale 2022 valuation mark keep the current risk-reward from clearing a buy threshold.
DeepWay has built uncommon autonomous-trucking commercial scale in China, but the current investment case is still dominated by thin truck-hardware margins, single-source dependencies, and an unproven transition to high-margin autonomy software.
Outrider looks like one of the most credible autonomous yard-operations specialists in market, but the absence of public valuation, revenue, pricing, and concentration data keeps the investment case below underwriting grade for now.
SecurityScorecard is a category-defining cyber risk ratings platform with real enterprise scale and strong strategic positioning, but a five-year-stale $1B valuation, secondary market compression to $360–$470M, and undisclosed NRR and gross margin make this a track recommendation pending economic validation.
RapidSOS has credible category leadership in emergency-response intelligence and interoperability, but the public file is still too thin on revenue quality and margin structure to support a buy decision at or above the latest private marker.
CATL Intelligent has a credible parent-backed chassis-platform story and real AVATR-linked technical proof, but thin standalone disclosure, high customer concentration, and policy sensitivity still justify a research-more stance rather than a pricing-confident underwriting call.
Agile Robots is a credible, scaled industrial robotics platform with real manufacturing depth and strong strategic partners, but the current entry case remains blocked by private-company opacity on pricing, margins, burn, and post-acquisition execution quality.
Firmus has a credible sovereign-AI infrastructure thesis and exceptional financing momentum, but the expected IPO valuation still outruns the public disclosure package.
PaXini has built a credible tactile-sensing and dexterous-manipulation position inside China's embodied-AI supply chain, but its $1.5B valuation still rests more on category leadership and strategic backing than on disclosed recurring economics.
Research-more: Transmit Security has credible enterprise product and customer proof, but its private valuation is still too opaque and too rich to underwrite comfortably from public evidence alone.
Quince's M2C model and >$1B revenue milestone are genuinely impressive, but the $10.1B Series E implies a 5–10x EV/revenue multiple the public record cannot support and active deceptive-pricing litigation adds binary legal risk — warranting a track stance until margin data and litigation resolution improve underwriting visibility.
Ricursive combines rare AlphaChip-derived technical credibility with extraordinary financing speed, but the company still lacks public customer, revenue, and benchmark proof sufficient to fully underwrite a $4B valuation.
LogicMonitor is a credible scaled observability asset with fair public valuation support, but unresolved capital-structure opacity, incomplete unit-economics disclosure, and residual security/reliability trust debt keep the recommendation at TRACK rather than BUY.
Metropolis has real scale, operational reach, and product optionality, but the current $5B valuation still looks stretched until EBITDA quality, leverage reduction, and regulatory overhang are materially de-risked.
Infinium has stronger public customer and sponsor proof than most electrofuels peers, but the current public record still supports a watchlist posture because price, plant economics, and delivered-volume evidence remain too opaque for a conviction entry call.
Interesting scaled operator, but public evidence supports caution because valuation still looks expensive relative to visible peers and visible disclosure.
Research-more: Loggi is a real, scaled Brazilian last-mile platform with credible breakeven levers, but the stale ~US$2B private valuation anchor and thin disclosure make the current case too price-sensitive to underwrite publicly.
HIF Global has real operating proof and unusually strong strategic backers, but public evidence still supports a research-more stance because commercial-scale execution, economics, and current price discovery remain too opaque.
Compelling physical-AI thesis with elite backing, but too little commercial disclosure to underwrite the $1.7B mark confidently.
OfBusiness is a real scaled and profitable industrial B2B commerce-plus-finance platform, but without fresh parent audits and a public DRHP it is only worth tracking near the roughly $4 billion secondary anchor, not the floated $6-9 billion IPO range.
Dexory has credible product differentiation, real customer traction, and strong investor support, but the public evidence still supports only a research-more stance because valuation and software-like economics remain under-disclosed.
Axiom Space is strategically important and has real execution proof, but the public file is still too thin to justify paying the 2026 rebound mark as clean common equity.
Faire has real marketplace scale and improving monetization breadth, but public evidence is still too thin on credit losses, margin structure, and partner dependency to justify more than a track posture at the current valuation.
Research more: Ascend Money has real scale, strategic sponsorship, and Thai virtual-bank upside, but valuation above the last $1.5 billion public anchor looks stretched until audited economics and current price discovery are disclosed.
Tempo combines elite strategic sponsorship and a credible stablecoin-payments product thesis with unusually thin public monetization and governance evidence, so the right stance remains research-more rather than paying up at the last reported valuation.
Verdiva is one of the best-capitalized private oral-obesity startups, but public-only evidence still supports a track posture because the valuation already assumes meaningful clinical success while key efficacy, CMC, IP, and financing details remain opaque.
Degreed has enough market relevance, customer proof, and product depth to merit continued diligence, but the public record is still too opaque on retention, runway, cap table, and current valuation to justify a buy recommendation in the tougher 2026 software multiple environment.
Distyl has credible proof that it can move enterprise AI workflows into production, but the public record is still too thin on revenue quality and durability to justify underwriting the $1.8 billion valuation.
Chapter appears to be a credible, fast-scaling Medicare-navigation company with partner-led distribution and strong public growth signals, but the current private price is hard to justify from disclosed evidence alone because valuation, retention, and capital-structure details remain opaque.
Polymarket is the dominant global prediction-market platform with credible institutional and regulatory progress, but governance concentration, market-integrity questions, and a valuation far ahead of disclosed fundamentals keep it in track territory.
Meter has a credible full-stack networking product and real customer proof, but the current ~$1B mark is hard to underwrite without revenue, margin, and concentration data.
EnerVenue has genuine chemistry differentiation and strong strategic financing, but revenue opacity and China-centered manufacturing keep the investment case in research-more territory.
Game Science proved with Black Myth: Wukong that a founder-led Chinese studio can ship a world-class premium hit, but single-franchise concentration, limited financial disclosure, and unclear sequel economics keep the investable posture at research-more rather than buy.
d-Matrix has a differentiated inference architecture and credible commercialization momentum, but the $2B Series C still gets ahead of public proof on revenue, customer depth, and durable deployment economics.
Creatio looks like a credible late-stage workflow-automation platform, but missing public denominator data keeps the 2024 $1.2B mark in stretched territory and the recommendation at research-more.
Apex has credible product, factory, and government-demand proof, but the public record still lacks backlog conversion, unit economics, and financing details; at the last disclosed >$1B mark, the right call is research-more with a stretched valuation stance.
Heven AeroTech has credible strategic momentum in hydrogen UAS through Blue UAS Select, an Army BOA, and a fresh $100 million Series B, but the public record still lacks the revenue, backlog, and reliability proof needed to comfortably underwrite the current $1 billion financing anchor.
Articulate is a scaled, high-quality corporate learning platform, but the stale $3.75B 2021 mark and major disclosure gaps keep the investment case in research-more territory rather than buy territory.
Fourier is a credible rehabilitation-robotics company with real installed-base proof and a technically serious humanoid program, but absent economics, customer-quality disclosure, and named paid humanoid deployments leave the current RMB 8 billion anchor hard to underwrite. Keep the company in research-more mode rather than commit capital at the public mark.
Electra has credible technology differentiation and unusually strong strategic backing for a pre-commercial materials company, but the investment case remains gated by demonstration-plant performance, capital-intensity, and undisclosed valuation terms.
Watershed looks like a premium climate-native enterprise platform with strong logo quality and product breadth, but opaque economics, policy whiplash, and a stretched $1.8B mark keep the public-evidence stance at research-more.
Veza built a differentiated authorization-centric identity-security asset and won credible enterprise adoption, but the public record tops out at an $808M April 2025 standalone valuation and an acquired status with undisclosed transaction terms. Treat Veza as a closed strategic-exit case rather than a current standalone unicorn, and require private ARR and deal-term disclosure before assigning any premium beyond the last public mark.
Multiverse has real enterprise traction and a fresh $2.1 billion price signal, but public evidence still supports a research-more stance because losses, policy-linked delivery risk, and disclosure gaps make the valuation look stretched.
Corelight is the credible open NDR leader with strong analyst validation, but an undisclosed valuation and opaque financials justify TRACK over BUY until key data room items are confirmed.
Helsing is Europe's most capitalised defense AI startup with proven NATO deployments, but a €12B entry valuation outruns public evidence on revenue, margins, and customer concentration.
Research-more: Cellares has unusually strong public customer proof for a private cell-therapy manufacturer, but undisclosed pricing and missing economics keep the investment case high-risk and price-sensitive.
Research-more: insitro has real partner proof and a plausible route to premium techbio value, but public evidence does not support underwriting an aggressive private valuation without clean terms and stronger clinic-ready proof.
sennder has the network scale and strategic anchors to be Europe's defining digital freight platform, but entry requires data-room access to validate profitability trajectory and CHR integration cost.
Bilt Rewards commands a $10.75B valuation on the first rent-rewards moat, but unit economics are unverifiable and the LoyaltyOne precedent warrants elevated caution.
Sunrise has credible product and financing momentum in domestic inference infrastructure, but the current RMB 20B valuation still gets ahead of public proof on revenue quality, customer depth, and unit economics.
Krutrim may become one of India’s most important sovereign-AI platforms, but the current public evidence still supports a research-more stance because strategic ambition and reported pricing are ahead of disclosed economics and durable customer proof.
Cityblock demonstrates scaled Medicaid-first value-based care with strong revenue growth but faces valuation reset, margin uncertainty, and regulatory exposure
DJI is the profitable, category-defining global drone leader, but a private, opaque Chinese company whose largest premium market and exit optionality are capped by US regulatory exclusion.
Luminance appears to be a real legal-AI scale asset with meaningful customer breadth and a plausible mid-hundreds-of-millions value, but the current public record is still too opaque to underwrite a premium unicorn-style price with confidence.
Strong regional relevance is real, but current valuation still looks expensive relative to Noon’s public disclosure depth and available comparables.
Xynova sits in a strategically attractive part of the humanoid stack: dexterous hands and actuators. The company has raised enough capital and attracted enough strategic interest to matter, but the public record still lacks the named-customer, reliability, economics, and financing-term evidence needed to underwrite the current unicorn valuation with high conviction.
Scientifically distinctive breeding platform with a large opportunity, but an unproven-at-scale core claim and a rich pre-revenue valuation warrant more diligence before investing.
VulcanForms looks strategically important and technically differentiated, but the current public record still supports a research-more posture rather than a buy call because price support trails business quality.
Mark43 has enough category importance, product breadth, and customer proof to merit continued diligence, but the public record is still too thin on revenue quality and financing terms to fully underwrite the $1.0B headline valuation.
LigaChem has a credible ADC platform and unusually strong partner validation for its stage, but the current public valuation looks stretched enough that better human proof, cleaner CMC evidence, or a cheaper entry is needed before a fresh high-conviction buy call is justified.
Tyme Group is a structurally credible emerging-market neobank with proven South African unit economics and Nubank's strategic endorsement, but information asymmetry — no consolidated group audited financials, unconfirmed Philippine profitability, and partial cap table disclosure — prevents a high-confidence buy recommendation on publicly available evidence alone; track and request group financials before committing.
XREAL is the most credible independent mass-market AR-glasses vendor in the current public record, but the present valuation already prices in optionality that still needs proof.
Structurally moated UK sports promoter at a full valuation — exceptional business quality, insufficient margin of safety at £1B+ entry.
SiliconFlow looks like a real and increasingly important China-based inference platform, but the disclosed June 2026 price already asks investors to underwrite future margin improvement, enterprise durability, and supply / compliance execution that the public record still does not fully prove.
Track DeepSeek for technical leadership and demand momentum, but underwrite cautiously because opaque financials and elevated geopolitical, IP, and governance risks make current pricing hard to justify.
Unisoc is a scaled private Chinese fabless chip vendor with meaningful global share in value-tier smartphone silicon and active IPO momentum, but governance history, geopolitical risk, and incomplete financial disclosure support a TRACK recommendation rather than a buy call.
A rapidly scaling, technically credible chiplet-packaging unicorn with record yields and a marquee founding team, offset by near-total financial and customer opacity, extreme capital intensity, and a stretched ~US$1.55B private mark.
Track: Genesis has stronger pharma validation than many private AI-drug-discovery peers, but public valuation support is still narrower than bullish premium narratives and the disclosure gap remains material.
Sygnum appears to be a strategically credible regulated digital-asset bank with real institutional proof and scarce regulatory positioning, but public evidence still leaves enough revenue, retention, concentration, and margin gaps that the right call is research-more rather than an unconditional pass.
Inertia combines elite inertial-fusion pedigree, unusual launch-stage capital, and real LLNL-linked strategic assets, but public information still does not support a confident valuation mark or customer-conviction underwrite.
Technically credible frontier AI spinout with a differentiated gameplay-data thesis, but the current $2.3B mark is ahead of public customer and economics proof.
High-profile pre-full-launch DeFi super-app with a novel perpetual-put fundraising primitive, credible SAFT syndicate, and a $1B FDV that is mechanically anchored to the redemption reserve; recommendation is TRACK pending public audit disclosure, MiCA/OFAC compliance stack, and post-subsidy retention data.
Research more: Yassir is a credible North-African super-app with real scale and a visible unicorn mark, but the current public file still does not justify paying the last headline valuation with conviction.
FINN has built real scale in car subscriptions, but the 2026 unicorn round already prices in strong execution despite unresolved disclosure, capital-intensity, and service-risk questions.
Norm Ai has built a structurally distinctive full-stack legal AI platform targeting financial services institutions, validated by Khosla Ventures and elite institutional co-investors, but material information barriers — undisclosed revenue, unresolved ABA Rule 5.4 compliance structure, and a single named founder — limit full investment conviction without private diligence.
A broad, fast-growing, AI-forward post-purchase platform with a proven ex-Divvy team and owned international logistics, priced at a $1.25B unicorn mark on undisclosed financials and a regulation-exposed shopper-fee model.
High-upside Telegram/TON infrastructure platform with real distribution leverage, but opaque economics and structure keep it in research-more territory at the current unicorn mark.
Track: credentialed founding team and named enterprise traction support a watch position, but undisclosed unit economics and a concentrated customer base require more diligence before a buy call.
A well-partnered, richly valued option on co-located power for AI data centers—strong contracted proof, but pre-revenue, single-customer, and capital-intensive.
Oxide has built a differentiated rack-scale private-cloud platform, but the visible ~$1.6B Series C mark already prices in execution that public disclosures do not yet prove.
Cart.com has built a real scaled unified commerce and logistics platform with named enterprise customers and repeat institutional capital, but opaque revenue, debt, and preference economics make the $1.6B benchmark hard to underwrite for new investors.
Strong AI-networking tailwinds and funding momentum justify a track rating, but insufficient public commercial proof keeps Upscale AI below a buy at $2B.
Parallel has credible agent-web infrastructure, real workflow proof, and elite backers, but the $2 billion Series B asks investors to underwrite economics that remain largely private.
AscenPower has real policy-backed momentum, a credible automotive-grade SiC manufacturing buildout, and a publicly recognized unicorn narrative, but revenue opacity, customer-proof gaps, and heavy capex execution risk keep the company in RESEARCH-MORE territory rather than a high-conviction buy.
Firestorm combines a differentiated deployable microfactory thesis with credible U.S. military traction, but public underwriting is constrained by opaque financials, concentrated government demand, and no verified post-money valuation.
Cosm has enough strategic traction to stay on the watchlist, but the company is not yet publicly underwritable at a clean price because venue economics and Series C terms remain opaque.
Just Salad looks like a real scaled concept with differentiated sustainability branding and credible growth momentum, but the current $1 billion mark already prices in strong execution while audited economics, capital-structure details, and retention data remain private.
A differentiated full-pallet warehouse-automation platform with real customer proof and top-tier backers, but limited public financial disclosure, unresolved concentration questions, and a possibly stretched private valuation keep Mytra in research-more territory rather than clear underwriting range.
Aviatrix has credible multicloud security technology and real enterprise proof points, but opaque financials, a difficult competitive landscape, and a sharp gap between its 2021 primary valuation and 2026 secondary signal keep the stock in track-not-buy territory.
Personio is the established European HR-tech category leader with strong EU compliance moats, but the $8.5B 2022 valuation is structurally unsupported by 2026 SaaS multiples and opaque financials preclude confident underwriting.
Research more: SheMed has a credible women-focused GLP-1 and diagnostics narrative, but the reported $1 billion last-round valuation already prices in a great deal of execution before public economics, cohort quality, and cap-table terms are visible.
TymeBank is a structurally credible emerging-market neobank with proven South African unit economics and Nubank's strategic endorsement, but information asymmetry — no consolidated group audited financials, unconfirmed Philippine profitability, and partial cap table disclosure — prevents a high-confidence buy recommendation on publicly available evidence alone; track and request group financials before committing.
Huihe looks like a real and strategically interesting Chinese interventional-device platform, but investors need much more financial and customer-cohort evidence before underwriting the reported unicorn valuation with confidence.
I-care Group is a credible global PdM leader with proven technology, strong revenue momentum, and a $232M+ order book—but the insider-only unicorn valuation, ongoing losses, deferred IPO, and opaque revenue mix justify a "track" stance until the Phase 2 external raise provides independent price discovery and WaaS transition progress is quantified.
Farther is a category-defining AI-native wealth platform with exceptional AUM growth velocity and elite institutional backing, but the absence of audited financials and three unexplained Form ADV disciplinary alerts prevent underwriting a confident buy at its greater-than-$1B unicorn valuation — track with a 90-day review cadence pending financial disclosure.
Scandit is the global #1 enterprise data capture SDK with 170M+ active devices, 2,100+ customers, and $119M last-disclosed ARR, but its stale $1B 2022 valuation mark at 8.4× ARR is roughly 2.5× the current public SaaS median — warranting a track stance pending audited ARR re-acceleration or a lower entry multiple.
EcoVadis appears strategically relevant in supply-chain sustainability infrastructure, but public disclosure is too thin on current financials and valuation to support a bullish underwriting call.
XPeng-backed Xpeng AeroHT has real product differentiation, factory momentum, and early order signals, but public underwriting still hinges on CAAC certification timing and a fresh private valuation mark.
SemiDrive is China's most capable domestic automotive chip designer with proven OEM-scale penetration and state-capital backing, but revenue opacity and US export-control risk constrain buy conviction — TRACK pending revenue disclosure and C-round valuation confirmation.
Clari is strategically relevant and plausibly fairly valued on a combined-ARR basis, but the current public record is not strong enough to support a buy call because post-merger retention, margin, and cap-table economics remain opaque.
Securonix is a conditional buy at or below the ~$1.0–1.5B base-case range: a Gartner-leading cloud SIEM with 40% ARR-growth signals and a credible AI roadmap, gated by financial opacity and Microsoft bundling pressure.
Webflow remains a category leader in no-code web publishing and enterprise web operations, but the best-known $4 billion valuation anchor is old and the 2026 public record still leaves too many financial proof points private to justify an aggressive entry call.
Sarvam AI has become one of India's most strategically important AI startups, but the current public evidence still supports a research-more stance because valuation and sovereign-AI prestige are ahead of disclosed software economics.
World Labs has one of the strongest founding teams in AI and clear early product momentum in spatial intelligence, but the public record still lacks the commercial evidence needed to underwrite a multi-billion-dollar entry price with conviction.
ApplyBoard is a category-leading, AI-native international student recruitment platform with genuine scale, but a ~74% implied valuation decline from its 2021 peak, opaque private financials, and acute Canada policy exposure support only a track stance.
Eavor has real strategic sponsorship and tangible commercial proof around Geretsried, but incomplete operating economics, opaque financing terms, and unresolved execution questions keep the company in research-more territory rather than a clean buy call.
Judi Health is building a structurally differentiated transparent PBM and unified claims platform at meaningful scale, but the $3.25B September 2025 valuation prices in substantial admin-fee revenue growth that has never been publicly disclosed, warranting a Track stance with medium conviction pending confirmation of unit economics.
Photonic has one of Canada's most credible private quantum architecture stories, but the public evidence still supports follow-up diligence more than price-insensitive conviction at a $2.0 billion mark.
Hithium has become a scaled global ESS battery contender with credible shipment and revenue momentum, but current public evidence supports a track stance rather than a buy because valuation clarity, litigation exposure, receivables quality, and IPO-readiness disclosure remain too thin.
Research-more: Standard Bots has a credible AI-native cobot product narrative and real customer anecdotes, but the June 2026 $1B valuation is too price-sensitive to underwrite from public evidence because revenue, margins, and deployment efficiency remain undisclosed.
Modular has real technical differentiation, fresh capital, and early customer proof, but public revenue, margin, retention, and cap-table disclosure remain too thin to underwrite a buy at the latest $1.6 billion valuation.
team.blue is Europe's best-capitalised SMB digital platform with a proven buy-and-build flywheel and Tier-1 PE backing, but complete financial opacity, a failed leveraged loan repricing, and a valuation multiple that implies a 3–5× premium to public European peers limit conviction to a "track" rating until the debt structure and revenue base are independently confirmed.
EGYM is an EBITDA-profitable global fitness-technology platform with $800M+ combined 2025 revenue, 75% subscription mix, and genuine network effects, but the 9.4× combined EV/revenue multiple is stretched versus public comps, and key underwriting drivers—NRR, gross margin, and post-integration unit economics—remain undisclosed in a fully illiquid private vehicle.
Pleo shows real product breadth, scale, and monetization progress, but the supportable public-data conclusion remains research-more because the latest mark still looks stretched against disclosed evidence and too many underwriting-critical operating metrics remain private.
BetterUp has credible enterprise product-market fit and meaningful scale, but limited disclosure and a still-demanding late-stage valuation argue for continued diligence rather than immediate conviction.
Carbon has real production-scale DLS proof and insider-backed runway, but opaque financials and a stale $2.4B valuation anchor make further diligence—not underwriting at face value—the right posture.
Highview holds a credible strategic position in UK long-duration energy storage, but valuation remains under-determined until Carrington proves commercial execution and private financing terms become clearer.
Versa Networks is a credible late-stage unified-SASE platform with meaningful channel and customer traction, but opaque financial disclosure, execution complexity, and a still-debatable 2024 valuation keep the current stance at research-more rather than buy.
Positron has credible early proof—real financing, named lighthouse customers, and a differentiated memory-first product roadmap—but at a $1B+ entry price with undisclosed revenue, margins, and security terms, the prudent stance is to track rather than underwrite the round as clearly attractive.
Epirus has credible Army proof and strong counter-drone tailwinds, but its likely down-round reset, opaque economics, and prime-backed competition keep the investment stance at track rather than buy.
New Limit combines elite capital access and unusually detailed preclinical progress with no human data, making it a high-upside but still high-risk research-more opportunity at the current price.
Vultr has credible independent-cloud and GPU-infrastructure positioning plus real financing validation, but the public record is still too thin on revenue, margins, debt terms, and customer quality to justify a clean buy at its last $3.5B mark.
Trendyol is the dominant Turkish e-commerce platform with decacorn GMV scale and domestic profitability, but its $16.5B last mark is five years stale, implying a 6.6–9.2x EV/Revenue premium to emerging-market peers, making it unattractive at the 2021 price with no confirmed exit mechanism.
Dataminr is a real, scaled, differentiated intelligence platform, but the unchanged 2021 valuation headline looks hard to underwrite after 2025 bridge-like convertibles and persistent disclosure gaps.
Enpal combines category-leading scale in German residential solar with a broadened home-electrification bundle and unusually deep structured-finance access, but opaque post-2023 valuation, limited audited profitability disclosure, service-quality/legal friction, and policy sensitivity justify a Track rating rather than an invest-now recommendation.
Ambience Healthcare leads the ambient AI scribe category but trades at a steep 42x estimated ARR multiple that leaves little margin for execution risk.
Hai Robotics is a real category leader in ACR-based warehouse automation, but the public record still supports tracking rather than buying because pricing, dilution, and recurring-economics disclosure remain incomplete while losses and concentration stay material.
Function Health has executed a textbook celebrity-physician DTC launch into the preventive-health market — roughly one million members and a self-reported $100M ARR in under three years, anchored by Mark Hyman's brand and Quest Diagnostics' nationwide lab footprint. The $298M Series B at $2.5B (~25x ARR) is stretched against public DTC-health comparables, the effective $100 ARPU is unreconciled against the $499 list price, and adverse press from the NYT Well desk, TIME, and independent scientific critics raises overdiagnosis, FTC endorsement, and laboratory- developed-test (LDT) regulatory questions. Track until unit economics, retention, and clinical/regulatory posture clarify.
Sila has real product and factory proof, but the absence of disclosed revenue, margin, and a confirmed valuation keeps it a price-sensitive track rather than an actionable buy.
MoEngage looks like a real, scaled engagement platform, but public disclosure is too thin and the late-2025 pricing too rich to support a buy call from public evidence alone.
Verkor is one of the more credible remaining European battery platforms because it has a live Dunkirk asset, Renault-backed demand, and €3B+ of committed capital, but the equity case is still too opaque and execution-sensitive for a buy call after Northvolt showed how fast battery-scale optimism can unwind.
Mura Technology is the first commercial operator of hydrothermal advanced plastic recycling, with best-in-class environmental credentials and KBR's institutional backing, but faces critical financial opacity, an outstanding IP security charge, and the Böhlen cancellation as adverse commercial signals.
EvenUp appears to be the category leader in plaintiff-side legal AI, but the >$2B valuation is hard to underwrite without audited ARR, gross margin, and retention data.
Tyme Group is a structurally credible emerging-market neobank with proven South African unit economics and Nubank's strategic endorsement, but information asymmetry — no consolidated group audited financials, unconfirmed Philippine profitability, and partial cap table disclosure — prevents a high-confidence buy recommendation on publicly available evidence alone; track and request group financials before committing.
Tamara is a credible, SAMA-licensed BNPL unicorn with strong Saudi alignment and a growing merchant network, but trails Tabby in scale, lacks financial transparency, and faces credit-risk opacity that warrants close monitoring rather than immediate conviction.
Helion Energy is the world's most commercially advanced fusion company, holding the only signed commercial fusion PPA (Microsoft, 2028), a $5.425B Series F valuation, and unique Faraday direct-conversion technology — but faces a binary outcome: net energy gain demonstration with Polaris by 2026-2027 is the single most consequential technical milestone in the history of commercial fusion.
BETA Technologies has serial-production tooling and named customers, but the public evidence package still hinges on FAA type-certification timing before a 2026 valuation mark can be underwritten.
Toss is Korea's most valuable private fintech with a proven super-app model and $330M+ revenue trajectory, but its $7.4B 2021 valuation faces compression from repeated IPO delays, a fintech market re-rating, and the challenge of growing into a multiple that requires sustained profitability none of its business lines has yet achieved at scale.
ShipBob has real operational scale and durable Shopify channel proof, but the stale 2022 mark against repriced 2026 public comps and undisclosed financials support research-more rather than a price-sensitive buy call.
Dragos is the category-defining OT cybersecurity platform with compelling threat intel moat; investment blocked by financial opacity and uncertain post-2023-layoff trajectory. Track for future entry if ARR >$70M confirmed at <$2B valuation.
Stack AV offers a compelling team and AV trucking thesis but remains pre-commercial with high capital intensity and unresolved regulatory, technology, and commercialization risks — warranting a Track recommendation.
1Password has a credible 150k-business-customer XAM platform and a defensible security architecture, but the $6.8B 2022 valuation has not been refreshed and unit economics remain non-public.
Nium's 40-license regulatory moat and $50B+ annual transaction volume position it as a credible B2B payments infrastructure IPO candidate, but India legal risk, 53% operating loss margin, and growth deceleration create elevated pre-IPO risk requiring active monitoring before increasing position conviction.
Fervo Energy is the global EGS leader with 658 MW of binding PPAs and a $7.2B backlog, but trades at an 87% premium to operational geothermal comparables on pre-commercial financials — the $6.5B IPO is only justified if Cape Station Phase 1 delivers on time.
Cognition AI is a category-defining autonomous software engineering platform with exceptional ARR growth ($1M → $73M in 9 months), but the $10.2B valuation at ~140× ARR prices in near-flawless execution in a market facing rapid benchmark commoditization and critical undisclosed financial metrics.
Neko Health has exceptional early demand metrics — 80% annual repurchase, 100,000+ UK waitlist, £299 price point — but its $1.8B Series B valuation is highly stretched at 360-600x estimated revenue and rests on clinical AI claims with no peer-reviewed validation. Track until clinical evidence and multi-city revenue prove the thesis.
Figure AI has done what no humanoid robotics company has achieved before: a proven, multi-month deployment at automotive production scale, with BMW manufacturing metrics that are independently corroborated. The $39B valuation prices in a future that requires displacing Tesla Optimus, Agility/Amazon, and every industrial automation incumbent — at 250–650x estimated revenue. The deployment proof is extraordinary; the valuation is extraordinary risk. Specialists with 7–10 year horizons and deep robotics domain expertise may find a speculative entry defensible; generalist growth investors should avoid at this multiple.
Hello looks strategically important and plausibly valuable, but the current ~$6 billion mark still appears fair-to-full until private financials, cap-table terms, and remediation quality become materially clearer.
SpinQ is a credible late-stage quantum platform and likely low-unicorn asset, but thin public economics and cap-table disclosure keep the case in track territory rather than buy territory.
Animoca Brands has real strategic substance, disclosed 2024 scale, and meaningful ecosystem optionality, but conflicting current valuation signals and thin price-critical disclosure keep the disciplined call at research-more.
Tridge appears commercially real and strategically relevant in agri-trade, but current public evidence does not justify underwriting the old unicorn price without a major private-data refresh.
GTA Semiconductor appears to be one of the more strategically relevant specialty-foundry assets in China’s automotive and power semiconductor stack, but the current private mark is only defensible with better private proof than the public record supplies. The correct public- information stance is research-more: category value and strategic scarcity are real, yet underwritten equity returns still depend on loading, margin conversion, customer concentration, dilution discipline, and incident-free execution.
DispatchHealth has credible strategic relevance and enterprise proof in a hard-to-replicate care-at-home niche, but open evidence does not support paying a peak private-market mark without audited operating data and explicit reconciliation of the 2026 financing signal.
Quaise Energy has credible superhot-geothermal upside and strong strategic backers, but public evidence still supports a research-more / track stance because valuation, financeability, and operating proof remain incomplete.
Amarenco is a strategically interesting solar IPP platform, but the public record still supports only a discounted valuation range and a research-more recommendation.
Omio is a strategically credible multimodal travel platform, but the current roughly $1 billion mark looks stretched on public evidence because it implies a revenue multiple far above public travel-tech comparables without matching disclosure depth on revenue quality, retention, concentration, or debt terms.
Tradeshift looks like a real global B2B network asset, but the public valuation anchor remains stale and expensive relative to 2026 AP and e-invoicing software comps.
Mariana Minerals has a credible strategic-market position and unusually concrete software-plus-asset story, but the current $1.5 billion valuation appears full on public evidence because customer, economic, and financing proof remain under-disclosed.
Manner has genuine scale, brand relevance, and investor-quality signals, but private-company opacity keeps the call at research-more rather than buy.
Xsight looks like a credible AI-networking semiconductor challenger with unusually strong public proof for a private chip company, but the July 2026 $2.8 billion valuation still appears stretched until private diligence fills in the revenue, margin, concentration, and working-capital denominators.
Research-more: Resilience has real strategic manufacturing value and unusually strong Lilly-backed validation for a private CDMO, but the post-2025 reset, leverage, and missing operating disclosure make the equity case highly price-sensitive.
Research-more: Erebor may become a valuable frontier-sector banking franchise, but current public evidence does not yet justify underwriting the reported $8B valuation talk without deeper diligence and better price discipline.
Neo is an intriguing, well-funded agentic-security startup with a coherent product thesis, but the public record is still too thin on customer proof and price clarity to justify more than a track stance.
Keyuan looks like a real industrial unicorn rather than a paper one, but the current public record supports deeper diligence more than it supports conviction pricing.
Track: CuspAI has a high-quality strategic story and credible early proof, but the June 2026 $2.6B mark already assumes commercial success that is not yet visible in public economics.
Well-timed defense-industrial roll-up with real assets and top-tier backing, but financially opaque — research more rather than underwrite the ~$1.1B price on public evidence.
Origin Quantum looks like one of China’s most credible full-stack quantum infrastructure companies, but incomplete financial disclosure, customer-transparency gaps, fault-tolerance uncertainty, and geopolitical friction keep the investment stance at research-more rather than conviction buy.
Glow has the ingredients of a serious endpoint AI security company, but the public record is still too thin to underwrite a confident buy at a unicorn valuation.
Research more: 8090 has a real product, real capital, and a credible regulated-enterprise workflow thesis, but the current valuation already assumes operating proof that public sources do not yet provide.
Research more: StockX is clearly a scaled authenticated-resale platform with real brand relevance, but the current public file is still too thin on audited financial quality, trust-cost burden, and cap-table detail to support a high-confidence fresh valuation.
Tengden has credible engineering depth and category leadership in large Chinese UAVs, but the underwriting case is constrained by losses, concentration, and acute policy risk.
Research more: BrainCo has real product breadth and financing scale, but the current unicorn price looks stretched until private diligence proves stronger customer quality, regulatory progress, and governance clarity than public materials reveal.
DexForce has enough evidence of real product depth, investor support, and early commercial deployment to merit continued diligence, but the current unicorn valuation outpaces the quality of public proof on audited economics, independent customer durability, and scalable margin.
ModRetro has credible enthusiast product pull and enough capital to attempt a broader physical-IP platform, but public disclosure is still too thin to underwrite the market-reported ~$1B valuation confidently.
Apeel has a credible product, customer, and sustainability story, but the public file is still too thin on economics and financing quality to justify taking price at a premium valuation without more diligence.
Solace has built a compelling, reimbursement-backed patient-advocacy platform with real national scale, but the public record still supports only a track stance because core economics, payer mix, and Series C terms remain too opaque for a clean late-stage underwrite.
VoltaGrid has real hyperscale demand and sponsor validation, but the current valuation still requires faith in an unaudited 2028 EBITDA target, a smooth Propell manufacturing ramp, and favorable regulatory outcomes.
Rox shows real enterprise product signal, but the reported $1.2B price still looks stretched on public economics.
Astromech may be building a differentiated biological-AI platform with strong Colossal adjacency, but the public record still lacks the customer, revenue, and validation proof needed to underwrite the reported $2 billion valuation confidently.
JSW One has built a strategically relevant industrial-procurement and embedded-finance platform for Indian MSMEs, but incomplete disclosure on current terms, profitability, and credit quality makes it a continue-diligence case rather than an invest-now one.
Track: ShareChat still owns meaningful vernacular-social and short-video scale in India and has repaired operations faster than many consumer-internet peers, but the stale $5 billion mark remains stretched until cleaner financing terms, audited cash-flow proof, and steadier leadership support a firmer IPO case.
PaleBlueDot AI shows credible demand and differentiated APAC-oriented AI compute positioning, but the >$1B Series B price is hard to underwrite without disclosed ARR, margins, or customer breadth.
Factorial has unusually strong OEM validation for a solid-state battery startup, but the stock already prices in strategic option value despite zero revenue, finite runway, dilution overhang, and unresolved manufacturing-scale risk.
Avatr is a strategically backed premium EV platform with credible scale and improving disclosed margins, but weak 2026 momentum, partner dependence, and limited valuation transparency keep the supportable call at research-more.
GalaxySpace is one of China's most credible private LEO broadband and satellite-manufacturing platforms, but public disclosure still falls well short of what is needed to underwrite a $4.4B valuation with confidence.
Skeleton has credible traction in AI-power and grid-stability infrastructure, but manufacturing and disclosure gaps make a pre-IPO entry hard to price with conviction.
Hermeus has real proof of life—Mach 1.21 flight, a $219 million DIU-backed defense pathway, and a blue-chip investor set—but it is still pre-production, economically opaque, and dependent on difficult Mach 3 / payload-release and acquisition-transition milestones, so the prudent stance is research-more rather than buy.
CMBlu combines credible long-duration storage differentiation and strategic capital with a valuation that currently runs ahead of commercial proof, supporting a research-more call rather than a buy.
Code Metal has a differentiated verification-first product and credible defense and industrial demand signals, but at the disclosed $1.25B Series B price the public KPI record is still too thin to underwrite without more diligence.
Wonder has assembled a credible multi-surface mealtime platform, but public evidence is still too thin on standalone economics and post-acquisition integration quality to underwrite confidently above the reported $7B valuation.
Startorus Fusion looks like one of China's more credible private fusion platforms, but the current unicorn valuation still depends more on milestone delivery, policy support, and future disclosure than on proven commercial traction.
Rebel Foods is a scaled, strategically relevant food-tech platform, but the public evidence still supports a price-sensitive watchlist posture rather than a conviction buy at the old unicorn mark.
MiRus has unusually strong strategic validation for a private medtech company, but the current price still depends on pivotal-trial success and private financial facts that public evidence does not yet supply.
Mind Robotics has a rare industrial data and capital wedge, but public proof still lags its multibillion-dollar valuation.
Solace has built a compelling, reimbursement-backed patient-advocacy platform with real national scale, but the public record still supports only a track stance because core economics, payer mix, and Series C terms remain too opaque for a clean late-stage underwrite.
GrubMarket has built a rare scaled hybrid of food distribution and vertical ERP software, but the SEC's revenue-overstatement settlement, acquisition-roll-up complexity, and still-thin audited disclosure make the current price a watchlist story rather than a buy today.
Avride is strategically relevant and commercially live across robotaxis and delivery robots, but the active NHTSA probe, partner concentration, and sparse financial disclosure support only a cautious track posture and a discount to headline unicorn narratives.
Xcimer pairs a differentiated laser-fusion architecture and strong early investors with real technical ambition, but no public valuation, no public customer proof, and very high technical and capital-intensity risk keep the name in research-more territory until milestone and commercial evidence materially improve.
Revel has a credible control-software wedge and unusually strong founder-market fit, but public metrics remain too thin to justify conviction at the third-party-reported $1B+ valuation.
Track: Udaan's turnaround is credible enough to defend a scenario-based $1.4-1.9B base case, but the current $1.8B mark is not a wide-margin-of-safety entry while revenue quality remains inventory-led and key runway, credit, and dilution inputs are still undisclosed.
Darktrace still looks like a scaled, strategically relevant cyber platform, but sponsor-era opacity on debt, governance, and current operating performance keeps the name in track rather than buy territory.
Credible legal-workflow leader, but the current ~$3B mark is ahead of public proof on margins, investor terms, and realized AI economics.
SumUp is a scaled and strategically relevant SMB-payments platform, but the public record still supports only a track call because economics, capital structure, and governance disclosure lag the valuation narrative.
Sierra Space is a well-capitalized but still under-disclosed space-and-defense platform whose $8 billion March 2026 valuation looks stretched until Dream Chaser converts its late-2026 demo into contracted demand and management opens the revenue, margin, and term-sheet denominator.
SambaNova has credible technical differentiation and sovereign/government traction, but opaque economics, customer concentration, and valuation ambiguity keep the equity story in research-more territory.
BigID looks like a real, strategically relevant late-stage data-security platform, but public evidence is still too opaque to underwrite aggressively above a disciplined secondary-entry price.
Electric Hydrogen has one of the strongest Western large-plant electrolyzer platforms, but its stale unicorn valuation still outruns proof of commercial conversion in a deteriorated green-hydrogen market.
Isar Aerospace combines unusual strategic relevance, capital access, and real launch progress for a European private launcher, but without orbital success, clean commercial disclosure, or transparent convert terms, it remains a research-more story rather than an underwritable buy.
Flex appears to have built a genuine distribution moat in rent-payment flexibility, but undisclosed capital structure, opaque credit economics, and a meaningful record of servicing failures keep the correct call at research-more rather than a price-sensitive underwriting.
Substack has genuine creator-platform scale and differentiated network effects, but the 2025 unicorn valuation looks expensive against estimated ARR, visible creator churn pressure, and elevated legal-platform risk.
Armada has a credible sovereign-edge infrastructure wedge and unusually strong early deployment proof, but opaque economics, factory-scale execution risk, and a stretched 2026 price keep the company in research-more territory.
Hunters appears to be a credible next-gen SOC platform with real enterprise logos and a differentiated vendor-agnostic architecture, but the absence of current financial disclosure and price discovery keeps the name in research-more territory rather than an investable buy.
Sunfire is a strategically relevant European electrolyzer scale-up with real industrial proof, but public-only evidence supports a research-more stance because economics, disclosure, and subsidy-linked project conversion remain too opaque to justify a full-price buy.
Mercor is a real frontier-AI workflow franchise with credible benchmark and software upside, but the $10B mark already prices in cleaner economics, better diversification, and stronger trust than the public evidence currently proves, so the right call is TRACK.
Chainalysis remains the category leader in blockchain intelligence with durable government traction, but the valuation reset and opaque private financials keep the call at research-more and the ~$2.5B mark only marginally defensible.
MUBI has a real premium arthouse brand, a rebound to 1.7M subscribers, and a differentiated streamer-curator-distributor model, but backlash sensitivity, hit-driven film economics, opaque segment margins, and a $1B mark justify a research-more stance.
Imprint appears strategically credible and commercially real, but incomplete disclosure, credit-and-funding intensity, and a stretched public valuation bridge support a research-more recommendation rather than a buy call.
Element has become a credible sequencing challenger with real commercial momentum, but at or above the last disclosed unicorn mark the public evidence still supports research-more rather than an immediate buy.
OPSWAT appears to be a real, scaled OT/IT cybersecurity platform with credible product breadth and customer traction, but public evidence is too thin to underwrite the rumored ~$1.8B valuation or form a high-confidence investment view without audited financials and cap-table disclosure.
Wispr shows genuine usage-scale traction and a credible lead-investor thesis behind its $2B Series B, but the valuation cannot be confirmed as fairly priced without disclosed absolute revenue, and an unresolved SOC 2 Type II compliance lapse plus active industry-wide voice-biometric regulatory risk keep this a track/research-more call.
Fabric remains a live but opaque robotic fulfillment platform: current customer proof and software repositioning justify continued diligence, but repeated layoffs and missing financial disclosure leave the 2021 unicorn mark looking stretched.
LifeMine is worth tracking because the science story and 2026 financing reset are real, but the public evidence still supports a valuation below any clean unicorn mark and does not justify a fresh buy recommendation.
Juwan has credible XFC battery technology and real strategic value, but current public evidence is too thin to justify a fresh investment at prior unicorn marks without either a discount or much better diligence.
Track: Flink looks materially healthier than most quick-commerce peers after surviving the category reset and claiming EBITDA profitability in core markets, but the current ~$0.9B-$1.0B private band already reflects much of that recovery while labor, retention, and cash-flow proof remain incomplete.
VerSe Innovation is a real scaled Bharat media asset with improving FY25 economics, but stale price discovery, governance overhang, and thin product- level disclosure keep the investable call at track rather than buy.
Flow has real operating substance and unusual access to capital, but the public record still does not justify high-conviction comfort on governance, unit economics, or a $2.5B private valuation.
Atoms is a boldly capitalized, Kalanick-led bet on industrial automation whose reported ~$10B valuation runs ahead of the private, unproven divisional economics visible in public sources.
Bulage may become an important China embodied-AI platform, but public evidence still does not justify underwriting the reported $2B valuation as a buy today.
Strategically credible video-AI unicorn, but financially opaque — track / research more rather than buy at a presumed ~$1B entry.
Zilch looks like a real and differentiated UK fintech platform, but the current private valuation still requires selective, price-sensitive underwriting rather than a clean buy call.
Pump appears to be a credible and differentiated cloud-cost-optimization company with real customer proof, but the reported valuation is stretched relative to the public evidence available on revenue quality, margin durability, and concentration.
Kin appears to be a real specialty-insurance winner with credible revenue scale, renewal momentum, and differentiated catastrophe-market positioning, but the current $2B mark already prices in meaningful future execution while carrier-level and financing-term disclosure remain too thin for a clean yes.
A strategically compelling AI-biotech platform with real partner and customer proof, but still an under-disclosed valuation story.
Track: Gokin has real scale and global channel proof, but the current CNY14 billion headline mark still looks stretched relative to stressed public peers and the company's limited audited disclosure.
GI Water as a Service appears strategically credible and commercially worth following, but public evidence is still too thin on economics, governance, and round structure to endorse the current unicorn valuation with comfort.
Spiber still looks like one of the most strategically interesting climate-materials platforms in Asia, but the 2026 reset means investors should value the surviving option carefully rather than assume the old unicorn thesis still holds.
Core Automation has elite frontier-AI talent and credible research ambition, but the public evidence remains too thin on product, customers, and revenue to justify high-conviction underwriting at the reported valuation targets.
Salla is a well-evidenced, dominant Saudi e-commerce SaaS platform with real institutional capital, but no disclosed valuation, revenue, or reconciled scale metric supports a price-sensitive call today.
Starcloud has enough real technical proof to merit continued diligence, but the current public price looks expensive relative to the still-thin customer, reliability, regulatory, and economic disclosure base.
Elite AlphaChip founders and a real market bottleneck make Recursive Intelligence worth tracking, but a $4B entry price is ahead of public customer and revenue proof.
StepFun pairs genuine device-and-automotive distribution and a record 2026 financing sprint with a $10-12 billion IPO target that public disclosure -- thin, unaudited, and third-party-reported -- cannot yet underwrite.
SVOLT has enough real manufacturing scale, export momentum, and technology ambition to merit continued diligence, but the current headline valuation looks stretched versus stale financial transparency, unresolved concentration risk, and heavy capital intensity.
Chando has real beauty-market scale, strategic outside backing, and a live HK IPO path, but the current evidence still supports only a track stance because brand concentration, family control, and marketing-heavy economics keep the valuation fair near the last round rather than clearly attractive.
Signifyd is a real enterprise commerce-protection platform with differentiated guarantee-backed products and credible customer proof, but the absence of current valuation, margin, and reserve disclosures makes the company more suitable for monitoring than underwriting at the last public unicorn mark.
Etraveli is a scaled, EBITDA-positive hybrid flight-commerce platform with real partner validation, but the undisclosed current entry price, leverage opacity, and partner-concentration economics keep the asset in research-more territory on public evidence alone.
Neysa has a credible sovereign-AI infrastructure wedge and sponsor-backed scale capital, but the current ~$1.4B price is not yet supported by public evidence on revenue quality, utilization, margins, or debt structure.
Impulse Space has unusually strong public proof for a private orbital-logistics startup—three flown Mira missions, credible commercial and government backlog, and founder-market fit—but opaque revenue, burn, and preference terms plus Helios execution risk make research-more the disciplined call.
PowerSchool remains a category leader in K-12 vertical SaaS, but post-LBO opacity, unresolved breach liability, and a rich 7.8x ARR entry multiple leave the stock-less private asset in research-more territory rather than an investable buy.
Noah Medical has built a credible robotic bronchoscopy platform with leading clinical evidence and real commercial traction, but the absence of any financial disclosure, two open FDA recalls, and an unconfirmed $2.0B valuation demand data-room validation before underwriting.
United Imaging Intelligence has genuine state-backed deployment scale and a credible platform, but public evidence leaves the ~$1.4B mark hard to underwrite without any standalone economics.
Olix has the ingredients of a serious photonic inference contender, but the current unicorn valuation already discounts technical and commercial milestones that remain unproven in public.
Veritas Finance has built India's fastest-growing MSME NBFC franchise and achieved unicorn status, but deteriorating returns, rising NPAs, and a 17-month IPO delay all argue that the ₹8,500 crore unicorn mark is stretched; public-market investors should track until ROTA stabilises above 3.5% and the RHP price band provides a clearing anchor.
ZYT is a credible, production-proven ADAS supplier with a defensible compute-efficiency advantage and growing OEM base, but geopolitical lineage from DJI, financial opacity, and intensifying cost competition make the risk/reward compelling only with additional diligence on standalone economics.
Bringg is a credible enterprise last-mile orchestration business with real customer scale and ecosystem depth, but the 2021 unicorn mark now implies a 24.5x ARR multiple against moderate growth and limited disclosure — warranting a track stance until updated private metrics justify the price.
Hopper has real travel-fintech differentiation and B2B partner traction, but the current private valuation remains hard to underwrite after Capital One's 2026 insourcing and without audited financial disclosure.
Frore Systems has credible product and capital momentum, but the current $1.64B valuation runs well ahead of publicly verified revenue and customer proof, especially for the still-unconfirmed LiquidJet hyperscaler story.
Forter appears to be a real category leader in enterprise commerce fraud prevention, but the combination of stale valuation, private-company opacity, and unresolved unit-economics questions supports only a research-more stance.
UForce is strategically compelling as a Western wrapper for battle-proven Ukrainian autonomous systems, but the current unicorn valuation outruns the quality of public economic disclosure.
Divert has assembled a defensible end-to-end food waste circular economy platform with genuine operational switching costs, but its $1B+ Series C valuation implies revenue well above two-facility run-rate reality and complete financial opacity precludes independent underwriting, warranting a track posture pending disclosure.
Alloy Therapeutics looks strategically relevant and partner-rich, but the current $1.0B mark already assumes durable economics that public disclosures do not yet substantiate.
Spirit AI has stronger technical and partner proof than most young embodied-AI startups, but the public record still does not justify underwriting the current valuation without deeper financial diligence.
RADAR has genuine first-mover scale and compelling customer proof in retail RFID, but the $1B price cannot be validated without ARR, gross margin, or NRR disclosure.
You.com has credible product breadth, customer proof, and capital access, but public evidence still underwrites relevance more convincingly than durable economics, leaving the $1.5B Series C mark looking stretched.
Xpansiv looks like strategically important climate-market infrastructure with credible unicorn price support and real workflow breadth, but persistent financial and cap-table opacity plus a fragile voluntary-carbon backdrop keep the correct public-markets posture at research-more.
Sunday pairs a differentiated real-home data loop and elite robotics pedigree with blue-chip financing, but the public record still lacks the price, customer proof, and unit economics needed to underwrite the $1.15 billion valuation.
Advanced Navigation appears to be a real, strategically relevant assured-PNT company, but the public record still does not support paying a late-stage unicorn-style price with confidence.
SpreeAI shows credible product, partner, and brand momentum, but public economics are too thin to justify the reported $1.5B valuation with conviction.
Deep technical moat, credible federal and financial-services wedge, but no disclosed revenue or valuation makes underwriting the $389M capital base speculative at any price.
Zepz is a real scaled remittance incumbent with strong corridor coverage and product optionality, but public-only underwriting remains weak because valuation, governance, and financial disclosure have not kept pace with its private-market history.
Mach Industries has credible defense-autonomy momentum, real manufacturing ambition, and enough Army-linked proof to stay on the radar, but weak revenue-quality disclosure and a stretched $1.8 billion Series C keep the name in TRACK rather than buy territory.
Trulioo is a high-quality global identity platform with re-accelerating revenue growth and strong enterprise proof, but the 4-year-stale $1.75B valuation anchor, unaudited financials, and leadership transition support a track rather than buy posture.
Windsurf built a strategically valuable AI coding platform with real enterprise traction, but the independent company has effectively been broken into talent, technology, and successor-product components, eliminating a clean new equity entry.
Blink has real national prescription-access reach and fresh Series D support, but opaque economics, conflicting private-market marks, and elevated regulatory and operational risk keep the case at research-more with a stretched valuation stance.
Thought Machine has real product differentiation, credible customer proof, and strong modernization tailwinds, but the public record still does not justify underwriting the stale 2022 valuation without materially deeper financial diligence.
Jumbotail has built a strategically relevant B2B commerce and new-retail platform for kiranas and MSMEs, but public evidence still shows wholesale-heavy, loss-making economics and elevated integration or control risk, so the current unicorn pricing belongs on a watchlist rather than in the portfolio.
ZaiNar has a plausible network-positioning wedge and unusual patent depth, but absent named partners, clean backlog quality, and disclosed unit economics, the current public record supports tracking rather than underwriting the $1B-plus mark.
Research-more: Nyobolt has credible product proof, strategic validation from Symbotic, and clear commercial momentum, but the May 2026 $1B valuation still looks stretched until diligence closes the revenue, margin, concentration, and preference-term gaps.
SandboxAQ is a technically credible Alphabet spinout with real government traction and elite investor backing, but a $5.75 B valuation at ~315× unverified ARR demands revenue confirmation before a buy case can be supported.
Talkiatry is the category-leading in-network telepsychiatry provider group with 800+ employed psychiatrists, broad payer coverage, and validated outcomes, but a labor-intensive W-2 model, fully undisclosed unit economics, prescribing-regulatory exposure, and an unconfirmed ~$1.4B inferred mark make it a track / research-more rather than an underwrite-now opportunity.
Proof has built the leading RON and identity-authorization platform with 7,000+ customers and real transaction scale ($200B+ annually), but the investment case is complicated by financial opacity, housing-cycle concentration, a 2022 restructuring, and a Forge secondary mark (~$987M) that implies double-digit revenue multiples versus public comps—without disclosed ARR, margin, or NRR evidence to validate the premium.
Curative has a credible employer-plan wedge, real 2025 financing validation, and enough public member scale to stay on the watchlist, but the current $1.275 billion mark still looks stretched because audited underwriting, reserve, and renewal data remain private.
Peregrine has exceptional growth credentials and Tier-1 investor validation but is priced at ~61x ARR — more than twice the concurrent Flock Safety comp — in a market with escalating civil-liberties risk and entirely undisclosed unit economics; conditional track pending ARR audit, NRR confirmation, and valuation step-down.
Job&Talent shows real operating scale, improving profitability, and credible AI workflow traction, but the 2025 down round and opaque capital structure leave the current entry price too demanding for a higher-conviction underwriting call.
Bitdefender is a real, profitable hybrid cybersecurity franchise with credible endpoint/XDR technology and global distribution, but private-company disclosure gaps, a consumer-heavy mix, and preference-stack opacity keep the case at research-more rather than buy ahead of any IPO.
Druva is a real, scaled cloud-data-protection platform with confirmed historical unicorn status, but stale valuation anchors, thin 2026 disclosure, and AWS/secondary-market concentration keep it in track territory.
Track: Gopuff has genuine category leadership as the last scaled vertically integrated quick-commerce platform in the US and UK, but today's $8.5B private mark already prices in much of the operational recovery while audited financials, free-cash-flow timing, and capital-structure overhang remain opaque.
Tekever is a rare battle-proven European UAS unicorn with credible sovereign demand anchors, but the £1B+ entry price is stretched against unaudited revenue and an undrawn OVERMATCH framework — track until data-room access confirms the financial thesis.
CMR Surgical is a compelling strategic asset — the only globally deployed non-ISRG soft-tissue surgical robot with both CE mark and FDA authorization — but a 2021 vintage $3B valuation, fully opaque financials, and unproven US commercial execution justify a Track recommendation at medium confidence with high risk.
AG1's genuine $600M revenue scale and durable subscription moat are real but insufficient to justify a conviction BUY absent audited financials, resolved FDA inquiry, and NRR disclosure; TRACK with medium confidence and high risk.
Relativity has a differentiated manufacturing-plus-launch thesis and meaningful signed demand, but Terran R is still pre-flight, backlog is not revenue, and opaque post-2021 financing plus brutal launch competition make the equity interesting to track rather than underwrite aggressively today.
Vast Space has achieved real hardware progress with a credible team, first-mover positioning in post-ISS LEO stations, and a $500M institutional round—but the binary dependencies on SpaceX, NASA CLD award, and pre-revenue status at >$2B implied valuation make this a research-more / track situation, not a buy.
CRED has built real premium consumer-fintech scale and improved operating leverage, but under-disclosed credit economics, partner complexity, and a still-stretched $3.5 billion mark make fresh underwriting premature.
Eruditus has the strongest university-partner moat in online executive education and improving fundamentals, but its $3.2B flat-round valuation at 7.1x FY24 revenue — a 3-5x premium to public edtech comps — combined with opaque consolidated financials and undisclosed debt terms make research-more the only defensible call.
GOAT is a real, scaled resale asset, but the public evidence still supports avoidance at the current visible $3.3B-$3.7B range: post-FTC trust risk, thin financial disclosure, and mixed secondary signals leave investors underpaid for opacity.
Miro has real platform scale and strategic relevance, but the public evidence does not justify paying toward the 2022 $17.5B mark without fresh proof on ARR quality, retention, and current price.
Zocdoc has real marketplace scale, a materially improved per-booking model, and credible AI / partner expansion paths, but the underwriting case remains constrained by severe financial opacity, provider-friction risk, and a current valuation signal that is far below its legacy unicorn headline.
Age of Learning has a durable brand and 15 years of product investment in early childhood education, but the $3B 2021 last-round mark is materially stretched relative to current EdTech multiples, undisclosed financials, and subscriber attrition since the COVID peak.
Discord has real consumer-scale proof and a durable community moat, but the $15B entry price outruns the public financial disclosure package.
upGrad is India's most credible edtech investment post-Byju's, but the $2.25B entry mark requires bull-case delivery on FY26 EBITDA.
Tenstorrent is a technically credible AI chip challenger with a differentiated RISC-V architecture and $2B in capital, but unconfirmed revenue, software immaturity, and TSMC sole-source risk warrant a research-more stance at a $3.2B valuation.
Eikon has Nobel-pedigree platform science and a Merck-partnered pivotal trial, but the IPO at ~60% below private valuation and unvalidated core SMT platform demand careful diligence.
Hippocratic AI commands a $3.5B valuation on unverified revenue of an estimated $10–50M ARR, implying 70–350x trailing multiple — stretched even for a high-growth healthcare AI leader. Track pending audited revenue disclosure and observable NRR data from named health system customers.
Thinking Machines is a strategically credible Southeast Asian applied-AI company with real partner and customer proof, but public evidence does not support a premium unicorn narrative or high-conviction valuation call; research-more until revenue quality, terms, and concentration become legible.
Twenty has a real strategic-defense cyber story and enough customer proof to merit serious diligence, but the latest $1.2B private mark is still difficult to underwrite from public evidence because the financial denominator remains opaque.
Betterfly has enough strategic substance to merit continued diligence, but not enough public economics disclosure to support a confident pricing call.
Research more: SmartNews remains a credible late-stage consumer media asset with real Japan positioning and monetization optionality, but the legacy $2B mark looks stretched until current financial, user, and IPO-readiness evidence improves.
Research more: Volant is a serious, well-funded passenger-eVTOL contender, but the current unicorn mark looks ahead of the public evidence on economics, contract quality and certification confidence.
Slate is pursuing a credible white-space thesis in affordable electric trucks, but public evidence still supports only a track stance because launch execution, preorder conversion, service readiness, and valuation precision remain unresolved ahead of late-2026 deliveries.
Reve looks like a technically interesting creative-tooling company with real product differentiation, but the public evidence base is still too thin on economics and customer durability to support a positive underwriting call at the visible private-market mark.
Zap Energy has moved beyond a slideware fusion story with credible plasma, systems, and DOE-reviewed plant-engineering progress, but the 2026 fusion-plus-fission expansion widens commercialization, licensing, and financing risk before customers, economics, or current price discovery are visible.
Powerful backers and a credible payer pain point are real positives, but Tala's public evidence is too thin to justify its $1.2B entry price today.
Loadsmart has credible platform breadth and improving operating discipline, but limited financial disclosure, freight-cycle sensitivity, and stale unicorn pricing keep the investable call at research-more.
Strive has real kidney-care scale, channel breadth, and product relevance, but the public record still cannot bridge its September 2025 ~$1.8 billion mark to disclosed revenue, margin, renewal, and post-reset economics, so the right public-only posture remains research-more.
Komodo Health has a credible Healthcare Map data asset and 600+ customer footprint, but a stale 2022 Series D mark, severe peer compression, and rising regulatory scrutiny make the $3.3B valuation hard to defend without fresh disclosure.
Vayyar combines credible 4D radar traction in automotive and care with sparse financial disclosure, making the current unicorn-level valuation plausible but not yet fully underwriteable.
ENN Fusion is a credible, parent-backed Chinese fusion moonshot with a real proton-boron technical program and a reported ~$1.6B July 2026 valuation, but the public evidence still looks like option value rather than investable fundamentals: no revenue, no named customers, no plant economics, and no clear licensing path. The right call is to track it closely or invest only with strong structure and milestone discipline.
TauRx has real late-stage Alzheimer’s option value, but the current tracker-style ~$2.5B valuation looks stretched relative to the public evidence and unresolved binary risks.
Research-more: Ticaros has credible platform science and a visible lead clinical path, but public pricing, economics, and financing terms remain too opaque to support confident entry valuation.
ENN Fusion is a credible, parent-backed Chinese fusion moonshot with a real proton-boron technical program and a reported ~$1.6B July 2026 valuation, but the public evidence still looks like option value rather than investable fundamentals: no revenue, no named customers, no plant economics, and no clear licensing path. The right call is to track it closely or invest only with strong structure and milestone discipline.
Beast Industries has real scale, category-creating creator leverage, and credible multi-line monetization, but at roughly $5B the valuation looks fair rather than attractive and the investability case is still limited by disclosure gaps and live operational/regulatory risk.
DEEPX has crossed into real physical-AI commercialization, but the current private-market valuation still runs ahead of public disclosure quality on margins, customer durability, and financing certainty.
Volta has a real shot at becoming a differentiated AI-infrastructure intermediary, but the current public evidence supports research-more discipline rather than conviction at the reported $2.4B valuation.
ONE has enough product, customer, and policy evidence to stay investable in principle, but the public record still does not justify paying the historical unicorn benchmark as though the post-pivot business were already proven.
Treeline pairs Loxo-caliber founders, a broad multi-modality platform and >$900M of pro-forma cash with a complete absence of human proof-of-concept, making its ~$2.5B implied valuation a cash-supported option that only 2027 clinical data can re-rate.
Rokid is China's most proven independent AI/AR glasses maker, with 300,000+ units ordered in 2025 and genuine international traction — but the US$2.1B pre-IPO mark demands post-listing revenue and margin proof that has not yet been publicly disclosed.
Linkerbot shows unusually strong, multiply-corroborated shipment scale and top-tier investor backing for a dexterous-hand maker, but a near-total absence of audited financials, independent market-share verification, and reconciled funding-round data mean its $3B valuation cannot yet be independently underwritten.
Beren has credible orphan-drug approval optionality and better financing than most single-asset biotechs, but approved competitors, structured-capital leakage, and still-limited public launch economics make the current private benchmark worth tracking rather than chasing.
Focused Energy has emerged as Europe's strongest laser-fusion financing story, but absent valuation disclosure, customer contracts, or integrated high-repetition technical proof, the investable stance remains research-more pending Biblis execution, financing-roadmap clarity, and subsystem-to-system validation.
Neuralink is the flagship invasive BCI platform with credible clinical and financing momentum, but absent public economics, unresolved reimbursement and long-term support dependencies, and a stretched ~$9B-$9.6B valuation anchor keep the name in research-more territory.
Outschool appears to be a real, scaled K-12 live-learning marketplace, but public evidence does not justify underwriting the 2021 $3B mark without private financial and retention data.
Xendit is a credible regional payments infrastructure winner with real scale and product breadth, but opaque current economics, concentration, and regulatory or operational exposure keep the recommendation at research-more and make premium pricing above the unicorn floor look stretched.
Replit has real category-leading adoption and enterprise momentum, but the current $9B mark still outruns the quality of public financial disclosure.
Kunlunxin has real, independently corroborated commercial traction (China Mobile, Tencent) inside a booming domestic chip market, but its reported ~$50B IPO target rests on unreconciled revenue, an unconfirmed manufacturing foundry, and a chip-purchase-linked structure flagged by analysts for circular-financing risk.
Mission-driven EOR unicorn with B Corp certification and strong G2 recognition, facing intense competition from better-capitalized rivals in a commoditizing compliance-infrastructure market, with fully opaque unit economics at a $1.2 billion valuation.
Valo Health has assembled compelling strategic-deal momentum with Novo Nordisk and Merck KGaA but still faces a long financing-disclosure gap, unproven approval path, and a visible pipeline failure.
Svante holds the world's only solid-sorbent carbon-capture filter gigafactory and the strongest strategic investor syndicate in its category, but is pre-revenue with all commercial projects pre-FID and no disclosed financials, warranting a research-more stance pending FID confirmations and greater disclosure.
SiMa.ai is a credible, well-backed Physical AI silicon company, but its reported roughly USD1.4 billion valuation prices execution that is not yet independently visible and sits far above public edge-AI comparables, so the disciplined stance is research-more pending audited financials.
A credible, marquee-backed limestone-DAC leader whose thesis rests on unproven unit economics, heavy subsidy dependence, and an unverified valuation — a track / research-more, not a buy.
A scientifically validated, first-in-class Treg cell therapy with a strong pivotal trial, but priced at a $1.2B mark against a narrow initial label, high manufacturing intensity, and an entirely unproven commercial ramp.
A technically credible enterprise document-AI platform whose January 2025 down round to ~$1.24B signals valuation reset and competitive pressure, warranting cautious diligence.
A scientifically credible but unproven, pre-revenue neutral-atom moonshot priced at ~$1.5B — high-conviction watch item, not yet an underwritable entry.
Strategically vital, government-backed sovereign-launch champion carrying a unicorn valuation ahead of a proven orbital rocket — high potential, high binary technical risk.
High-growth humanoid robotics leader with explosive unit sales but pre-profit financials, aggressive IPO valuation, and concentrated competitive market.
Fast-growing Chinese EV battery challenger with strong OEM relationships but facing intense price competition, margin pressure, and a down-round valuation signal.
Freenome's multi-omics cancer detection platform shows scientific promise but faces significant execution risk as a pre-revenue company with competitive pressure and pending clinical data disclosure.
Science Corporation has the strongest clinical evidence ever published for implantable vision restoration, but the $1.5B entry mark outpaces expected value until CE Mark outcome and EU commercial traction are confirmed.
Mammoth has elite science and partner validation but remains preclinical and under-disclosed.
Inari has raised enough capital and assembled enough crop-specific technical proof to warrant continued diligence, but the lack of public commercialization economics, ongoing IP litigation, and the 2026 workforce reset keep the investment case in research-more territory rather than buy territory.
Innovation-led premium robot vacuum-mop challenger with strong product reviews, fast revenue growth and a ~$1.4B unicorn tag, but a richly priced, opaque, China-manufactured hardware exporter exposed to tariff, commoditization and key-person risk.
JumpCloud's cloud-native IAM platform serves 250,000+ organizations at an estimated $200M ARR, but the $2.625B Series F anchor is 2–4x above current analytically supportable fair value; the stance is Hold/Watch pending secondary entry below $1.2B with confirmed ARR and exit-path clarity.
A genuinely profitable, policy-protected national OS champion whose appraisal-based valuation and mandate-dependent demand can be tracked but not independently underwritten without standalone disclosure.
Sudu Technology represents a high-risk, high-potential bet on China's embodied AI future, combining world-class technical pedigree with an unproven commercial path and extreme pre-revenue valuation.
vVardis has created a genuinely novel dental therapeutic category with rapid US institutional adoption and unicorn-level backing, but the complete absence of disclosed financials and persistent insurance reimbursement gaps support only a research-more stance until an S-1 filing provides the evidence needed to underwrite the $1B+ private-market valuation.
Differentiated brokerage infrastructure asset with a credible self-clearing moat and rapid ARR growth, but private opacity on margins, concentration, and the cap table prevents a conviction buy at the $1.15B mark.
Svante holds the world's only solid-sorbent carbon-capture filter gigafactory and the strongest strategic investor syndicate in its category, but is pre-revenue with all commercial projects pre-FID and no disclosed financials, warranting a research-more stance pending FID confirmations and greater disclosure.
LumApps has built a credible AI employee hub at genuine enterprise scale with $150M combined ARR and Bridgepoint sponsorship, but private-company opacity, Beekeeper integration risk, and a stretched >$1B valuation limit confidence to a track stance until NRR and gross margin are disclosed.
Boom Supersonic holds the most credible post-Concorde supersonic aviation position — with 130 aircraft pre-orders, a June 2025 regulatory tailwind from the overland ban repeal, and proven XB-1 aerodynamics — but remains pre-revenue and a decade from commercial service, making this a high-risk speculative position appropriate only for patient strategic capital.
Newcleo has stronger technical depth and regulatory traction than many European advanced-nuclear peers, but the public case still depends on repeated financing, future customer conversion, and milestone execution at a valuation that already prices in meaningful success.
80 Acres Farms appears to be the most credible remaining U.S. vertical-farming consolidator, but no audited financials and no disclosed valuation justify TRACK rather than BUY.
Tomorrow.io has a technically differentiated satellite moat validated by NOAA and institutional investors at unicorn scale, but an unresolved 4× ARR discrepancy, undisclosed gross margin, and capital-intensive DeepSky program make commitment at $1B unjustifiable without data-room confirmation.
Also has authentic Rivian engineering DNA, a differentiated DreamRide propulsion system, and a DoorDash commercial anchor—but it is a pre-revenue hardware startup valued at $1 billion before mass production, with unresolved delivery timelines, battery-safety regulatory exposure, and capital requirements that make the current benchmark high-risk for new investors.
Fuse Energy is a founder-led, vertically integrated UK energy challenger with credible traction and product breadth, but the reported $5 billion valuation is hard to underwrite from public evidence because ARR quality, margins, liquidity, and private-round terms remain opaque.
Veho is a high-growth last-mile delivery operator with genuine brand differentiation and strong customer outcomes, but existential IC reclassification risk, a four-year-stale $1.5B valuation mark, and complete financial opacity cap conviction at "track" pending audited financials and a capital raise event.
Wellhub is the global leader in employer-sponsored wellness benefits with $319M ARR and genuine platform scale, but its $4.2B secondary-market valuation implies a 13.2x EV/ARR multiple on undisclosed financials — stretched versus all public and private comps — warranting a Track stance until gross margin, NRR, and post-USC integration economics are confirmed.
Lyten holds genuinely differentiated Li-S battery chemistry and the acquired manufacturing infrastructure to scale it — but deep commercial opacity, no audited revenue, a stretched $1.3–1.5B estimated valuation relative to peers, and a heavy capital burden from two European facility acquisitions make this a Track at Low confidence until EXIM conversion, binding OEM contracts, or audited financial disclosure reduces uncertainty.
Track Rappi until its IPO S-1 surfaces audited financials; the equity-round valuation ($5.36 B) is stretched at ~4× unverified revenue while secondary markets clear at $1.77–2.0 B, a 66% discount.
Eon's repeat-exit founders, tier-1 investor syndicate, and triple-digit revenue growth are compelling, but its $4B valuation is structurally unverifiable without disclosed ARR — TRACK until a data-room package closes the gap.
xAI has real compute, distribution, and execution advantages at scale, but the $230B valuation cannot be underwritten from public data — research-more until private financials are accessible.
KEENON is the uncontested global leader in commercial service robotics with 70,000+ deployed robots and IDC Triple No.1 rankings, but a four-year funding silence, complete financial opacity, and compounding geopolitical risk constrain conviction to a track/research-more stance at the implied $2B valuation.
Doctolib has real European workflow-platform scale and improving subscription economics, but the current ~€3.6B secondary still looks stretched given opaque margins and capital structure plus a live French antitrust overhang.
Covariant is a technically differentiated AI robotics software company at an inflection point: the $2.7B valuation is hard to justify without the founding team, but the installed base and RFM-1 technology retain real strategic value for acquirers and patient investors.
PsiQuantum has the most credible photonic FTQC thesis and strongest government backing in the sector, but the $7B entry price is wholly speculative on a 2027 milestone that has no independent validation and carries critical timeline and execution risk.
Flock Freight is the only patented STL category creator in a large US freight market, but complete financial opacity and a $1.4B 2021 peak valuation support only a conditional hold above $1.0B EV.
Formation Bio has a compelling AI-pharma thesis backed by $615M in blue-chip capital and top-10 pharma partnerships, but the $1.8B valuation rests on unverifiable AI performance claims, undisclosed financials, and a high-risk drug pipeline where industry-wide failure rates exceed 90%.
Pass-with-watch in 2026: 2024 restructuring overhang, undisclosed retention / concentration metrics and uncertain FortoLabs production scope outweigh the multi-vertical breadth and CSRD/CBAM tailwind; deal-stage trigger on next-round disclosure or accretive financing event.
Altos Labs is a scientifically ambitious but extremely high-risk pre-revenue longevity research platform with a world-class team, a $3B war chest, and no proven path to clinical translation or commercial revenue within the next decade.
MasterClass is a premium EdTech brand with strong content differentiation, but faces a severe valuation gap from its 2021 peak, ongoing financial pressure from layoffs and high content costs, and growing commoditization risk from AI.
Overhaul is a conditional pass — a vertically differentiated, Fortune-100-proven cargo security platform with a credible demand thesis, but financial opacity and sector multiple compression require data-room confirmation before conviction at any entry price above $500M.
Lalamove is Asia's dominant on-demand intra-city logistics network with a credible investment thesis, but its Series F valuation (9.6x EV/Revenue) is unsupported by public comparables; entry at base-case multiples (5–7x, US$5.2–7.3B) requires confirmed IPO progress and resolution of the gig-worker and PIPL regulatory overhangs before a positive view is warranted.
Grammarly has an unmatched distribution moat (30M+ DAU, 96% F500) and genuine AI writing IP, but is overvalued at $13B (~18–20× ARR) with 12% growth; do not enter at current price — TRACK and re-evaluate at $5–7B when post-rebrand KPIs and GC covenant terms are confirmed.
Dream Security has built a technically credible sovereign AI cybersecurity platform with exceptional ARR velocity, but the $1.1B valuation at fewer than ten signed government contracts—combined with unresolvable leadership legal risk and zero public financial disclosure—argues for a conditional 'track' rather than 'buy' until three sovereign references, external legal opinion, and audited financials are confirmed.
Machina Labs has a genuinely differentiated electromagnetic forming technology with real defense traction, but sub-unicorn scale, revenue opacity, and tooling-scope limitations constrain near-term investability.
Character.AI has built a dominant AI companion platform with 45M MAU and a cash fortress from the Google deal, but the teen safety litigation cluster and Google API dependency create a risk profile that is difficult to price at the current $2.7B implied valuation.
Flexport: Credible digital freight platform at a stretched valuation — TRACK until profitability confirmed
Wayve has built the most advanced OEM-licensable AV system in Europe and secured $1.05B in validation from SoftBank, NVIDIA, Microsoft, and Uber — while remaining entirely pre-revenue after eight years of operation. The UK AV Act 2024 creates a genuine regulatory first-mover window, but Wayve's core technical approach (black-box end-to-end neural networks) directly conflicts with regulatory certification requirements that DVSA has not yet formally addressed. TRACK until first OEM commercial agreement or DVSA certification pathway is publicly confirmed. Entry above $5B inadvisable before those milestones.
Thinking Machines Lab has assembled arguably the strongest AI infrastructure team in history, but it is pre-revenue, has lost three of six founding co-founders in Year 1, and is targeting a $50B valuation with no financial evidence to support it. Research-more at current reported price; re-evaluate after first ARR cohort.
Velaura AI pairs a genuinely production-proven, power-efficiency silicon platform and a credible board with a $1B+ valuation that currently rests on zero named AI-silicon customers and no disclosed revenue or royalty rate.
Collibra looks like a real late-stage category platform, but public evidence is too opaque to justify underwriting anywhere near its 2021 $5.25B mark without major private diligence.
Panthalassa pairs a marquee Thiel-led syndicate and a genuinely novel ocean-compute concept with pre-revenue, unproven-at-scale technology and no priceable disclosure, making it a high-risk venture-optionality bet.
Angitia is a credible, well-funded bone-biologics company with real Phase 2 option value, but the public record is too opaque on cash, CMC, pricing, and true current valuation to justify a conviction premium-price investment today.
Xingchen looks like a credible early commercialization option in Chinese embodied robotics, but the public evidence still supports a disciplined track stance rather than a valuation-forward buy call because finance, customer durability, and later-stage pricing remain under-disclosed.
Cathedral pairs elite-investor backing and unusual founder access to the US defense-cyber buyer with an extraordinary $1.4B pre-revenue valuation and acute political, execution, and verification risk.
SHAREBOT addresses a real adoption pain point in robotics, but the company is too young and too lightly disclosed to justify strong conviction at a unicorn valuation.
D-Robotics has assembled credible developer ecosystem depth, post-Horizon engineering pedigree, and $370M in capital to pursue an edge-AI-chip platform play in robotics — but the unicorn valuation asks investors to price a revenue story that public evidence has not yet confirmed.
Track — Generalist AI pairs elite embodied-AI talent and a potentially differentiated data engine with a relatively lower peer valuation, but public evidence still stops short of revenue, named customers, and deployment-grade validation.
Shihang Intelligent shows unusually strong financing, order, and field-validation signals for a 2023-founded marine-robotics company, but opaque valuation, revenue conversion, and regulatory execution keep it in research-more territory.
Seekr pairs genuine defense/intelligence AI traction and a credible trustworthy-AI platform with an extreme ~67x revenue entry multiple and opaque economics, supporting only a research-more stance until audited financials and financing terms are disclosed.
Botshare addresses a real adoption pain point in robotics, but the company is too young and too lightly disclosed to justify strong conviction at a unicorn valuation.
Agilink shows unusually strong early commercialization and investor pull for a dexterous-hand startup, but thin disclosure, parent dependence, and a stretched $1B+ valuation justify a research-more stance.
Robot Era has stronger public deployment and financing proof than most humanoid startups, but the current mark still looks investable only with more diligence because commercialization quality and economic disclosure lag the valuation narrative.
HomeLight has built a real multi-product residential transaction platform with meaningful reach and credible customer pain-point fit, but opaque current financials, capital-sensitive product mix, regulatory exposure, and a post-2022 valuation reset keep the recommendation at research-more.
ICON has real technical and deployment proof, but the public record is still too thin to justify paying anywhere near the old ~$2B mark with confidence after layoffs and a much smaller, valuation-undisclosed Series C.
Flash Express is a real Thai logistics scale winner with verified 2024 profitability, but thin margins, opaque private-market terms, and a stale 2022 valuation anchor justify a research-more stance rather than fresh underwriting at the last mark.
Pacific Fusion combines elite scientific talent, unusually transparent technical evidence, and extraordinary early capital, but the public record still lacks the price, structure, and customer proof needed for a responsible underwriting call. Recommendation: research-more until term-sheet, full-module, and counterparties evidence closes the gap.
Kikoff has real customer reach and a differentiated low-friction credit-building bundle, but the public record still leaves too much uncertainty around retention, complaint quality, and revenue to underwrite the reported unicorn valuation with conviction.
Acronis is a credible channel-anchored cyber-protection platform with a fresh EQT capital event at an implied $3.5B EV, but no audited financials and a first-ever FASCSA federal exclusion order make this a research-more, not a conviction, story for 2026 underwriting.
New Ruipeng is a strategically important scaled pet-healthcare asset, but the current Hurun-like valuation reference still looks expensive versus the last disclosed revenue base and the available public comp set.
Fora has built credible category traction in advisor-enabled travel and a differentiated AI-product narrative, but the current $1 billion valuation is still difficult to underwrite from public evidence because the revenue, margin, and cohort-quality denominator remains opaque.
Mirador combines elite private funding with a credible precision-immunology platform, but the public record is still too opaque on assets, valuation, and commercial readiness to justify a fully priced premium thesis; research-more with medium confidence and high risk.
Even Realities is credible enough to keep on an active diligence list, but public evidence does not justify paying through the July 2026 $1 billion round without deeper private economics and term verification.
eMed has a credible employer GLP-1 distribution story and marquee strategic backing, but the $2B+ valuation appears stretched relative to public digital-health comps because revenue, customer concentration, and unit economics remain materially undisclosed.
FBN has built a credible, scaled ag-commerce and farm-finance platform with genuine product breadth and farmer reach, but the public record still supports only a research-more stance because current economics and July 2025 pricing remain too opaque to justify the legacy headline valuation.
Roark Aerospace appears to be a real operating counter-UAS business with material revenue and genuine financing activity, but it is unusually opaque relative to the late-stage valuation and scale narrative being circulated around it.
Epic Games owns exceptional gaming and engine assets, but current public evidence supports only a cautious research-more stance because Fortnite concentration, platform dependence, and private-company opacity make the last hard $31.5 billion valuation look expensive.
IM Motors is credible enough to keep diligencing because it has sponsor backing, product depth, and real deliveries, but the missing valuation and subsidiary-financial evidence keep it in research-more territory rather than investable conviction.
Fintech-IT Group controls the technology and economics behind Ukraine's dominant mobile-first neobank, but a $1B tech-entity valuation implies a stretched 11× FY2024 revenue multiple against a wartime backdrop of declining developer revenues and opaque consolidated financials — warranting deep further diligence before any commitment.
Fangqing has a credible technical and strategic story in a hot domestic AI-compute market, but the current unicorn valuation already runs ahead of public product, customer, and financial proof.
Aaru has real early proof and category intrigue, but the $1B entry mark still outruns the public economics package.
Sudo AI is a credible frontier robotics company to track, but the current public evidence supports technical promise more strongly than commercial proof, making the reported ~US$1.9B valuation look stretched rather than clearly investable today.
AMI is an exceptionally capitalized physical-AI lab with elite leadership, but public evidence supports research-more rather than buy because product, customer, economics, and governance proof trail its seed valuation.
Endless looks like a credible but still opaque early-stage Web3 infrastructure bet: the financing signal is real, but the public file is too thin on revenue, users, governance, and treasury quality to justify blind underwriting at the current $1B mark.
STARK has real strategic momentum in European autonomous strike systems, but the reported $1.2 billion valuation is difficult to underwrite without audited revenue, qualification confirmation, and clearer evidence on product reliability.
monobank is Ukraine's dominant mobile-first neobank with irreplaceable brand and 10.3M clients, but a $1B tech-entity valuation implies a stretched 11× FY2024 revenue multiple against a wartime backdrop of declining developer revenues and opaque consolidated financials — warranting deep further diligence before any commitment.
Elite Robots is a credible Chinese cobot challenger with strong hardware execution and global reach, but material IP litigation, safety concerns, opaque financials, and geopolitical risks warrant caution and deep diligence.
Hive Box has unmatched domestic smart-locker density and early profit improvement, but unresolved redemption litigation, consent-driven regulatory pressure, and a stale 2024 private mark keep the case in watchlist territory.
Galaxea AI has best-in-class academic credentials, a credible product roadmap, and genuine developer traction, but zero verified commercial revenue, a stretched ~$2.9B valuation implying >290x on 2025 guidance, and high geopolitical and disclosure risk that make it uninvestable without further transparency.
Tenex is a credible AI-native MDR operator with exceptional fundraising momentum and real early customer proof, but the public file is still too thin and too self-reported to justify conviction at a reported valuation above $1B.
Plus.ai has credible L2+ traction and a differentiated camera-first architecture, but the $1.2B SPAC entry price requires L4 commercial proof that does not yet exist.
Etched is a technically credible Transformer-ASIC bet with a compelling throughput thesis, but zero customers, no tape-out confirmation, and existential architecture-shift risk make this a high-conviction speculative position at any valuation above $600M.
Hailo has genuine technology differentiation and a growing edge AI platform, but undisclosed financials, a 4-year funding gap, and an opaque customer base limit conviction at the $1.13B last-known valuation.
Colossal's de-extinction narrative is genuine and its team is world-class, but a $10.3B entry price implies 1,000x trailing revenue with no near-term de-risking catalyst — the math only works in a narrow bull case.
Climeworks leads commercial DAC but its flagship plant is producing 0.3% of capacity—a binary operational risk that dominates the investment case until resolved.
CAUTION — World-Class Team, Extreme Valuation; Watch for Commercial Proof Before Entry
Track: Dogotix has unusual strategic quality for an early humanoid company, but the current valuation is still ahead of independently underwritten proof.
Neo Fusion is strategically important inside China's fusion roadmap, but thin disclosure, unproven commercialization, and high milestone risk keep the recommendation at research-more with medium confidence and an unknown valuation stance.
Reflection AI combines elite founder quality, investor support, and sovereign-AI optionality, but the public record still lacks a shipped frontier model, named commercial customers, and revenue proof to underwrite the discussed 2026 valuation.
Substrate is pursuing a bold and strategically relevant U.S. lithography-and-foundry thesis, but the current public record still supports only a medium-confidence research-more stance: the company has fundraising momentum and intriguing technical signals, yet lacks customer, throughput, yield, and financing proof commensurate with its roughly $1 billion valuation.
Exceptional founder pedigree + massive market; valuation is a pre-product conviction bet with high execution risk and severe evidence gaps at every chapter of diligence.
Exceptional founder credentials and strong market timing create a compelling story at the low end of global world-model valuations, but complete pre-product status, China risk premium, and GPU export controls support a neutral rather than buy recommendation.
StepStar is a technically credible, well-capitalized member of China's foundation-model "Big Six" with a distinctive multimodal and AI-terminal strategy, but undisclosed financials and contested, steeply escalating valuation marks keep it a research-more rather than a buy.
Magic has genuine frontier-model upside in code generation, but public proof remains too thin to justify aggressive entry at the last cited $1.5B mark.
High-conviction investor identity (Sequoia, Goldman, Granite Asia) but every operating metric is private; base-case EV modelling sits below the current $1.2B mark and every scenario carries a wide error band.
ADGT is a well-capitalized, PE-and-strategic-partner-backed UAE gaming-payments platform with a credible regulatory positioning claim, but it has no public operating track record and its widely repeated ~US$1 billion valuation is not verified by any primary disclosure.
Fundamental Technologies carries genuine technical differentiation and elite distribution, but its $1.4 billion valuation prices success ahead of any disclosed revenue or retention data — the right posture is track and re-evaluate at first ARR disclosure.
Recursive Superintelligence is an elite-pedigree frontier AI lab pursuing recursive self-improvement — a technically ambitious but unproven thesis — at a $4.65B valuation with no revenue, no product, and no customers; the recommendation is research-more pending first proof-of-improvement evidence.
Factory is a credible enterprise agentic-software-development platform with real product breadth, customer proof, and channel momentum, but public evidence is still too thin on ARR, margins, and contract quality to underwrite the April 2026 $1.5 billion valuation.
PhysicsX has credible technical and commercial momentum in AI-native engineering, but limited public disclosure on absolute revenue, margins, retention, and concentration makes the $2.4 billion Series C price difficult to endorse from public evidence alone.
Nothing has built a rare design-led consumer-hardware brand with real scale and an investable valuation mark, but private-company opacity, uneven product execution, and reliance on continued category expansion keep the name in track rather than buy territory.
A first-of-its-kind commercial plasma-pyrolysis producer with real technology and blue-chip backing, but thin public financials, single-plant scale, customer/loan concentration and a DOE loan under cancellation threat warrant deeper diligence before underwriting the $1B+ valuation.
Deepwatch has credible AI-native MDR product-market fit and enterprise customer proof, but pervasive financial opacity, three CEOs in under two years, and workforce reductions that targeted core MDR delivery staff make this a high-risk tracking position rather than an actionable buy until financial and leadership clarity improves.
Devo has genuine cloud-native SIEM differentiation and strong NRR, but the $2 billion valuation at ~28x ARR is materially unsupported by current market comps — a constructive investment stance requires price discovery, an updated ARR milestone, or Gartner MQ re-inclusion before the risk-reward is favorable.
Orca Security is the agentless CNAPP pioneer under existential competitive pressure from Wiz; its $1.8B Series C mark is at severe risk of markdown given Wiz's 3x estimated ARR lead, active IP litigation, and a financing environment that has penalised cybersecurity late-stage rounds since 2022.
Historically well-funded NDA-stage biotech with real asset credibility, but stale valuation anchors and missing private metrics keep the call at research-more.
Source Foundry attacks a real and strategically important semiconductor bottleneck, but the public record still falls far short of what is needed to cleanly underwrite the reported ~$5B valuation.
OrCam is a real assistive-tech company with real mission value, but public evidence does not support paying a legacy unicorn price without direct diligence on current terms, revenue, and recap mechanics.
Ineffable Intelligence combines one of the strongest founder-led frontier AI theses in Europe with one of the least underwritable public valuation setups: $5.1 billion at seed, zero revenue, zero customers, and unresolved technical and governance risks.
Retro has credible science, elite backers, and a real first-in-human milestone, but public evidence still supports a research-more stance because the $1.8 billion pre-money mark is ahead of disclosed efficacy, economics, and commercial proof.
Story Protocol has credible technical differentiation and real AI/IP narrative tailwinds, but public evidence still supports only a research-more stance because revenue, enterprise adoption, and legal enforceability remain unproven while valuation looks stretched versus token-market and usage signals.
Sidecar Health has a differentiated transparent-plan model and real strategic validation from Koch, but the company still withholds the underwriting, scale, and cap-table data needed to price the risk with conviction.
Xpanceo has assembled rare capital and a credible prototype engine around a potentially important post-screen interface, but the company is still years from a publicly validated commercial product and the last disclosed valuation already prices in milestones that remain unproven.
Statsig built a credible integrated experimentation platform, but the announced OpenAI deal and still-private economics make it an avoid for fresh capital.
Aiven has credible product breadth, enterprise customer proof, and multi-cloud differentiation, but the stale $3B 2022 mark is not investable in 2026 given opaque financials, heavy competitive pressure, and uncertain capital adequacy.
Rebellions has the strongest strategic positioning of any Korean AI chip startup, but the current $2.34B price is supported far more by sovereign-AI optionality and investor backing than by publicly disclosed commercial scale.
Morphi is strategically interesting, but the public record does not yet justify paying up at its reported unicorn valuation.
Humanity Protocol has real identity-market optionality and live token-market relevance, but the 2026 exploit and missing financial disclosure keep the call at research-more and the current sub-$1B FDV only conditionally fair.
Morphi is a credible company to track because the market, founders, and investor syndicate are all real strengths, but the current near-unicorn price already discounts major execution wins that have not yet been demonstrated in public.
Rentberry looks like a real rental-workflow product with global reach and persistent financing access, but public evidence still supports only a cautious, further-diligence stance because valuation, governance, and monetization disclosures remain materially inconsistent.
Flourish combines rare founder pedigree with a differentiated energy-efficiency thesis, but public evidence is still far too thin to underwrite a $2.5B pre-product valuation with conviction.
Exa looks like a real and differentiated agent-search infrastructure company, but the public economics and current $2.2 billion price are still too opaque to justify an invest-now call.
humans& has top-tier founder-market fit and capital for a frontier-AI platform, but the public record still supports only a research-more stance because product, customer, and financial proof lag the valuation narrative.
Genki Robotics combines elite founder pedigree and strong Japan robotics tailwinds, but the current $1 billion Series A price materially outruns public proof on product, customers, and economics.
GI WaaS has credible wastewater-treatment activity and Saudi market tailwinds, but the reported unicorn valuation outruns the quality of its public disclosure.
Skyroot has real technical progress, capital backing, and manufacturing ambition, but the orbital launch, customer, and unit-economics proof still trails the current $1.1B valuation.
GoodLeap is a scaled category survivor, but the stale $12B private mark, ABS stress, live consumer-finance litigation, and limited private disclosure make the right action track / research-more rather than buy near the historical valuation.
TAE has one of the stronger publicly visible private-fusion science programs, but today's entry price is unsupported by disclosed plant economics, customer proof, or the pending merger's full disclosure pack.
Ninja Van has real regional logistics scale and credible adjacencies in B2B restocking and cold chain, but weak public financial disclosure and a 2025 valuation reset leave the current underwriting case incomplete.
EvolutionaryScale produced frontier-quality protein language models (Science-validated ESM3) but the November 2025 CZI absorption — barely 14 months after the $142M Series A — eliminates the standalone investment thesis and leaves commercial investor returns publicly unaccounted for.
A credentialed, well-funded pre-clinical ADC platform with genuine differentiation potential but no data, no disclosed target, and no confirmed valuation — research-more until key facts are shown.
Unconventional AI is attacking a real and increasingly important AI power bottleneck with rare founder-market fit and exceptional access to capital, but public evidence still supports treating it as a thesis-driven research bet rather than an investable operating company at the current price.
Xingyun Group has real cross-border infrastructure, brand relationships, and optionality through Polibeli, but opaque parent financials, active governance/regulatory disputes, and a stretched implied valuation keep the investment view at research-more rather than buy.
Noom is a real, large-scale consumer-health brand whose 2021 $3.7B mark is no longer credible — secondary markets already imply ~$720M — and whose investability now hinges on whether the GLP-1 Noom Med pivot can offset behavioral-app revenue decline and structural disruption.
Psibot pairs an elite embodied-AI team, a platform-licensing model, and marquee strategic backers with a $1.48B unicorn price — but with no disclosed revenue, self-reported benchmarks, and China-specific regulatory exposure, the valuation is an option on execution that diligence must underwrite before committing at the current mark.
AESC has enough customer and plant proof to matter, but the present public file does not justify premium underwriting without audited revenue, margin, leverage, and cap-table evidence.
Mirendil pairs an elite ex-Anthropic/Google founding team and top-tier backing (a16z, Kleiner Perkins, NVIDIA) with a ~$1B seed valuation despite no product, no benchmarks, no revenue, and no customers. The talent-and-thesis case is real; the price is underwritten almost entirely on founder pedigree and TAM. Research-more / track at the current reported price; re-evaluate after the first technical proof points and design-partner evidence appear.
AI² Robotics is a credible Chinese embodied-AI contender with real strategic backing and an unusually large early customer contract, but the February 2026 unicorn valuation still runs ahead of disclosed fundamentals and keeps the company in research-more territory.
SSI is a high-conviction, pre-revenue AI safety bet priced at $30B on founder optionality alone — not current business fundamentals.
Sanctuary AI has top-tier humanoid-robotics IP and credible strategic backers, but the absence of disclosed customers, revenue, or valuation — combined with the November 2024 co-founder departure and contradictory financing reports — makes underwriting premature.
Brex's $5.15B Capital One outcome (April 2026) crystallises a 58% discount to the 2022 peak: a workable enterprise-fintech exit but a decisive failure of the standalone unicorn thesis — TRACK / AVOID at pre-acquisition private secondaries; the deal is now a Capital One integration story.
Xoople has a credible EarthAI thesis, strong Spanish and strategic backing, and a sensible distribution-first route into enterprise workflows, but the current public evidence does not justify underwriting a $1B+ entry price without disclosed commercial traction and a clearer constellation plan.
Hark has elite founder pedigree, capital, and compute access, but the public record still supports an avoid stance because a $6 billion Series A valuation is ahead of disclosed customer, product, and economic proof.
Zhipingfang Technology is a credible Chinese embodied-AI contender with strong strategic backing and a real industrial anchor order, but the June 2026 repricing above $2.8B materially outruns still-undisclosed fundamentals and keeps the company in research-more territory.
Elite Li Auto pedigree and strong early sponsorship make Zhijian Power worth tracking, but public evidence still stops at PoC and unnamed cooperation, leaving the reported >US$1B valuation unsupported.
EnergyX holds genuine DLE technology optionality and strategic-investor validation, but a $3.26 billion management-set implied valuation unsupported by commercial revenue, independent appraisal, or institutional follow-on keeps the stance at TRACK with LOW confidence and HIGH risk.
GVE has a credible strategic cyber-infrastructure thesis, but current public evidence does not justify paying the highest visible valuation marks; track it, do not underwrite it aggressively, until customer and financial proof catch up.
Recursive looks strategically important and technically credible for its age, but the current $4.65 billion valuation is not publicly underwritten enough to support a buy call.
Tongdun appears strategically relevant in Chinese and cross-border financial-risk infrastructure, but unresolved legal, disclosure, and valuation questions keep the current case in track / research-more territory.
GetYourGuide appears to be a scaled category leader in travel experiences with credible profitability momentum, but private-financial opacity and marketplace-quality risks keep the investment stance at track pending audited evidence.
Flapping Airplanes is an elite-talent, high-conviction AI research bet worth monitoring, but the public record does not support underwriting a $1.5 billion entry price while the company still has no product, no revenue, and no published benchmark evidence.
Trellix remains a scaled, relevant XDR platform with real enterprise and government reach, but declining revenues, a distressed capital structure, and unresolved breach-related trust risk make it a diligence-heavy situation rather than a clean equity investment.
Odyssey has credible world-model technical leadership and elite capital backing, but at a $1.45B valuation the absence of disclosed revenue, customer proof, burn data, and governance detail makes the current price too opaque to underwrite.
AMI Labs is a scientifically credible but commercially unproven world-model research bet — track at the $3.5B seed valuation pending JEPA benchmark evidence and a commercial anchor beyond Nabla.
Prometheus pairs a uniquely strong founder/investor stack with a credible long-term physical-engineering AI opportunity, but the current $41B price far exceeds any public evidence of product, customer, or revenue traction.
Nio GeniTech has strategic technology and policy tailwinds, but the current valuation already prices in more commercial proof than the public record provides.
ClickUp has real scale, breadth, and AI-driven monetization potential, but stale price discovery and thin public operating disclosure keep the investability call at research-more rather than a priced buy.
Reka has a credible wedge in efficient multimodal enterprise AI and real strategic validation from Snowflake and NVIDIA, but thin public financial disclosure and a roughly $1B price tag keep the public-evidence stance at research-more rather than invest-now.
Cornerstone Robotics is a credible APAC surgical-robotics contender with real regulatory and clinical momentum, but public commercial evidence is still too thin to support a conviction buy at the current implied unicorn valuation.
Terminus is a real scaled AIoT platform with unicorn-level funding and fast 2024 growth, but financial opacity, single-segment concentration, and repeated IPO lapses keep it in research-more territory rather than an investable buy.
Lightwheel has a credible early lead in physical AI infrastructure and unusually strong 2026 demand signals, but the absence of audited revenue, retention, and valuation evidence keeps it in research-more territory rather than an actionable buy.
Promising process IP never matured into a diversified base of gigawatt customers before partner concentration, capital intensity, and a battery-market downturn pushed 24M into liquidation.
Megvii has real technical depth and commercial breadth, but sanctions, biometric-regulation risk, and opaque current financials keep the investment case below threshold for a confident long position.
Turntide has a differentiated technology platform but zero public financial evidence, zero named customers and a stale $2.8B valuation make it uninvestable from public sources alone.
Shrapnel pairs a credible UE5 product and a unique China license with a $1.1B private mark that is roughly 1,000x its own token market and unsupported by live engagement or disclosed revenue.
Cowboy Space has Tier-1 backers, a credible founder, and a genuine structural market driver, but the $2B entry mark is entirely thesis-stage: the company is pre-revenue, its rocket is unbuilt, and the core thermal physics of a 1 MW orbital data center remain publicly unvalidated.
XpressBees is a network-scale Indian logistics unicorn facing acute cash depletion, a stale USD 1.4 billion valuation mark, and existential customer concentration risk from Meesho's Valmo internalization -- avoid new investment until liquidity and profitability signals improve.
Advance Intelligence Group is one of the most advanced SEA fintech multi-product platforms at profitability inflection, but undisclosed credit quality and an uncertain IPO path make this a conditional accumulate at or below the 2021 round valuation.
Haomo still has strategic and technical residual value, but the public evidence through August 2026 supports an avoid call because operations, solvency, and restart economics are unresolved while the historical unicorn mark is clearly stale.
Infinite Reality has assembled real immersive-commerce and media assets, but the gap between its confirmed fundamentals and its self-reported valuation remains so extreme that the equity case is currently dominated by governance, legal, and financing downside rather than platform upside.
Northvolt proved that Europe could assemble a strategically important battery platform with real customer demand and massive financing access, but the legacy equity story appears broken by insolvency; only successor asset exposure may merit fresh underwriting.
ArtIn Energy presents an extraordinarily high-risk profile with a $14.58B valuation unsupported by operational evidence, revenue, or independently verified financials.
Ascend Elements has real battery-material technology and customer interest, but its April 2026 Chapter 11 filing turns the case into a distressed-asset situation rather than a normal late-stage growth investment.
Natron Energy is a post-shutdown liquidation legacy file with real technology and manufacturing proof, but no live underwriting case and no publicly verified unicorn valuation.